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ABSTRACT
Previous studies in this laboratory have demonstrated that BrdU induces differentiation in 
the lung epithelial cell lines DLKP (derived from a poorly differentiated carcinoma of the 
lung) and A549 (derived from an adenocarcinoma of the lung). This differentiation 
involves the induction o f epithelial specific proteins, e.g. cytokeratins-8 and -18, and 
epithelial related adhesion molecules e.g. (X2P1 integrin. This thesis investigated the 
effects BrdU has on the expression o f Ep-CAM, a non-calcium dependent, homophilic 
cell-cell adhesion protein, in these cell lines. BrdU treatment induced Ep-CAM protein 
expression in DLKP after 7 days, with this induction reaching a plateau after 14 days of 
10(iM BrdU treatment. Similarly, in A549, Ep-CAM was induced following 7 days of 
BrdU treatment and the level o f induction also plateaued after 14 days of exposure to 
10(.iM BrdU. RT-PCR analysis revealed that the effect o f BrdU on Ep-CAM expression 
appears to be at the post-transcriptional/translational level, with no increase in mRNA 
levels compared to significant increase in protein levels in both cell lines.
Ep-CAM is believed to interfere with the functioning o f the Ca2+-dependent cell-cell 
adhesion molecule E-cadherin, by causing alterations in focal adhesion proteins. Analysis 
of two these proteins, a-actinin and a-catenin, showed that BrdU down-regulated their 
expression following Ep-CAM induction.
RT-PCR analysis of the Ep-CAM homologue GA733-1 revealed that, following BrdU 
treatment, mRNA expression is induced in DLKP. However, no induction is observed in 
A549.
The ability of other halogenated thymidine analogues to induce differentiation was also 
investigated. Three halogenated thymidine analogues were selected, each possessing a 
different mechanism of biological activity, CdU (which incorporates into DNA), 5,5'- 
FdU (which inhibits DNA synthesis) and 5-BUr (which incorporates into RNA). The 
ability of CdU to induce the expression of cytokeratin-8, cytokeratin-18, cytokeratin-19, 
Ep-CAM and (31 -integrin was demonstrated in both A549 and DLKP. RT-PCR analysis
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of A549 revealed that although the protein expression was induced, the mRNA level 
remained unchanged indicating that CdU was altering expression at a post- 
transcriptional/translational level. A significant up-regulation o f cytokeratin-8, 
cytokeratin-18, cytokeratin-19, Ep-CAM and |31 integrin also occurred in DLKP and 
A549 following 5,5'-FdU treatment. Analysis of mRNA levels following treatment with 
5,5'-FdU indicated that expression was being altered at a post-transcriptional/translational 
level. Treatment o f DLKP and A549 with 5-BUr did not produce any obvious alterations 
in protein expression or mRNA levels.
To develop models reflecting in vivo differentiation, DLKP and A549 were grown in a 
hormone supplemented medium (HSM) which contained a number o f physiologically 
relevant factors e.g. oestrogen and insulin. Growth in this medium induced expression of 
cytokeratin-8, cytokeratin-18, cytokeratin-19, and Ep-CAM in DLKP and A549. 
Experiments to identify the importance o f specific components in HSM revealed that the 
deletion of hydrocortisone, and cholera toxin from HSM cause an increase in induction of 
cytokeratin-19 and Ep-CAM. In contrast the removal of insulin from HSM, reduced the 
ability to induce expression of cytokeratin-19 and Ep-CAM in A549.
To further develop in vitro models reflecting in vivo differentiation, methods were 
established to generate primary cultures o f lung tumour cells and normal lung epithelial 
cells. The assessment o f a variety o f methods for the isolation of lung carcinoma cells 
from lung tumour samples did not reveal any advantages between the methods. 
Preliminary studies on isolated normal rat type II pneumocytes revealed morphological 
and antigenic changes during in vitro cultivation. These changes were consistent with the 
terminal differentiation of type II pneumocytes into type I pneumocytes. During the 
isolation o f lung tumour cells cultures o f fibroblasts were often established and these 
expressed the unusual feature o f cytokeratin protein expression, which is usually 
epithelial- specific.
XIX
1.0 INTRODUCTION.
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1.1 CELL TYPES OF THE LUNG
The lungs are organised into the intrapulmonary airways (bronchi and bronchioles) 
which account for 6-10% of the lung volume, and the gas exchange area or 
parenchyma, which accounts for approximately 80-90% of the lung volume. The lung 
is encapsulated by the viseral pleura, a layer o f connective tissue and mesothelial 
cells. The pleura, along with the nervous and vascular tissue associated with the lungs 
account for 9-10% of the lung volume. Thus, the lung is an extremely complex organ. 
This complexity means that the lung consists o f over 40 different cell types, allowing 
the organ to function as the principle gas exchange in the body, with a surface area o f 
70m2. The lung also has a number o f nonventilatory functions including 
humidification, thermal regulation, mucociliary clearance, anti-bacterial response, and 
elimination o f volatile substances.
Structure of Human Lungs
tr/irhoA
Figure 1.1 Basic Structure o f the Lung
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1.2 EPITHELIAL LUNG CELL TYPES
1 .2 .1  T R A C H E O B R O N C H I A L  A I R W A Y S .
At least seven epithelial cell types lining the tracheobronchial airways have been 
identified. These epithelial cells types are classified as follows: basal cells, ciliated 
cells, brush cells, goblet (or mucous) cells, serous cells, Clara cells, and 
neuroendocrine cells (the latter four function as secretory cells) (Crapo et al., 1982).
Basal cells
Basal cells are oriented with long axes parallel to and in contact with the basal lamina. 
The cytoplasm, containing many filaments and few organelles, is usually small in 
relation to the nucleus. It is thought to be a progenitor cell for the other cell types 
(Plopper, 1996).
Ciliated cells
These are epithelial cells, which possess cilia of approximately 0.25p,m in diameter. 
The function of these cilia is to sweep the mucous that lines the trachea to the 
oesophagus where it is swallowed and eliminated.
Goblet (or Mucous cells)
Goblet cells are columnar in shape but may become distended in shape due to their 
intracellular secretions. The cell cytoplasm is characterised by numerous secretory 
granules which contain high molecular weight mucous acidic glycoprotein and 
electron lucent granules.
Serous cells
Serous cells have basal, located nuclei and apical microvilli. They contain abundant 
rough endoplasmic reticulum (rER) and apical electron-dense sectretory granules. 
(Plopper, 1996)
Clara cells
Clara cells have characteristics of both sectretory cells and those capable of 
metabolising xenobiotic compounds. The secretory granules are discrete membrane 
bound electron dense structures that contain either neutral glycoprotein or low 
molecular weight protein such as cclO (Singh and Katyal, 1992). They also produce 
surfactant proteins A and C. Clara cells have mitochondria scattered throughout their 
cytoplasm and a variable amount o f a granualar ER and glycogen. The Clara cell is 
the predominant non-ciliated cell in all the generations of intra-pulmonary airways in 
laboratory animals (Plopper, 1996).
Neuroendocrine cells
Neuroendocrine cells are typically pyramid in shaped with their bases containing 
osmophilic granules, abundant ER, Golgi complex, ribosomes, and many filaments. 
These cells are most abundant in the early stages of life and are sometimes associated 
with nerve endings (Plopper, 1996).
Other epithelial cells
Other unidentifiable epithelial cells exist as a small population. They have none o f the 
characteristics o f the several cell types outlined previously and have a generalised cell 
structure (Plopper, 1996).
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1.2.2 TRANSITION ZONE.
The transition zone, the area where small air passages of the tracheobronchial tree join 
the gas exchange area, is the focus of many lung disorders. Their histological 
appearance is similar to that of terminal bronchioles with the exception that the 
epithelium is interrupted by alveoli (Plopper, 1996).
1 .2 .3  P A R E N C H Y M A .
Parenchyma (or respiratory area) consists of functional units called acini or terminal 
respiratory units. The acini are generally defined, as all the airspace’s distal to one 
terminal bronchiole. This includes the respiratory bronchiole branching from it and all 
the associated alveolar ducts, alveolar sacs, alveoli, and the airspace’s contained 
within these structures (Plopper, 1996). Two epithelial cell types line the interalveolar 
septa, type I pneumocytes and type II pneumocytes (Penny, 1988).
Type I  Pneumocytes
Type I pneumocytes are squamous cells with a centrally placed nucleus and possess a 
large cytoplasmic volume (cellular surface area is 5000 to 7000um ). There are few 
organelles present in the cells ultrastructure e.g. mitochondria, only minimal amounts 
of rER are observed, and a moderate number of endocytoic vesicles are present. The 
type I pneumocyte is the cell through which the gas exchange process occurs. Type I 
pneumocytes cover approximately 96% of the alveolar surface yet only account for 
45% of the cell mass in the alveoli (Plopper, 1996).
Type II Pneumocytes
Type II pneumocytes cover the remainder of the alveolar surface area (approximately 
3%). Type II pneumocytes are cuboidal cells possessing microvilli, and contain many 
cellular organelles e.g. mitrochondria (accounting for 5-9% of cell volume), rER,
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microvesicles, and Golgi complex. One of the main characteristic features o f this cell 
type is the presence of many osmophilic, laminated vesicles called lamellar bodies. 
These vesicles are storage bodies for surfactant, a heterogeneous mixture of lipid, 
carbohydrate and protein that forms a highly surface active complex, of which type II 
pneumocytes are the main producers (Plopper, 1996). The main role of surfactant is 
the reduction o f the surface tension at the air-liquid interface hence stabilising the 
alveoli and preventing lung collapse (Hollingsworth and Gilfillan, 1984). Other 
ancillary roles o f the surfactant system include host defence, acting as an opsonisation 
agent for the ingestion of bacteria by macrophages (Guzman et al., 1994), and the 
prevention of oedema in the alveoli spaces (Chevalier and Collet, 1972). The type II 
pneumocyte is also thought to act as a progenitor cell for both type I and type II 
pneumocytes (Sing and Katyal, 1992; Adamson and Bowden, 1975). Various studies 
both in vivo and in vitro have shown that type II pneumocytes must undergo a number 
of antigenic and morphological changes to adopt a type I cell phenotype (Paine et al.,
1995).
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1.3 LUNG DEVELOPMENT.
The development o f the lung requires cell proliferation, branching morphogenesis, 
alveolar saccule formation and cell differentiation. These processes require well co­
ordinated events, which are achieved by epithelial-mesenchymal interactions, 
activation and repression of transcriptional factors, cytokine signalling, cell cycle 
control and extracellular matrix expression and signalling (see section 1.5).
The lung originates as a ventral appendage of the endodermal epithelium lining the 
floor of the primitive embryonic pharynx. It then divides laterally into two buds and 
begins dichotomous branching into the surrounding splanchnic mesenchyme. This 
repetitive epithelial branching process, termed branching morphogenesis, is 
characteristic of lung formation and continues throughout gestation.
Lung development can be divided into four chronological stages:
I) The pseudoglandular stage during which the bronchial and respiratory tree 
develops and an undifferentiated primordial system forms. It is during this stage that 
the most significant growth and branching of the primitive lung epithelium takes 
place. This determines the pattern o f the lung system. The epithelial cells at this stage 
have a columnar morphology and are undifferentiated.
II) The canalicular stage during which the respiratory bronchioles emerge, and 
this is accompanied by the development of terminal sacs and vascularisation. Towards 
the end of this stage, the undifferentiated cuboidal cells begin to develop inclusion 
bodies, characteristic of type II pneumocytes and Clara cells.
III) The terminal sac stage during which the number of terminal sacs and 
vascularisation increases. During this stage differentiation o f type II and type I 
pneumocytes occurs.
IV) The alveolar stage during which terminal sacs develop and enlarge into 
mature alveolar ducts and alveoli.
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1.4 STEM CELL THEORY IN LUNG.
Stem cells are characterised by an ability for self-maintenance and to vary this self­
maintenance (i.e. to proliferate without maturation) and also to generate a large 
number of differentiated functional progeny following injury (Potten and Loffer,
1990). It should be noted that while a differentiation potential is a property o f stem 
cells it should not be confused as an essential feature o f ‘stem-ness’.
Although stem cells in adult organs are pluripotent, the ultimate differentiated lineage 
descendants are not usually expressed beyond the relevant organ in which the stem 
cell occurs, i.e. these stem cells are tissue determined stem cells (TDS cells) and are 
thus considered separate from embryonic stem cells (ES cells) (Sell, 1994). Another 
essential difference between TDS cells and ES cells is their differentiation status, all 
stem cells with the exception o f those present in the zygote (i.e. ES cells) are 
differentiated to a greater or lesser extent. The progeny of TDS cells may undergo 
further differentiation thereby giving rise to further differentiated descendants.
These TDS cells often divide and differentiate to give rise to transit cells, which are 
still capable of division. It is the division and further differentiation o f these transit 
cells that is responsible for increasing end cell number (Lajtha, 1982; Potten and 
Loffler, 1990). Transit cells are more mature than stem cells, often showing 
intermediate properties.
An important feature o f transit cells is that they are inexorably destined to move 
towards functional status. This can be demonstrated using the following model (figure 
1.4.1). If one stem cell is mobilised into differentiation and the transit cells it derives 
undergoes 10 cycles o f amplification then just over 1,000 cells are produced. If one 
assumes it takes 24 hours for all cell proliferation (stem cell and transit cell) then a 
small population of cells can maintain a high-end cell number. This is the situation 
which applies to bone marrow, skin and intestinal epithelium (Lajtha, 1982).
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Figure 1.4.1 Demonstrating how a small population of TDS cells can maintain 
high cell populations in tissue.
TDS cells are believed to undergo a slow cell cycle in order to reduce the risk of 
errors during DNA replication. As TDS cells are present throughout the life o f the 
organism, such error could become amplified in the organism (Lajtha, 1982). Indeed it 
is proposed that most tumours contain TDS cell populations (Khan et al., 1991) and 
that the overlapping expression o f differentiation markers (Gazdar et al., 1988) within 
cancer cells is indicative o f a stem cell origin for most lung epithelial tumours.
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1.4.1 GENERAL MODELS OF DIFFERENTIATION IN STEM CELLS.
During the differentiation process o f TDS cells, it is necessary that they maintain a 
constant cell number. One popular model for this is asymmetrical cell division. 
According to this model, when the stem cell divides one daughter cell remains a stem 
cell while the other becomes a transit cell and enters the differentiation process 
(Figure 1.4.2). This model suffers from a fundamental flaw in that it suggests that 
after receiving an appropriate stimulus it proceeds into a cell cycle that yields two 
different daughter cells (Lajtha, 1982).
Although proliferation and differentiation appear to be interlinked processes during 
stem cell maturation, they are quite separate events that occur concomitantly. This 
suggests the whole differentiation process may be understood in terms o f a spiral 
model (Potten and Loffler, 1990).
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Some TDS cells appear to be highly pluripotent giving rise to several different cell 
lineages, e.g. the haematopoietic system. Given this pluripotency, it can be envisaged 
that depending on the signal, a stem cell will adopt one direction of maturation over 
another.
According to a model proposed by Holtzer el al. (1975), TDS cells are only capable of 
binary decisions, e.g. stem cell A is capable o f generating cells B or C, and cell B may 
then differentiate to cells D or E. As the transit cells pass through this hierarchy they 
go through cell division.
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1.4.2 STEM CELL MODELS IN LUNG TISSUE.
The principle of stem cells and their in vitro cultivation and manipulation is now well 
established for a number of tissue types (see table 1.4.1).
Mammary gland Rudland and Barraclough (1988)
Liver Sell (1994)
Brian Bartlett et al. (1995)
Hematopoietic tissue Fraser et al. (1995)
Intestine Hermiston and Gordon (1995)
Skin Jones et al. (1995)
Table 1.4.1. In vitro cultivation of tissue stem cells.
The existence o f a similar stem cell in the lung is strongly suspected, given the ability 
of the lung to regenerate when exposed to local damage by atmospheric components 
(e.g. smoke, carbon black particles) and by lipophilic chemicals absorbed (e.g. 
through the gut) into the blood stream. However, identification o f such a stem cell is 
hampered by the complexity o f the respiratory system and the variety of cell types 
present (Plopper and Hyde, 1992; Paine and Simon, 1996; Mariassy, 1992).
The most predominant hypothesis for stem cells in vivo in lung is that a different set 
of progenitor cells exist (including basal cells) each destined to give rise to a discrete 
differentiated cell type (Evans et al., 1989; Jetten, 1991; Plopper et al., 1992). In the 
case of type II cells, these cells proliferate and then differentiate into type I cells 
(Adamson and Bowden, 1979) and Clara cells can differentiate into ciliated cells 
(Jetten, 1991).
However, an alternative proposal is that there is a single pluripotent stem cell for 
generating ciliated cells, Clara cells and the other differentiated cell types (McDowell, 
1987). This hypothesis suggests the existence of a monotypic stem cell, which gives
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rise to a transit cell described as a small mucous granule cell (SMGC). This cell is 
defined as being of a secretory yet premature type containing a few small granules 
which are periodic acid schiff reaction positive, and also possess a well developed 
endoplasmic reticulum, prominent Golgi complex and occasional tonofilament 
bundles. It is believed to possess an electron microscopically pale cytoplasm with 
apex reaching the lumen, and appears to show no evidence o f ciliary or mucous 
differentiation. This SMGC is believed to be able to arise through dedifferentiation of 
any differentiated secretory cell type. There is some empirical evidence for this 
hypothesis as Clara cells are found to be positive for surfactant protein-A (SP-A) and 
surfactant protein-B (SP-B) which were originally described as specific products of 
type II pneumocyte cells. This suggests that Clara cells and type II pneumocytes are 
derived from the same stem cell. Further tentative indications come from studies of 
fetal mouse lung where a definite population o f progenitor cells co-express SP-A 
(type II cells), cclO (Clara cells), and calcitonin gene-related protein (CGRP) 
(pulmonary neuroendocrine cells), each being a gene product used to indicate 
differentiated function in a different respiratory epithelial cell type (Wuenschell et al.,
1996).
In an attempt to reconcile these varying hypotheses, it is necessary to divide the 
respiratory system into two segments, the pseudo stratified epithelium and the simple 
epithelium. In the proposed model, the same stem cell is likely to occur for both at the 
fetal stage and to remain in the epithelium through the whole peri- and post-natal 
stages o f life (Figure 1.4.3). However, this stem cell at stage I does not appear to be 
involved in the steady state cell turnover but pursues its role to repopulate damaged, 
severely injured epithelia with various transit cells or predifferentiated secretory cell 
populations (stage II). These transit cells further differentiate into phenotypically 
functionally cell types (stage III). The majority of the differentiated cells present in 
stage III will differentiate irreversibly (stage IV) to their ultimate cell type. A small 
proportion of the differentiated cells remains at the stage III of the differentiation 
pathway. These cells at stage III are able to dedifferentiate into the presecretory or 
predifferentiated cells o f stage II, thus participating in steady state turnover between 
stage II and stage III. In the fetal stage of differentiation, the process seems to proceed 
directly from stage I to stage III (Emura, 1997).
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Figure 1.4.3 Proposed model for the generation and maintenance of epithelial 
cell lineages in lung.
The proliferation and differentiation o f type II pneumocytes into type I pneumocytes 
is an established fact even if specific elements are still unknown. The existence o f a 
population of stem cells for the whole lung is more controversial.
In summary, very little hard scientific data exists about stem cells in the lung, the 
pathways they follow, their distribution and mechanism of action. No markers yet 
exist for lung stem cells. The idea o f dedifferentiation is in contrast to the stem cell 
models developed in skin, liver and intestine in which the stem cell pre-exist in the 
epithelium (Emura, 1997). The lung is susceptible to local damage from a number of 
sources. These include atmospheric components (e.g. ozone, silica, and carbon black 
particles); lipophilic chemicals absorbed (e.g. through the gut) into the blood stream, 
and viral and bacterial infection. Therefore, it must possess some form o f mechanism 
to regenerate itself, even if limited. In attempting to identify if  a cell is a stem cell, its 
native state is often altered during the investigation. This may result in loss o f the
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stem cell or only a limited spectrum of responses being observed from the cell. Thus, 
due to the variety o f cell types present and by the complexity o f the respiratory 
system, identification o f a lung stem cell is a difficult task.
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1.5 FACTORS CONTROLLING DIFFERENTIATION IN THE 
LUNG
1.5.1 PHYSIOLOGICAL AGENTS OF LUNG DIFFERENTIATION.
The physiological agents involved in the modulation o f lung differentiation in vivo are 
largely unknown. A number of studies using isolated lung cells (both adult and fetal) 
and cell lines have implicated a number of candidate factors including glucocorticoid 
steroids, chemokines, cell-matrix and cell-cell interactions. The mechanisms and 
interaction o f these molecules are at best poorly understood.
1.5.1.1 Glucocorticoid Steroids.
The glucocorticoid steroids regulate gene expression by binding a specific receptor in 
the cytoplasm. Upon binding, a hormone-receptor complex is formed with an 
increased affinity for DNA and migrates into the nucleus. After entering the nucleus, 
alterations in transcription of specific genes occur. The glucocorticoid steroids can 
also act in a post-translational level by increasing the number o f ribosomes translating 
the messenger RNA (Palmiter, 1972).
The importance o f the glucocorticoid steroids in lung development can be observed in 
Corticotropin-releasing hormone-deficient (CRH-KO) mice. A consequence of this 
mutation is that mice are glucocorticoid insufficient and exhibit neonatal lethality. 
Death is due to respiratory insufficiency as a result of abnormal pulmonary 
development, and in particular, impaired maturation of type II pneumocytes and Clara 
cells (Muglia et al., 1999). In vivo studies have also implicated hydrocortisone in the 
development of the gas exchange area or the differentiation of type II alveolar cells 
(Kendall et al., 1990).
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Since glucocorticoids act in a systemic manner, often stimulating paracrine signals, it 
is therefore difficult to determine their exact role in a particular cell type. In vitro 
studies have helped to elucidate some o f the mechanisms of action o f glucocorticoid 
steroids in lung differentiation. Several studies have shown that the glucocorticoid 
steroids act on lung epithelial cells directly. For example, in studies using isolated 
type II pneumocytes and various cell line models such as A549, glucocorticoids 
induced functional differentiation as seen in the production of pulmonary surfactant, 
which they control at both transcriptional and post-transcriptional levels, and 
induction of alkaline phosphatase activity (a marker for type II pneumocytes) (Speirs 
et al., 1991). However, the majority of glucocorticoid effects on lung epithelial cell 
differentiation (in both fetal and adult systems) appear to be through the mediation of 
soluble factors from glucocorticoid stimulated fibroblasts (Post et al., 1984; Speirs et 
a l,  1991; McCormick et al., 1995). In the case of oestrogen, for example, both in vivo 
and in vitro studies have found that it accelerates lung differentiation at the expense of 
lung growth (Khosla et al., 1981; Adamson el al., 1990). The action of oestrogen on 
lung epithelium is mediated in part, by fibroblasts binding oestrogen and subsequently 
transferring a maturation factor(s) to the fetal epithelium (Adamson et al., 1990).
1.5.1.2 Chemokines.
A number o f different soluble factors have been implicated in lung epithelial cell 
differentiation. Most of these are produced by lung fibroblast cells and by other lung 
cells and appear to act in an autocrine and paracrine manner.
The Fibroblast Growth Factor (FGF) family, which contains several different 
polypeptides, appears to have an important role in lung development, with fetal lung 
epithelium having been shown to be positive for FGF-Receptor (Han et al. 1992). In 
vivo and in vitro studies have implicated several members of the FGF family in lung 
growth and development in both fetal and adult tissue. These include acidic-FGF, 
basic-FGF, and KGF (FGF-7) (Lesur et al., 1992; Leslie et al., 1993; Ulich et al.,
1994).
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Epidermal Growth Factor (EGF) has been implicated in general epithelial 
development as being essential for the development of rough Endoplasmic Reticulum 
(Beaulieu and Calvert, 1981). EGF has also been identified as a possible important 
regulatory molecule in lung epithelial cell differentiation (Sundell et ah, 1980; Gross 
et al., 1986). Studies investigating fetal lung development showed localisation in the 
developing bronchi and around both Clara cells and type II pneumocytes (Raaberg et 
al, 1992).
Insulin has also shown to be important in lung growth and differentiation, with 
receptors for insulin being demonstrated on whole fetal lung. Their number appears to 
increase during late gestation (Ulane et ah, 1982). One of the possible reasons for the 
importance of insulin is that glucose is a major substrate for the synthesis of the 
phospolipid, phosphatidylcholine, in type II pneumocytes. The receptors for insulin 
have been reported on type II pneumocytes from a number o f sources (Sugahara et ah, 
1987; Shapiro et ah, 1986).
1.5.1.3 Cell-Cell and Cell-Matrix Influences.
An important component in embryonic development is cell-cell interactions such as 
epithelial-mesenchymal and epithelial-epithelial. These interactions may be of a 
diffusable nature (Jessell and Melton, 1992) or through cell-cell adhesion molecules. 
Such interactions remain important in adult tissues e.g. skin (Fusenig, 1994).
Various studies have shown that soluble factors from lung fibroblasts can influence 
the growth and differentiation of lung epithelial cells in vivo e.g. the onset of 
pulmonary surfactant at birth (Smith and Fletcher, 1979). These studies have been 
confirmed by in vitro studies with cultured type II pneumocytes grown on fibroblast 
feeder layers producing surfactant and retaining differentiation characteristics such as 
morphology (Shannon et ah, 1987). Studies have shown that lung fibroblasts produce 
these soluble factors in response to glucocorticoid action. For example, the culture of 
A549 (which possesses features of type II pneumoctyes) with media from fibroblasts 
exposed to dexamethatasone (a synthetic hydrocortisone analogue) show an increase
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in various markers o f type II pulmonary cell differentiation e.g. pulmonary surfactant 
(McCormick et al., 1995; Speirs etal., 1991).
Similarly, interactions with the extracellular matrix play an important role in both 
development of the lung and its repair by determining cell fate and maintaining cell 
differentiation (Dobbs, 1990; Rannels and Rannels, 1989). For example, specific 
domains of the extracellular matrix are believed to determine the positions of type I 
and type II pneumocytes during lung growth and development, as well as during 
repair of the alveolar surface after injury (Lwebuga-Mukasa, 1991).
Investigations with isolated type II pneumocytes appear to support this theory. These 
studies show that fibronectin (a dimeric glycoprotein) promotes a loss of type II 
differentiation and an acquisition of type I characteristics, while laminin (a trimeric 
glycoprotein) promotes the retention o f type II pneumocyte function (Rannels and 
Rannels, 1989; Rannels et al., 1987). Furthermore, it appears that type II pneumocytes 
are responsible for the composition of the extracellular matrix (Dunsmore et al. 1995) 
and that the fibronectin-rich extracellular matrix (ECM) produced by isolated type II 
pneumocytes in vitro resembles the type I pneumocyte matrix (Rannels et al. 1987).
1.5.1.4 Retinoic acid.
Retinoic acid (RA), a derivative of vitamin-A, has been implicated in the control of 
both cellular proliferation and differentiation, and has been shown to effect over 200 
different gene products (Chytil, 1992). For example, RA regulates elastin production 
by lung fibroblasts during alveolar septal formation (McGowan et al., 1995).
Within the cytoplasm of the cell, RA binds to cytoplasmic retinoic acid-binding 
proteins (CRABPs) I and II and retinol binding proteins (CRBPs) I and II (Chytil and 
Ong, 1983). It is unclear if  these proteins act in the storage o f retinoids or in their 
metabolism (Yost et al., 1988). The expression of CRABP I occurs in both fetal and 
adult lung, while CRABP II is found in fetal lung but is absent in adult lung (Chytil, 
1992).
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In the nucleus RA acts through two sets o f transcription factors, the retinoic acid 
receptors (RAR) a, p, and y, and the retinoid X receptors (RXR) a, p, and y 
(Petkovich et a l,  1987; Yu et a l,  1991). RARs bind all-trans- and 9-cw-retinoic acid, 
while the RXRs selectively bind 9-cw-retionic acid (Leblanc and Stunnenberg, 1995). 
These receptors (RAR and RXR) recognise specific RA-responsive elements (RARE) 
within the promoter regulatory regions of several genes (McGowan et a l ,  1995).
In order to exert their influence, the receptors heterodimerise to each other, e.g. 
RXR:RAR, or with other members of the nuclear receptor super-family (Leblanc and 
Stunnenberg, 1995). This heterodimerisation leads to an increase in ligand specificity 
and the number of target genes that can be activated or repressed. Thus, the 
differential expression and ligand-selective activation of the six retinoid proteins leads 
to cell type-specific expression of programs for development and growth control 
(Sporn et al., 1994).
The a, P and y subtypes of the receptors regulate the expression of specific genes by 
being expressed in a specific spatial and temporal manner (Mangelsdorf et al., 1994). 
For example, in the developing mouse embryo RARa was detected throughout the 
lung, while RARP was localised near bronchi and RARy only appeared in the lung 
late in gestation (Dolle et al., 1990).
1.5.2 SYNTHETIC AGENTS OF DIFFERENTIATION, 5-BROMO-2- 
DEOXYURIDINE.
Low levels of the thymidine analogue 5-Bromo-2’-Deoxyuridine (BrdU) have been 
shown to alter the differentiation status of different kinds of cells. This modulation of 
differentiation may be inhibitory e.g. myoblast cells (O’Neill and Stockdale, 1974) or 
stimulatory e.g. neuroblasoma cells (Ross et al., 1995). Recent work in this laboratory 
has shown that BrdU induces differentiation in a poorly differentiated lung carcinoma 
cell line, DLKP (McBride et al., 1999; Meleady and Clynes, manuscript submitted).
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The exact mechanism by which BrdU exerts its differentiation-modulating effects is 
unclear but incorporation into DNA is seen as essential. This involves BrdU being 
converted to bromodeoxyuridine monophosphate, which competes with thymidine for 
incorporation into DNA (O’Neill and Stockdale, 1974). Experimental evidence for 
this hypothesis comes from a study by Keoffler et al. (1983) which showed that a 
thymidine kinase-deficient human myeloid cell line (HL-60) was unable to 
incorporate BrdU into its DNA and subsequently failed to respond to the ability of 
BrdU to modulate its differentiation status.
A number of models exist to explain the ability o f BrdU to modulate differentiation: 
Model 1:
This model envisages that BrdU induces chromosomal breakages. These breakages 
and the associated chromosomal aberrations can be associated with stepwise changes 
in the differentiation of a cell. These breakages are at specific points called fragile 
sites, 32 of which have been identified in murine chromosomes. It proposed that BrdU 
associates with these fragile sites which are known to be recombinogenic (Alexander 
et al., 1992). Some corroboration for this model comes from a study by Schwartz and 
Snead (1982) which found that BrdU seemed to concentrate within repetitive DNA 
nucleotide sequences rather than randomly throughout the nuclear DNA. However, 
such selective incorporation would suit the other models also.
Model 2:
BrdU alters the affinity o f DNA sequences for regulatory proteins. Studies on the lac 
operon with BrdU incorporated showed that the lac suppressor was bound with 
greater affinity (Lin and Riggs, 1972).
Model 3:
In this model BrdU has been found to exert its effects on differentiation by alteration 
of a key regulatory gene(s) that alters transcription of genes involved in differentiation 
(Arnold et a l., 1988; Rauth and Davidson, 1993). In BrdU inhibition o f myoblast 
differentiation, such an alteration occurs with the down-regulation or complete 
inhibition o f the key regulatory gene, M yoDl (Tapscott et al., 1989; Nanthakumar
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and Henning, 1995). It could be envisaged that BrdU-induced alteration of 
differentiation in other tissues e.g. inhibition in mammary epithelial cells and 
pancreatic acinar cells, could be by a similar mechanism. This is strengthened by the 
homology o f MyoDl to the myc family o f proteins, which have an important role in 
differentiation.
Indeed, in BrdU-induced differentiation o f neuroblastoma, a decrease of both N-wyc 
protein and mRNA levels occur (Ross et al., 1995).
Model 4:
This model envisages that BrdU incorporation causes an alteration in the reading 
frame o f the DNA template resulting in the formation of an abnormal mRNA, which 
is incapable o f synthesising the correct differentiation products (Hill et al., 1974).
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1.6 CELL ADHESION MOLECULES.
1.6.1 INTRODUCTION.
The expression on the surface o f cells of various types of cell adhesion molecules 
influences cell-cell sorting, tissue architecture and cellular differentiation. Cell 
adhesion molecules carry out these functions by binding other cell adhesion molecules 
or by binding to the extra-cellular matrix. The cell adhesion molecules are divided 
into several families such as integrins, selectins, cadherins and the immunogloblulin 
cell adhesion molecules. Alterations in the expression of these molecules have been 
linked to various pathological conditions, for example, the development of 
malignancy.
1.6.2 INTEGRINS.
The integrin receptors consist o f two heterodimer chains, a  and P, both of which form 
a non-covalently associated complex (Hynes, 1987). The a  subunit family of integrins 
possesses 15 variants, while the p subunit family contains 8 variants. Thus in theory, 
the a  and p subunits could associate to give over 100 integrins. However, the actual 
diversity is much more restricted and in reality the a  and p subunits combine into 22 
different integrins (Buck and Horwitz, 1987). The integrin family is sub-divided on 
the basis of its p subunit (Newham and Humphires, 1996). For example, the Pi 
integrins are involved principally in the adhesion between the ECM and the cellular 
cytoskeletion (Buck et al., 1987), while the p2 integrins participate in cell-cell 
interactions (Ruoslahti, 1991). The specificity of binding is not determined solely by 
integrin pairing but also by the cell type it is expressed in, for example the CC2P1
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integrin expressed on platelets will not bind laminin (Staatz et al., 1989) while this 
integrin expressed on other cell types will bind laminin (Elices and Hemler, 1989).
Integrins have been implicated in such diverse processes as inflammation, cellular 
growth, differentiation, and cell polarity (Albelda and Buck, 1990). For example, the 
interaction in developing lung between the ECM and the epithelium is mediated by 
integrin receptors, and allows normal lung branching to occur (Gumbiner, 1996).
As well as functioning as cell adhesion molecules, the integrins have signalling 
functions that regulate various aspects of cell behaviour and differentiation. This 
signalling is accomplished through the focal adhesion proteins, some of which have 
intercellular signalling functions (LaFlamme et al., 1992). In particular, the 
phosphorylation of focal adhesion kinase (FAK) can lead to a signalling event through 
the microtubial associated protein (MAP) kinase pathways (Davis, 1993).
1.6.3 CADHERINS.
There are at least twelve known members of the cadherin family, which are divided 
into subclasses, sharing a common basic structure. The three main subclasses are E- 
Cadherin (found on many types of epithelial cells), P-Cadherin (found in the placenta 
and epidermis), and N-Cadherin (found on nerve, heart and lens cells) (Takeichi,
1991).
The cadherins function as Ca2+-dependent homophilic cell-cell binding proteins (Nose 
et al., 1990). They are believed to modulate differentiation by co-signalling with other 
cell adhesion molecules e.g. E-cadherin and the integrins act together to modulate 
glandular differentiation in colorectal cells (Pignatelli et al., 1992)
The cadherin molecules interact with the actin cytoskeleton via the catenins (a, (5, and 
y) located in the focal adhesion complexes (Ozawa el al., 1990). Through these
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interactions with the catenins to the cytoskeleton, the cadherins form cell junctions in 
epithelial cells, which are crucial for epithelial cell polarity (Ranscht, 1994). A 
disruption of these catenins leads to a disruption of cadherin function (Ozawa et al., 
1990). E-cadherin can signal downstream via (3-catenin, which is an important 
component of the WNT-mediated signalling pathway (Christofori and Semb, 1999; 
Dale, 1998).
Epithelial-cadherin (E-Cadherin) is a glycoprotein with a molecular weight of 124kDa 
and is thought to be important during embryonic development (Shirayoshi et al., 
1986). It is also involved in generating and maintaining epithelial layers in adult 
tissues (Shirayoshi et al., 1986).
Down-regulation of the E-cadherin/catenin complex has been implicated in 
oesophageal cancer (Kadowaki et al., 1994), gastric cancer (Streit el al., 1996) and 
colon cancer (Vermeulen el al., 1995). E-cadherin suppression is also associated with 
various stages of differentiation and development (Christofori and Semb, 1999). 
Down-regulation of E-cadherin mediated cell-cell adhesion can occur via signalling 
from the Rho family o f small GTPases (Tapon and Hall, 1997). Two members of this 
family, cdc42 and racl, have been shown to down-regulate E-cadherin, by activating 
IQGAP1, which competes for a-catenin with [5-catenin thereby inducing the 
disassociation of a-catenin from the E-cadherin cell adhesion complex (Kuroda et al., 
1998).
1.6.3 IMMUNOGLOBULIN SUPER FAMILY CELL ADHESION  
MOLECULES.
The immunoglobulin super family cell adhesion molecules (CAMs) are so identified 
because they possess one or more domains homologous to those found on 
immunoglobulins. The CAMs are divided into sub-families; the three most important 
being neural cell adhesion molecule (N-CAM) (Cunningham, 1995), intercellular
-I
adhesion molecule (I-CAM) (Montefort et al., 1993) and vascular cell adhesion 
molecule (V-CAM). They are single pass transmembrane proteins, and mediate cell- 
cell adhesion by Ca -independent homophilic binding. Knockout experiments in 
mice have shown their importance in development. For example, deletion of N-CAM 
results in distortion of the nervous system (Tomasiewicz el al., 1993). Furthermore, 
the promoter regions of the CAM gene sequences contain targets for the products of 
the developmental Hox and Pax genes (Cunningham, 1995).
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1.7 Ep-CAM, A CELL-CELL ADHESION MOLECULE.
1.7.1 INTRODUCTION.
The various proteins involved in cell-cell adhesion and cell-matrix interactions also 
have roles in a number of other cellular and morphological processes. These include 
proliferation, differentiation, cellular locomotion, tissue organisation and regulation of 
other cell adhesion systems. One such protein is Ep-CAM, which is also known as 
epithelial specific antigen (ESA), 17-1A antigen, epithelial glycoprotein (EPG), 
GA733-2 antigen, KSA, EPG40, EPG2, C017-1A antigen, KS1/4 antigen, and MOC 
31 antigen. The exact function o f this protein has yet to be clarified, but it appears to 
function as a homophilic, Ca2+-independent intercellular adhesion molecule, capable 
of mediating cell aggregation, preventing cell scattering, and directing cell 
segregation (Litvinov et al., 1997). Ep-CAM is found expressed in a polarised manner 
on the basolateral (and sometimes the basal) surface o f the majority of simple 
cuboidal, columnar, pseudo-stratified columnar and transitional epithelia (Simon et 
al., 1990; Litvinov et al., 1994).
1.7.2 SEQUENCE AND STRUCTURE OF Ep-CAM.
The gene family identified as GA733 is composed (to date) o f two highly homologous 
genes GA733-1 and GA733-2. Ep-CAM has been identified as the protein product of 
the latter (Linnenbach el al., 1989; Szala et al., 1990).
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1.7.2.1 Sequence of Ep-CAM Gene.
The gene GA733-1 is an intronless functional gene. This unusual phenomenon is 
possibly due to retrotransposition (a flanking direct repeat is observed) and thus may 
be the mechanism for gene duplication in this family (with truncation occurring at the 
319 untranslated sequence o f the precursor cDNA) (Linnenbach et a l,  1989). 
Transcription of the GA733-1 gene produces a 1.8 kb. mRNA. The 35.7 kDa protein 
encoded is similar, but not identical to Ep-CAM (Szala et al., 1990; Fomaro et a l,
1995).
The possible promoter region for GA733-1 includes a GC box, which appears to be 
identical to the simian virus GC, box IV though it is not clear yet if  Ep-CAM is SP-1 
responsive. In addition, present in the promoter region are an atypical CAAT box and 
a canonical TATA box (Linnenbach et al., 1989).
The GA733-2 gene (Ep-CAM) is located on chromosome 4q (Helfrich et a l ,  1997; 
Linnenbach et a l ,  1993). When the sequence for Ep-CAM (GA733-2) was compared 
to the previously established cDNAs it emerged that GA733-2 consists of 9 exons 
interspaced with introns o f variable length (Linnenbach et a l ,  1989). Northern blot 
analysis has shown a single 1.5 kb mRNA species (Perez and Walker, 1989). cDNA 
studies show that the 3'-non coding region of Ep-CAM contains the sequence 
ATTTA. This sequence has been proposed as a recognition signal for mRNA 
initiation of cytokines and proto-oncogenes. The 3'-non coding region of Ep-CAM 
also contains a copy of TTATTTAT which has been identified as a consensus 
sequence in the 3 '-non coding region o f inflammatory mediators, suggesting that Ep- 
CAM shares a similar post-transcriptional regulatory mechanism with a number of 
proto-oncogenes and inflammatory mediators (Perez and Walker, 1989).
Limited northern blot data has indicated that GA733-1 and GA733-2 are expressed 
differently. High expression levels of GA733-1 mRNA are found in the pancreatic 
carcinoma cell line BXPC-3 relative to the colorectal cell line SW 948. Expression of 
GA733-2 (Ep-CAM) mRNA is low in the BXPC-3 cell line relative to the high 
expression level in SW 948 (Szala et a l,  1990). Such differences in expression levels
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are not unanticipated since a characteristic feature o f a retroposon, like GA733-1, is 
the acquisition o f a heterologous promoter. In northern blots, no cross hybridisation 
between the two different-sized transcripts was observed, reflecting that at the DNA 
level the coding regions are only 54% identical (Szala et ah, 1990).
Also playing a role in the evolution of the Ep-CAM gene family is exon shuffling, as 
portions of these genes are found to be homologous to exon 8 o f thyroglobulin. This 
exon shuffling would have preceded any gene duplication events o f the GA733 
family. The GA733 family also shows homology to exon 2 o f the IL-2 receptor, 
which encodes for sequences involved in growth factor binding. The significance of 
the presence of these sequences is unknown (Linnenbach et ah, 1989). Ep-CAM is 
found to be highly conserved in a range of species. This is seen with highly 
homologous sequences to the human GA733-2 gene, which encodes for Ep-CAM, 
found in monkey, hamster, and chicken genomes, and an 85% homology between 
murine and human forms of Ep-CAM (Bergsagel et ah, 1992). This related family of 
conserved proteins are associated almost exclusively with epithelial tissues 
(Linnenbach et ah, 1993; Borkowski et ah, 1996).
1.7.2.2 Structure of Ep-CAM Protein.
Ep-CAM does not have any structural similarities to the other four major types of cell 
adhesion proteins, such as cadherins, integrins, selectins and the immunoglobulin 
superfamily (Litvinov el ah, 1997). It thus may represent a new family of cell surface 
proteins. The Ep-CAM protein is a 314 amino acid, 40 kDa type I (single pass) 
transmembrane glycoprotein with an isoelectric point between 6.9 and 7.7 (Ross et 
ah, 1986; Linnenbach et ah, 1989).
Over 80% of the mature protein is expressed extracellularly. This N-terminal 
extracellular domain contains two cystine-rich EGF-like domains followed by a 
cystine poor region. The two EGF-like repeats overlap a thyroglobulin-like repeat. It 
also has a small domain homologous to nidogen (an extracellular laminin binding 
protein) and placental protein 12 (an IGF-1 binding protein), though it does not share 
any functional similarities (Simon et ah, 1990; Litvinov et al., 1994). The
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hydrophobic transmembrane region contains 21 amino acids. On the cytoplasmic side, 
there is a basic 4 amino acid stop transfer sequence which is followed by a short (26 
amino acid) cytoplasmic tail (Simon et al., 1990; Litvinov et a l, 1997), of which 9 are 
positively charged (Linnenbach et al., 1989). The extracellular region also contains 
three potential N-linked glycosylation sites (Asn-Xaa-Ser/Thr). Posttranslational 
glycosylation o f these sites increases the molecular weight from 34 kDa for the de 
novo protein to its final weight of approximately 40 kDa (Simon et al., 1990; Litvinov 
et al., 1994).
Comparison of the amino acid sequences of GA 733-1 and GA 733-2 (Ep-CAM) with 
alignment programs shows that the two proteins are 49% identical. However, when 
conserved substitutions are taken into account this increases to 67% homology. Strong 
conservation occurs with the position o f hydrophobic and hydrophilic residues in both 
antigens (Szala et al., 1990).
There exists two regions of high homology, one is located in the transmembrane 
region with the proteins sharing 97% homology. The other region of high homology is 
in the extracellular domain. This 39 residue region is 79% homologous. The 
homologous extracellular domain is in turn homologus to the type I repeat o f the 
thyrogloglobulin and (human leukocyte antigen-DR) HLA-DR associated invariant 
chains (Szala et al., 1990).
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1.7.3 FUNCTION AND MECHANISM OF Ep-CAM.
As stated earlier, Ep-CAM appears to be involved in cell-cell adhesion. Evidence for 
its role in cell-cell adhesion conies from in vitro studies which showed no 
involvement o f Ep-CAM in cell-substrate contacts on a number of substrates, rather 
Ep-CAM was present at areas o f intercellular contact (Litvinov et al., 1994). Its exact 
functions have yet to be determined, but it may play a role in cell segregation in 
multilayered epithelia and in the organisation o f epithelial tissues. Ep-CAM also is the 
main cell-cell adhesion molecule in most adenocarcinomas (Litvinov et al., 1994). 
The location o f Ep-CAM expressed on the membranes of highly differentiated cells is 
mainly in areas of intercellular contact. This differs from tumour cell where 
expression is homogenous on the cell membrane (Simon et al., 1990; Litvinov et al., 
1994).
Ep-CAM has been implicated in cell-cell sorting in a number of tissues, in particular, 
glandular epithelia. Where two layers o f epithelia are present Ep-CAM is not 
expressed in the basal layer. This differential expression may be important in sorting 
mature ductal and alveolar epithelial cells from a stem cell/myoepithelial cell 
population. Other organs where Ep-CAM cell segregation may play a function 
includes the pancreas and the sorting of p cells from non-P Islet cells, as P-islet cells 
are reported to express Ep-CAM (Litvinov et al., 1994). In human fetal pancreas the 
highest levels o f Ep-CAM expression occurs in developing P-islet-like cell clusters 
budding from the ductal epithelium, a cell compartment thought to comprise of 
endocrine progenitors. In the adult, the reverse pattern was observed with the P-islet 
cells exhibiting the lowest level of Ep-CAM and the ductal cells the highest. It was 
also shown that blockage of the Ep-CAM function by KS1/4 MAb induced insulin 
and glucagon gene transcription and translation in fetal pancreatic cell clusters (Cirulli 
et al., 1998).
In vitro aggregation studies with Ep-CAM-transfected and non-transfected cells 
showed that they aggregated separately (Litviniov et al., 1994). This can be explained 
in part by the finding that high Ep-CAM expression diminishes the effect o f other
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intercellular contacts (Litvinov et al., 1994; Litvinov el al., 1997). This feature is 
similar to that reported by Benchimol et al. (1989) for carcinoembryonic antigen.
These changes in intercellular adhesion are through alteration o f cadherin-mediated 
cell-cell adhesion (Litvinov et al., 1997). Transfection o f Ep-CAM into E-cadherin 
(E-CAD) positive cells did not reduce the number of E-CAD molecules, but rather 
caused a redistribution of them on the cell surface and a reduction in the number o f E- 
CAD mediated cell-cell adhesions (Litvinov et al., 1997). E-CAD interacts with the 
actin filament component of the cytoskeleton via a- and (3-catenins (figure 1.7.2(a)).
Investigation o f these interactions in Ep-CAM-transfected cells revealed a possible 
mechanism of action (Litvinov et al., 1997). In all cells (wild type and transfected), 
approximately similar levels of p-catenin was found irrespective of the level of Ep- 
CAM expression. There was however, a reduction in the p-catenin detergent insoluble 
fraction in transfected cells. O f more significance, was a reduction in both the total 
and detergent insoluble fractions of a-catenin (i.e. the fraction associated with the cell 
membrane focal adhesions). Thus, Ep-CAM expression effects E-CAD junctions by a 
reduction in a-catenin. Similar results were obtained in cells where the main cadherin 
is N-CAD, e.g. the human mammary cell line HBL-100. When the Ep-CAM levels 
are elevated in a cell, adhesion mediated by E-CAD and N-CAD is weakened and 
replaced with Ep-CAM intercellular adhesion, suggesting a co-ordination between the 
molecules rather then a simple anti-adhesion effect (Litvinov et al., 1997).
Induction of high levels of Ep-CAM also changes morphology and leads to a more 
scattered phenotype, although the cells still remain attached to each other. Cells 
transfected with a mutant Ep-CAM molecule, which was lacking the cytoplasmic 
domain showed no alteration to E-CAD distribution and binding (Litvinov et al.,
1997). This result implies that the cytoplasmic domain of Ep-CAM is important for 
the co-ordinated regulation o f the two molecules. Ep-CAM interacts with the actin- 
based cytoskeleton via a-actinin without the involvement of either a - or P-catenin 
(figure 1.7.2.(b)) (Balzar et al., 1998). Ep-CAM appears to possess two potential 
binding sites for a-actinin on its cytoplamic tail at positions 289 to 269 and 304 to 
314 (Balzar et al., 1998). This suggests that Ep-CAMs negative effect on cadherin
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junctions may be due to a redistribution o f a-actinin molecules away from cadherin 
molecules to Ep-CAM. An alternative mechanism may be Ep-CAM actively 
signalling which leads ultimately to a down-regulation o f a-catenin, This mechanism 
for action exists for ICAM-1 which down-regulates Pi integrin expression to which 
Ep-CAM possess some similarities (Litvinov et al., 1997).
E-cadherin is capable o f down-regulating Pi integrin expression during terminal 
differentiation in keratinocytes (Hodivala and Watt, 1994). Thus if Ep-CAM alters the 
function o f E-cadherin an increase in Pi-integrin should occur. Such a relationship can 
be observed in cervical intraepithelial neoplasia lesions where the expression o f Pi 
integrin is similar to that o f Ep-CAM (Litvinov et al., 1996).
Figure 1.7.2 Schematic diagram of E-Cadherin binding to the actin
cytoskeleton (A). Schematic diagram of Ep-CAM binding to the 
actin cytoskeleton (B). Note that in both cases a number of other 
proteins may also be involved to form focal adhesions e.g.
Vinculin.
An alternative function for the GA733 family has been suggested by study by Fomaro 
et al. (1995). They found that both GA733-1 and GA733-2 had homology to IGF-II
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binding proteins and could find no role for the proteins in cell adhesion. Ripani et al. 
(1998) found that the cytoplasmic tail of GA733-1 possesses potential serine and 
tyrosine phosphorylation sites and a phosphatidyl-inositol binding consensus 
sequence. Using antibodies against the protein, increased internal calcium levels were 
observed in MCF-7 (breast) and OvCA-432 (ovarian) cell lines. Thus, the alternative 
proposed function for the GA733 family is that o f a cell receptor for a yet unidentified 
ligand.
1.7.4 REGULATION OF Ep-CAM EXPRESSION.
The regulation o f Ep-CAM expression is still not fully elucidated. However, it does 
appear that cell density is important. In a series of experiments, Litivinov et al. (1994) 
observed that in cultures where single cells predominated (5% confluency), Ep-CAM 
was present at the pseudo-apical domains of the cell membrane. In cultures of greater 
density (70% confluency), the majority of Ep-CAM molecules relocated to the cell­
cell boundaries. The formation of intercellular contacts seems to cause a slight 
decrease in Ep-CAM at the surface, as shown by flow cytometry. Low calcium caused 
a slight decrease in surface expression in the differentiated cell lines RC-6 and MCF-7 
(Litivinov et al., 1994).
1.7.5 TISSUE DISTRIBUTION OF Ep-CAM.
Ep-CAM has a wide distribution in normal human epithelia, with expression to be 
found on most simple, columnar and pseudostratified epithelia e.g. bronchiolar and 
alveolar epithelial cells, mucous acinar cells in the gastrointestinal tract, pancreatic 
islet cells and thyroid follicular cells (Momberg et al., 1987). No Ep-CAM expression 
occurs in squamous stratified epithelial cells, epidermal keratinocytes, gastric parietal
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cells, fibroblasts, thymic cortical epithelium, myoepithelial cells, hepatocytes and the 
peripheral blood of bone marrow (Momberg et a l,  1987; Moldenhauer et a l , 1987; 
Pantel et a l ,  1993; Litvinov et al., 1994; Litvinov et al., 1996). As no expression of 
Ep-CAM is detected in peripheral blood of bone marrow with MAbs, it is considered 
a useful tumour marker for circulating tumour cells and bone marrow development 
(Momberg et a l ,  1987).
In most adenocarcinomas increased levels of Ep-CAM can be found (Varki et al., 
1984), and in carcinomas that originate from squamous epithelia, de novo expression 
of Ep-CAM can be observed (Litvinov et al., 1996). Particularly strong staining 
reactions are usually seen in colon carcinoma and small cell lung carcinoma cell lines 
(Moldenhauer et al., 1987). Ep-CAM is believed to function as the main intercellular 
adhesion protein for some carcinoma cells (Litvinov et al., 1994). The distribution of 
Ep-CAM on the cell membrane of the breast cell line RC-6 is different in single cells 
as compared to colonies. In single cells the molecule is distributed more widely to 
include the pseudoapical domain, but when two cells form a stable intercellular 
contact, the Ep-CAM molecules relocate to the lateral domains (Litvinov et al., 1994). 
The membrane distribution o f Ep-CAM differs between normal cells and tumour 
cells, with normal cells exhibiting an apolarised expression while tumour cells show a 
more homogenous staining (Simon et a l,  1990). For example, in normal glandular 
tissues e.g. mammary gland epithelium Ep-CAM is found localised mainly at cell-cell 
boundaries between epithelial cells. In some mammary carcinomas the intensity of 
staining may be less then in normal tissue with some showing an increase in 
cytoplasmic staining compared to membrane staining (Litvinov et a l, 1994). In a 
study by Moldenhauer et a l (1987) using the anti- Ep-CAM antibody HEA125 
against a panel of human cell lines, no reaction was observed in any of the non­
carcinoma cell lines used, which were derived from melanoma, neuroblastoma, 
sarcoma and leukaemia/lymphoma.
Litvinov et a l  (1996) investigated the expression of Ep-CAM in cervical squamous 
epithelia. It was noted that reserve cells, which are capable of differentiating into 
squamous epithelia both in vitro and in nude mice, expressed Ep-CAM. This normal 
expression o f Ep-CAM is repressed as soon as the trans-differentiating cells acquired 
the squamous phenotype. However, in dysplastic/neoplastic squamous epithelium this
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expression continues. The survey also showed that the appearance of Ep-CAM in 
cervical squamous epithelia correlated with loss of tissue-specific markers, including 
the markers for terminal differentiation of squamous epithelial cells and expression of 
markers for simple epithelia and enhanced proliferative activity. Cytokeratin 13 (a 
squamous differentiation related cytokeratin) expression was observed mainly in Ep- 
CAM negative regions of mature squamous metaplasia. Ep-CAM positive cells also 
failed to express involucrin (a marker o f terminal differentiation o f keratinocytes).
The expression patterns of simple epithelial cell cytokeratins 8 and 18 and of Ep- 
CAM were identical in metaplastic tissue o f the utrine cervix (Litvinov et al., 1996). 
The expression of Ki-67, a marker for proliferation, was found to be concurrent with 
Ep-CAM expression. Co-expression also occurred with cytokeratins 5 and 14, which 
mark proliferating cell populations. The expression of Ep-CAM in squamous cervix 
epithelia is clearly a disturbance of normal proliferation and differentiation, and 
reflects an early event in cervical carcinogenesis. Hence, Ep-CAM may serve as an 
early marker o f dysplastic/neoplastic changes in cervical squamous epithelium.
1.7.6 CLINICAL RELEVANCE OF Ep-CAM.
Ep-CAM is of clinical interest as a prognostic indicator (Varki et al., 1984; Songun el 
al., 1996), as a means of detecting metastatic cells in peripheral blood, microtumour 
visualisation via radioimmunolocalization (Momburg et al., 1987; Kievit at al., 1997) 
and as a possible target of various therapies.
Clinical interest exists in the detection of circulating tumour cells in peripheral blood 
as such detection may aid in the choice o f treatment given to a patient. For example, 
in treatments involving the use o f intensive high-dose chemotherapy combined with 
autologous bone marrow transplantation or peripheral stem cell reinfusion, the 
presence of contaminating tumour cells may worsen the prognosis (Helfrich et al., 
1997; de Graaf et al., 1997). As Ep-CAM has not been found with monoclonal 
antibodies on peripheral blood cells or bone marrow (Moldenhauer et al., 1987) to this
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end, RT-PCR of Ep-CAM has been investigated as a possible highly sensitive and 
reliable method of detection and quantification of circulating tumour cells (Helfrich el 
a l, 1997; de Graaf el al., 1997). Both labs found that this method was not reliable 
enough to use in a clinical situation. The potential problems included low level 
illegitimate (ectopic) expression of Ep-CAM in bone marrow and peripheral blood 
cells. The significance o f this illegitimate expression is not known, but similar 
expression has been found for cytokeratin 19 (Krissmann et al., 1995) and prostate- 
specific antigen (Smith et al., 1995) and PGP-9.5 (Norris et al., 1994).
It was also found that among a panel of cell lines, widely different levels of 
expression was detected with cell lines such as MDA-MB431 (breast carcinoma) and 
GLC4 (small-cell lung carcinoma) showing very low levels o f expression and cell 
lines such as MCF-7 (breast carcinoma) and T47D (breast carcinoma) showing very 
high levels of expression. Thus, quantification of the number of tumour cells present 
was not possible. In spiking experiments, de Graaf et al. (1997) could detect only one 
positive cell per 2 x 104 mononucleucocytes where as Helfrich et al. (1997) could 
detect one positive cell per 1 x 105 mononucleucocytes. Monoclonal antibody 
techniques can usually detect one carcinoma cell per lx l  04 - 5 x 105 
mononucleucocytes (de Graaf et al. 1997; Helfrich et al. 1997). Thus, further 
refinement is needed before RT-PCR is suited to a clinical setting. However, it may 
prove to be more reliable when used in conjunction with monoclonal antibody 
methods.
Due to its high expression in tumour cells, Ep-CAM has been tested for its ability to 
induce tumour kill by cytotoxic T lymphocytes. In a study by Ras et al. (1997) 410 
peptides derived from Ep-CAM were screened by their binding characteristics to the 
human leukocyte antigen, HLA-A*0201. From this, six peptides were selected for 
further studies. HLA-A*0210Kb transgenic mice were immunised with these peptides 
and the T lymphocytes were isolated from the spleens and tested for their ability to 
lyse Jurkat HLA-A*0210Kb cells exposed to peptide. Only one peptide, with the 
sequence GLKAGVIAV, showed a response. In a different approach, Kroesen et al. 
(1997) developed a chimeric MAb (called BIS-1) which has specificity for the CD3 
complex present on all T lymphocytes and is specific for Ep-CAM. The T-cells were 
pre-activated in vitro prior to treatment o f the carcinoma patients involved in the study
37
(who suffered from malignant ascites or interpleural effusions). Though the in vitro 
assays with the patients blood demonstrated anti-tumour activity and previous studies 
with rat models showed that BIS-l/IL-2 could be effective against low systemic 
tumour burdens, no clear clinical responses were observed in the patients (Kroesen et 
al., 1997).
Ep-CAM is o f interest to those investigating the use o f MAb conjugates for the 
treatment o f various malignancies. In one such study, Zimmerman et al. (1997) 
combined the MAb MOC31 with a recombinant form o f Pseudomonas exotoxin A, 
which lacks the cell-binding domain ETA252-613. This construct, at concentrations 
of 0.0InM to 0.3nM, gave a 50% inhibition in the growth of the small cell lung 
carcinoma (SCLC) and adenocarcinoma cell lines tested. In athymic mice, regression 
was seen in small (40 mm ) chemoresistant tumour xenografts. In larger tumours (120 
mm3), growth was delayed. In another study, Elias et al. (1990) evaluated a KS1/4- 
methotrexate immunoconjugate in patients with stage IIIB or IV NSCLC. Patients 
received a dose maximum of 1661 mg. The study yielded just one possible clinical 
response, which reveals the problems associated with MAb conjugated to 
chemotherapy agents, toxins, or radioisotopes infused into patients. As most 
monoclonal antibodies utilised are murine, treatment often elicits a human anti-murine 
antibody response. Such responses can cause IgE-mediated allergic reactions or even 
more serious type 3 immune responses with associated organ and/or tissue damage. 
Such reactions may also effect MAb distribution and may neutralise it or prevent 
adequate tumour binding. In a study looking at this anti-murine antibody response, 
Petersen et al. (1991) investigated two KS1/4 Vinca alkaloid conjugates KS1/4- 
desacetylvinblastine and KSl/4-desacetyl-vinblastine-3-carboxyhydrazide. In the 44 
patients treated, 32 elicited an anti-mouse antibody response.
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1.8 AIMS OF THESIS
Previous research in this laboratory has shown that the halogenated thymidine 
analogue, bromodeoxyuridine (BrdU) induces the in vitro differentiation of the lung 
cell lines DLKP and A549. This differentiation is indicated by induction of the early 
cytokeratins -8 , -18 and -19  (McBride et o l ,  1999; Meleady and Clynes, manuscript 
submitted). Also shown to be induced by BrdU are the integrins ai(3i and a2Pi (Paula 
Meleady, Ph.D thesis 1997, DCU). Preliminary research by Dr. Meleady indicated 
that the cell-cell adhesion molecule Ep-CAM was also induced in these cell lines 
following BrdU treatment.
1.8.1 THE ROLE OF EP-CAM IN EPITHELIAL LUNG CELL LINE 
DIFFERENTIATION.
♦ The main aim of this thesis to confirm, and expand on this preliminary result. 
Knowledge of the role and function of Ep-CAM in the differentiation o f epithelial 
lung cells is very limited. It was the aim o f this work to use the induction of 
differentiation in DLKP and A549 as models for the role of Ep-CAM in lung 
differentiation. In this thesis, the molecular mechanism by which BrdU modulates 
Ep-CAM induction was to be addressed. Such information may aid in the 
elucidation of the control o f expression of Ep-CAM in vivo.
♦ It is believed that Ep-CAM may cause an alteration in the levels of focal adhesion 
proteins, thereby modulating the function of other cell adhesion proteins; it may 
therefore have a role in cell-cell sorting. Another aim o f the work conducted in 
this thesis was to investigate the effect of Ep-CAM induction on two focal 
adhesion proteins, utilising BrdU-treated DLKP and A549 as models.
♦ It was also decided to perform preliminary research on the effect o f BrdU on the 
translation of GA733-1 (a homologue o f Ep-CAM). There is no literature 
available on the role of GA733-1 in differentiation, and only limited studies have 
been performed on its expression in vivo.
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1.8.2 THE EFFECT OF OTHER HALOGENATED THYMIDINE
ANALOGUES ON EPITHELIAL LUNG CELL DIFFERENTIATION.
♦ The halogenated thymidine analogue BrdU has been shown in this laboratory to 
induce the expression o f cytokeratin and integrin proteins. The ability o f other 
halogenated thymidine analogues to alter the expression of these proteins was also 
to be investigated.
♦ It was hoped that such an investigation would help us gain a better understanding 
o f the mechanisms by which differentiation may be regulated. Potentially, this 
knowledge could be used in the design of therapeutics for differentiation therapy.
1.8.3 THE DEVELOPMENT OF IN  VITRO  MODELS THAT REFLECTED 
I N  VIVO  DIFFERENTIATION.
♦ As part of our programme to design in vitro models of in vivo differentiation, we 
decided to build on the research of Emura (1997). Who described a complex 
hormone supplemented media that induced differentiation in hamster fetal 
epithelial lung cell line. Work presented in this thesis investigated if various 
modifications of the medium induced differentiation in the lung epithelial cell 
lines DLKP and A549. Further investigations were conducted to identify which 
were most significant modulators of differentiation, by the deletion of specific 
components of this media.
♦ Investigations were conducted into the development o f in vitro models that 
reflected in vivo differentiation. This involved the establishment of primary 
cultures of type II pneumocytes to represent normal cells and primary cultures of 
lung tumours to represent cancer states. In the course o f this study, fibroblast cells 
were isolated; unusually these were found to be cytokeratin positive. Preliminary 
investigations were conducted into the expression o f cytokeratin, by the fibroblast 
cells derived in the course of this thesis and by three primary cultures of 
fibroblasts sourced from other established culture collections.
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2.0 MATERIALS AND METHODS.
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2.1 WATER
Ultrapure water was used in the preparation of all media and solutions. This water 
was purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP) 
to a standard of 12 - 18 MQ/cm resistance.
2.2 GLASSWARE
All solutions for to cell culture and maintenance were prepared and stored in sterile 
glass bottles. Bottles (and lids) and all other glassware used for any cell-related work 
was prepared as follows: - all glassware and lids were soaked in a 2% (v/v) solution of 
RBS-25 (AGB Scientific) for at least 1-hour. This is a deproteinising agent, which 
removes proteineous material from the bottles. Glassware was scrubbed and rinsed 
several times in tap water, the bottles were then washed by machine using Neodisher 
detergent, an organic, phosphate-based acid detergent. The bottles were then rinsed 
twice with distilled water, once with ultrapure water and sterilised by autoclaving.
2.3 STERILISATION
Water, glassware and all thermostable solutions were sterilised by autoclaving at 
121 °C for 20 minutes (min) under pressure o f lbar. Thermolabile solutions were 
filtered through a 0.22^m sterile filter (Millipore, millex-gv, SLGV-025BS). Low 
protein-binding filters were used for all protein-containing solutions.
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2.4 MEDIA PREPARATION
Medium was routinely prepared and sterility checked by Mr. Joe Carey (technician) 
as in SOP NCTCC 003-02. The basal media used during routine cell culture were 
prepared according to the formulations shown in Table 2.4.1. lOx media were added 
to sterile ultrapure water, buffered with HEPES and NaHC0 3  and adjusted to a pH of 
7.45 - 7.55 using sterile 1.5M NaOH and 1.5M HC1. The media were then filtered 
through sterile 0.22(j.m bell filters (Gelman, 121-58) and stored in 500ml sterile 
bottles at 4°C. Sterility checks were carried out on each 500ml bottle o f medium as 
described in Section 2.5.5.
The basal media were stored at 4°C up to their expiry dates as specified on each 
individual lOx medium container. Working stocks of culture media was prepared as 
100ml aliquots, supplemented with 2mM L-glutamine (Gibco, 25030-024) and 5% 
fetal calf serum (Bio-Whittaker; 14-601F, Lot No.- 55B007; Sigma, F7524, Lot No.- 
48H3377). This was stored for up to 2 weeks at 4°C, after which time, fresh culture 
medium was prepared.
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DMEM
(Gibco, 12501- 
029)
Hams F12
(Gibco, 21700- 
109)
MEM
(Gibco, 21430- 
020)
10X Medium 500ml Powder 500ml
Ultrapure H2O 4300ml 4700ml 4300ml
1M HEPES*
Sigm a, H-9136
100ml 100ml 100ml
7.5% NaHCOs
BDH, 30151
45ml 45ml 45ml
* HEPES = N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
Table 2.4.1 Preparation of basal media
For most cell lines, ATCC (Ham’s F 12/ DMEM (1:1)) supplemented with 5% FCS 
and 2mM L-glutamine was routinely used. MEM was supplemented with 5% FCS, 
2mM L-glutamine, lx  NEAA (Gibco, 11140-035) and lx  sodium pyruvate (Gibco, 
11360-039).
2.5 CELL LINES
All cell culture work was carried out in a class II down-flow re-circulating laminar 
flow cabinet (Nuaire Biological Cabinet) and any work, which involved toxic 
compounds, was carried out in a cytoguard (Gelman). Strict aseptic techniques were 
adhered to at all times. The laminar flow cabinet was swabbed with 70% industrial 
methylated spirits (IMS) before and after use, as were all items used in the cabinet. 
Each cell line was assigned specific media and waste bottles and only one cell line 
was worked with at a time in the cabinet which was allowed to clear for 15min 
between different cell lines. The cabinet itself was cleaned each week with industrial
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detergents (Virkon, Antec. International; TEGO, TH.Goldschmidt Ltd.), as were the 
incubators.
The cell lines used during the course of this study, their sources and their basal media
* •  •  2 requirements are listed in Table 2.5.1. Lines were maintained in 25cm flasks (Costar;
3050) or 75cm2 flasks (Costar; 3075) at 37°C and fed every two to three days.
2.5.1 SUBCULTURE OF ADHERENT LINES
During routine sub-culturing or harvesting of adherent lines, cells were removed from 
their flasks by enzymatic detachment.
Waste medium was removed from the flasks and rinsed with a pre-warmed (37°C) 
trypsin/EDTA (TV) solution (0.25% trypsin (Gibco, 25090-028), 0.01% EDTA 
(Sigma, EDS) solution in PBS A (Oxoid, BR14a)). The purpose of this was to inhibit 
any naturally occurring trypsin inhibitor, which would be present in residual serum.
      ^ o
Fresh TV was then placed on the cells (2ml/25cm flask or 4ml/75cm flask) and the 
flasks incubated at 37°C until the cells were seen to have detached (5-10 min). The 
trypsin was deactivated by addition of an equal volume of growth medium (i.e. 
containing 5% serum). The entire solution was transferred to a 30ml sterile universal 
tube (Sterilin; 128a) and centrifuged at 1,000 rpm for 5 min. The resulting cell pellet 
was resuspended in pre-warmed (37°C) fresh growth medium, counted (Section 2.5.3) 
and used to re-seed a flask at the required cell density or to set up an assay.
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Cell Line Cell Type Source Basal Medium
DLKP Human poorly- 
differentiated lung 
carcinoma
Dr. Geraldine Grant, 
NCTCC
Hams F-12:DME 
(1:1) (ATCC).
A549 Human lung 
adenocarcinoma
ATCC 
American Type 
Culture Collection
Hams F-12:DME 
(1:1) (ATCC).
MCF-7 Human breast carcinoma ATCC 
American Type 
Culture Collection
MEM
Table 2.5.1 Cell lines used during the course of study.
2.5.3 CELL COUNTING
Cell counting and viability determinations were carried out using a trypan-blue 
(Gibco, 15250-012) dye exclusion technique.
An aliquot of trypan-blue was added to a sample from a single cell suspension in a 
ratio of 1:5. After 3 min incubation at room temperature, a sample of this mixture was 
applied to the chamber of a haemocytometer over which a glass coverslip had been 
placed. Cells in the 16 squares of the four outer corner grids of the chamber were 
counted microscopically, an average per comer grid was calculated with the dilution 
factor being taken into account and final cell numbers were multiplied by 104 to 
determine the number of cells per ml (volume occupied by sample in chamber is 
0.1cm x 0.1cm x 0.01cm i.e. 0.0001cm3 therefore cell number x 104 is equivalent to 
cells per ml). Non-viable cells were those, which stained blue while viable cells 
excluded the trypan-blue dye and remained unstained.
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2.5.4 CELL FREEZING
To allow long term storage o f cell stocks, cells were frozen and cryo-preserved in 
liquid nitrogen at temperatures below -180°C. Once frozen properly, such stocks 
should last indefinitely.
Cells to be frozen were harvested in the log phase o f growth (i.e. actively growing and 
approximately 50-70% confluent) and counted as described in Sections 2.5.3. 
Pelleted cells were re-suspended in serum and an equal volume of a DMSO/serum 
(1:9, v/v). The solution was slowly added drop-wise to the cell suspension, as DMSO 
is toxic to cells. A final concentration of at least 5x106 cells/ml was generated. The 
suspension was then aliquoted into cryovials (Greiner, 122 278) which were then 
quickly placed in the vapour phase o f liquid nitrogen containers (approximately - 
80°C). After 2.5 to 3.5 hours, the cryovials were lowered down into the liquid 
nitrogen where they were stored until required.
2.5.5 CELL THAWING
Immediately prior to the removal of a cryovial from the liquid nitrogen stores for 
thawing, a sterile universal tube containing growth medium was prepared for the rapid 
transfer and dilution of thawed cells to reduce their exposure time to the DMSO 
freezing solution which is toxic at room temperature. The suspension was centrifuged 
at 1,000 rpm. for 5 min, the DMSO-containing supernatant removed and the pellet re­
suspended in fresh growth medium. A viability count was carried out (Section 2.5.3)
to determine the efficacy of the freezing/ thawing procedures. Thawed cells were
• 2placed into tissue culture flasks with the appropriate volume of medium (10ml/25cm 
flask and 15ml/75cm2 flask) and allowed to attach overnight. After 24 hours, the cells 
were re-fed with fresh medium to remove any residual traces o f DMSO.
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2.5.6 STERILITY CHECKS
Sterility checks were routinely carried out on all media, supplements and trypsin used 
for cell culture. Samples o f basal media were inoculated into Columbia (Oxoid, 
CM331) blood agar plates, Sabauraud (Oxoid, CM217) dextrose and Thioglycollate 
(Oxoid, CM173) broth’s which should between them detect most contaminants 
including bacteria, fungus and yeast. Growth media (i.e. supplemented with serum 
and L-glutamine) were sterility checked at least 2 days prior to use by incubating 
samples at 37°C which were subsequently examined for turbidity and other 
indications of contamination.
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2.6 MYCOPLASMA ANALYSIS
Mycoplasma examinations were carried out routinely (at least every 3 months) on all 
cell lines used in this study. These analyses were performed by Dr. Mary Heenan, 
Ms. Bojana Cumpf, and Mr. Michael Henry.
2.6.1 INDIRECT STAINING PROCEDURE
In this procedure, Mycoplasma-nQgaXi\Q NRK cells (a normal rat kidney fibroblast 
line) were used as indicator cells. As such, these cells were incubated with 
supernatant from test cell lines and then examined for Mycoplasma contamination. 
NRK cells were used for this procedure because cell integrity is well maintained 
during fixation. A fluorescent Hoechst stain was utilised which binds specifically to 
DNA and so will stain the nucleus of the cell in addition to any Mycoplasma DNA 
present. A Mycoplasma infection would thus be seen as small fluorescent bodies in 
the cytoplasm of the NRK cells and sometimes outside the cells.
NRK cells were seeded onto sterile coverslips in sterile Petri dishes at a cell density of 
2 x l03 cells per ml and allowed to attach overnight at 37°C in a 5% CO2, humidified 
incubator. 1ml of cell-free (cleared by centrifugation at 1,000 rpm for 5 min) 
supernatant from each test cell line was then inoculated onto a NRK Petri dish and 
incubated as before until the cells reached 20 - 50% confluency (4-5 days). After this 
time, the waste medium was removed from the Petri dishes, the coverslips washed 
twice with sterile PBS A, once with a cold PBS/Carnoys (50/50) solution and fixed 
with 2ml of Carnoys solution (acetic acid:methanol-l:3)for 10 min. The fixative was 
then removed and after air drying, the coverslips were washed twice in deionised 
water and stained with 2ml of Hoechst 33258 stain (BDH)(50ng/ml) for 10 min.
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From this point on, work proceeded in the dark to limit quenching o f the fluorescent 
stain.
The coverslips were rinsed three times in PBS. They were then mounted in 50% (v/v) 
glycerol in 0.05M citric acid and 0.1M disodium phosphate and examined using a 
fluorescent microscope with a UV filter.
2.6.2 DIRECT STAINING
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an enriched Mycoplasma culture broth (Oxoid, CM403) - 
supplemented with 16% serum. 0.002% DNA (BDH; 42026), 2mg/ml fungizone 
(Gibco, 15290-026), 2 x l0 3 units penicillin (Sigma, Pen-3) and 10ml of a 25% (w/v) 
yeast extract solution - to optimise growth of any contaminants and incubated at 37°C 
for 48 hours. Sample of this broth were then streaked onto plates of Mycoplasma agar 
base (Oxoid, CM401) which had also been supplemented as above and the plates were 
incubated for 3 weeks at 37°C in a CO2 environment. The plates were viewed 
microscopically at least every 7 days and the appearance of small, “fried egg” -shaped 
colonies would be indicative o f a mycoplasma infection.
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2.7 DIFFERENTIATION STUDIES
2.7.1 HALOGENATED THYMIDINE ANALOGUES.
Differentiation studies were conducted using various halogenated thymidine 
analogues. The preparation, source, and final concentration o f usage are summarised 
in table 2.7.1. All compounds were stored at -20°C
Compound Source and Cat 
No.
Stock
Concentration
Treatment
Concentration
5-Bromo-2’-
DeoxyUridine
(BrdU)
Sigma, B5002 1 OmM in sterile 
UHP, and filter 
sterilise.
lOfxM
5-Fluro-5’-
DeoxyUridinc
(5,5'-5,5'-FdU)
Sigma F8791 lOmM in sterile 
UHP, and filter 
sterilise.
2 |iM
5-Chloro-2’-
DeoxyUridine
(CdU)
Sigma, C6891 1 OmM in sterile 
UHP, and filter 
sterilise.
lOfxM
5-BromoUridine
(5-BUr)
Sigma, B9752 1 OmM in sterile 
UHP, and filter 
sterilise.
70(iM
Table 2.7.1 Halogenated thymidine anloges used in differentiation studies.
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2.7.2 HORMONE SUPPLEMENTED MEDIUM.
Differentiation studies were conducted using a hormone supplemented medium 
(HSM). To ATCC supplemented with 5% FCS, and 2mM L-glutamine was added the 
components in the concentrations stated in table 2.7.2. This was prepared on the day 
of use.
Component Source and Cat. No. Final Concentration.
Insulin Sigma; I 1882 8|^g/ml
Hydrocortisone Sigma; H 0135 3fJ.g/ml
Oestrogen Sigma; E 2257 2.7r|g/ml
Epidermal Growth 
Factor (EGF)
Sigma; E 1264 20rig/ml
Cholera Toxin Sigma; C 8052 0.25fig/ml
Table 2.7.2 Components used for the preparation of HSM.
2.7.3 DIFFERENTIATION ASSAYS. IMMUNOCYTOCHEMISTRY.
2.7.3.1 Immunocytochemistry. Preparation of sample.
In all experiments, cells were plated onto 6-well plates (Costar, 3516) at densities of 
5x103 per well for DLKP and A549 1.5ml o f medium was sufficient for each well. 
The cells were allowed to attach and form colonies by incubating at 37°C, 5% CO2 for 
48 hours. The plates were covered with parafilm to prevent contamination. The 
medium was then removed and replaced with medium with the required 
concentrations o f halogenated thymidine analogue, or with HSM. Plates were 
wrapped in aluminium foil because of the light-sensitive nature of some of the 
compounds being used e.g. oestrogen. The plates were incubated for up to 7 days. 
Medium was replaced every 2-3 days over the course of the assay. All waste medium
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was retained for disposal by incineration.
At the end of the assay, medium was removed from the cells, the plates were rinsed 3 
times with PBS A and the cells were fixed with methanol as described in Section 
2.7.3.2. Immunocytochemistry was the carried out using a range of antibodies as 
described in Section 2.7.3.3.
2.132  Immunocytochemistry. Fixation of cells.
This procedure was used for all cells whether they were grown on 6-well plates, 
multiwell slides, or cytospins had been prepared from them. For fixation, cells were 
rinsed 3 times with PBS A and then incubated at -20°C for 7 minutes using ice-cold 
methanol. The methanol was the removed from the cells and the cells were allowed to 
air-dry for a number of hours or overnight and then stored at -20°C until required. 
This method appeared to be successful for all antibodies investigated during the 
course of the study.
2 .133  Immunocytochemistry. Procedure.
The avidin-biotin complex (ABC) immunoperoxidase technique combined with the 
diaminobenzidine (DAB) visualisation procedure was used in all 
immunocytochemistry experiments. The ABC method involves application of a 
biotin-labelled secondary antibody to cells probed with a primary antibody, followed 
by the addition of avidin-biotin-peroxidase complex which results in a high staining 
intensity due to the formation of an avidin-biotin lattice which contains peroxidase 
molecules. The peroxidase enzyme then reacts with a DAB solution to give an 
insoluble, brown-coloured precipitate. The formation of this brown precipitate- 
coloured precipitate is indicative of primary antibody reactivity.
The procedure used is as follows:
Cell preparations (cytospins, multiwell slides, 6-well tissue culture plates) which had 
been previously fixed in methanol and frozen at -20°C were allowed to thaw and 
equilibrate at room temperature. A grease pen (DAKO, S2002) was used to encircle
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cells on cytospins, multiwell slides and in tissue culture plates to contain the various 
solutions involved. The cells were incubated for 5 minutes with a 3% H2O2 solution 
to quench any endogenous peroxidase activity that may be present in the cells and 
could lead to false positive results. The cells were then rinsed with UHP water and 
placed in Tris-buffered saline (TBS) (0.05M Tris/HCl, 0.15M NaCl, pH 7.6) for 5 
minutes. The slides were then incubated for 20 minutes at room temperature (RT) 
with normal rabbit serum (DAKO, X092) diluted 1:5 in TBS to block non-specific 
binding. This was then removed and 25-30pl o f optimally diluted primary antibody 
was placed on the cells. The slides and tissue-culture plates were placed on a tray 
containing moistened tissue paper and incubated at 37°C for 2 hours. The primary 
antibodies used in the study are listed in Table 2.7.3. The slides were then rinsed in 
TBS/ 0.1% Tween (Sigma, P-1379), x3 in 15 min, and then incubated for 30 min with 
biotinylated rabbit anti-mouse immunoglobulins (DAKO, E354) diluted 1:300 in 
TBS. The slides were rinsed as before and incubated with strepABComplex/ Horse 
Radish Peroxidase (HRP) (DAKO, K377) for 30 min at RT, after they were rinsed x3 
in TBS/ 0.1% Tween in 15 min. The cells were then incubated with a DAB solution 
(DAKO, S3000) for 10-15 min. Excess DAB solution was then rinsed off with UHP 
water and the slides were counter-stained with a 3% methyl green (Sigma, M-5015). 
Slides were then mounted using a commercial mounting solution (DAKO, S3023).
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Antibody Dilution Supplier Catalogue No.
323/A3
(anti-Ep-CAM) *
1 : 150 NeoMarkers MS-181-P1
Ep-CAM Abl 
(VU-1D9) *
1 : 150 NeoMarkers MS-144-P1
Cytokcratin-8 1 : 200 Sigma C 5301
Cytokeratin-18 1 : 800 Sigma C 8541
Cytokcratin-19 1 : 50 Sigma C 6930
Pan-Cytokeratin 1 : 100 Sigma C 2562
Bi-Intcgrin 1 : 100 Serotech MCA 1188
* These anti-bodies were used together to increase sensitivity.
Table 2.7.3 Primary antibodies used in immunocytochcmical studies.
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2.7.4 DIFFERENTIATION STUDIES. WESTERN BLOT ANALYSIS.
Proteins for western blot analysis were separated by SDS-polyacylamide gel 
electrophoresis (SDS-PAGE).
2.7.4.1 Sample preparation
Cells were inoculated into 75cm2 flasks at a density of lx lO 5 cells per flask and 
allowed to attach and form colonies. Medium, at concentrations from 0-1 OuM. was 
then added to the cells after 48 hours. The medium was then removed and replaced 
with medium with the required concentrations of halogenated thymidine analogue, or 
with HSM. Flasks were wrapped in aluminium foil because of the light-sensitive 
nature o f some o f the compounds being used e.g. oestrogen. The flasks were 
incubated for 7 and 14 days. Medium was replaced every 2-3 days over the course of 
the assay. All waste medium was retained for disposal by incineration. The cells were 
then harvested by trypsinisation, washed three times in cold, sterile PBS A, pelleted 
and stored at -80°C until required.
Cells were then lysed in buffer containing 62.5mM Tris-HCl pH 6.8, 12.5% glycerol, 
2% Nonidet P40 (Sigma, N6507), 2.5mM phenylmethylsulphonyl fluoride (PMSF) 
(Sigma, P7626), 1.25mM EDTA, 12.5(j.g/ml leupeptin (Sigma, L2884), 116|j.g/ml 
aprotinin (Sigma, A 1153) for 30 min on ice. The extracts were used immediately for 
western blot analysis.
2.7.4.2 Gel electrophoresis
Resolving and stacking gels were prepared as outlined in Table 2.7.4 and poured into 
clean 10cm x 8cm gel cassettes which consisted of 1 glass and 1 aluminium plate, 
separated by 0.75cm plastic spacers. The resolving gel was poured first and allowed 
to set. The stacking gel was then poured and a comb was placed into the stacking gel 
in order to create wells for sample loading. Once set, the gels could be used 
immediately or wrapped in aluminium foil and stored at 4°C for 24 hours.
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Before samples were loaded onto the stacking gels, equal cell numbers (usually 2x104 
cells per lane) were further lysed in 2x loading buffer (2.5ml 1.25M-Tris/HCl, l.Og 
SDS, 5.8ml glycerol and 0.1% bromophenol blue (Sigma, B8026) made up to 25ml 
with distilled water). The samples were then loaded including 6(al of molecular weight 
colour protein markers (Sigma, C-3437). The gels were run at 250V, 45mA for 
approximately 1.5 hours. When the bromophenol blue dye front was seen to have 
reached the end o f the gels, electrophoresis was stopped.
Components Resolving gel 
(7.5%)
Resolving gel 
(12%)
Stacking gel
Acrylamide stock* 3.8ml 5.25ml 0.8ml
Ultrapure water 8.0ml 6.45ml 3.6ml
1,875M-Tris/HCl, pH 8.8 3.0ml 3.0ml -
1.25M-Tris/HCl, pH 6.8 - - 0.5ml
10% SDS (Sigma, L-4509) 150jil 150fj,l 50(il
10% Ammonium 
persulphate 
(Sigma, A-1433)
60(0,1 60(j.l 17 pi
TEMED 
(Sigma, T-8133)
lOfal I0[i\ 6 pi
Acrylamide stock = 29.lg  acrylamide (Sigma, A-8887) and 0.9g N N ’-methylene bis- 
acrylamide (Sigma, N-7256) made up to 100ml with distilled water 
Table 2.7.4. Preparation of electrophoresis gels
2.7.4.3 Western blotting
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer 
(25mM Tris, 192mM glycine (Sigma, G-7126) pH 8.3-8.5 without adjusting) for 20 
min. Protein in gels were transferred onto Hybond ECL nitrocellulose membranes
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(Amersham, RPN 2020D) by semi-dry electroblotting. Five sheets o f Whatman 3mm 
filter paper (Whatman, 1001824) were soaked in transfer buffer and placed on the 
cathode plate o f a semi-dry blotting apparatus. Excess air was removed from between 
the filters by moving a glass pipette over the filter paper. Nitrocellulose, cut to the 
same size of the gel, was soaked in transfer buffer and placed over the filter paper, 
making sure there were no air bubbles. The acrylamide gel was placed over the 
nitrocellulose and five more sheets o f pre-soaked filter paper were placed on top of 
the gel. Excess air was again removed by rolling the pipette over the filter paper. The 
proteins were transferred from the gel to the nitrocellulose at a current o f 34mA at 
15V for 23 min.
All incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus to ensure even exposure o f the nitrocellulose blot to all reagents.
The nitrocellulose membranes were blocked for 2 hours at room temperature with 
fresh filtered 5% non-fat dried milk (Cadburys; Marvel skimmed milk) in TBS/ 0.1% 
Tween. pH 7.5.
After blocking, the membranes were rinsed with PBS A and incubated with primary 
antibody (table 7.2.5) overnight at 4°C. The primary antibody was removed and the 
membranes rinsed 3 times with TBS/ 0.1% Tween. The membranes were then washed 
for 15 min, and then twice for 5 mins in TBS/ Tween. Bound antibody was detected 
using enhanced chemiluminescence (ECL).
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Antibody Dilution Supplier Catalogue No.
323/A3
(anti-Ep-CAM) *
1 : 300 NeoMarkers MS-181-P1
Ep-CAM A bl 
(VU-1D9) *
1 : 300 NeoMarkers MS-144-P1
Cytokeratin-8 1 : 400 Sigma C-5301
Cytokeratin-18 1 : 1000 Sigma C8541
Cytokeratin-19 1 : 300 Sigma C-6930
Bi Integrin 1 : 10,000 Chemicon AB1937
Table 2.4.5 Primary antibodies used in western blot analysis.
2.7.4.5 Enhanced chemiluminescence detection
Protein bands were developed using the Enhanced Chemiluminescence Kit (ECL) 
(Amersham, RPN2109) according to the manufacturer’s instructions.
Secondary antibody (1/1,000 dilution of anti-mouse IgG peroxidase conjugate 
(Sigma, A-6782) in TBS) was added for 1 hour. The secondary antibody was 
removed and the membranes were washed as before. A sheet o f parafilm was 
flattened over a smooth surface, e.g. a glass plate, making sure all air bubbles were 
removed. The membrane was then placed on the parafilm, and excess fluid removed. 
1.5ml o f ECL detection reagent 1 and 1.5ml o f reagent 2 were mixed and covered 
over the membrane. Charges on the parafilm ensured the fluid stayed on the 
membrane. The reagent was removed after one minute and the membrane wrapped in 
cling film. The membrane was exposed to autoradiographic film (Kodak; X-OMAT 
S, 500 9907) in an autoradiographic cassette for various times, depending on the
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signal. The autoradiographic film was then developed.
The exposed film was developed for 5min in developer (Kodak, LX24) diluted 1:6.5 
in water. The film was briefly immersed in water and transferred to a Fixer solution 
(Kodak, FX-40) diluted 1:5 in water, for 5min. The film was transferred to water for 5 
min and then air-dried.
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2.8 RNA EXTRACTION
For all procedures using RNA, most glassware, solutions and plastics were treated 
with 0.1% diethyl pyrocarbonate (DEPC) before use, which is a strong inhibitor of 
RNases.
RNA was extracted from the cells as follows:
Cells were seeded into 175cm2 flasks (Nunc, I-56502A) at a density of approximately 
2x l06 per flask and allowed to attach and form colonies for 48-72 hours at 37°C. The 
flasks were then treated with BrdU for time periods of 7 and 14 days. The cells were 
trypsinised and the pellet was washed once with PBS A. The cells were pelletted and 
lysed using 1ml of TRI REAGENT™ (Sigma, T-9424). The samples were allowed to 
stand for 5 min at RT to allow complete dissociation of nucleoprotein complexes. 
0.2ml of chlorofom was then added per ml of TRI REAGENT™ used and the sample 
was shaken vigorously for 15 sec and allowed to stand for 15 min at RT. The sample 
was then centrifuged at 13000rpm for 15 min at 4°C. This step separated the mixture 
into 3 phases; the RNA was contained in the colourless upper aqueous layer. This 
layer was then transferred to a new Eppendorf and 0.5ml o f isopropanol was added. 
The sample was mixed and allowed to stand at RT for 10 min before being 
centrifuged at 13000rpm for 10 min at 4 C. The RNA formed a precipitate at the 
bottom of the tube. The supernatant was removed and the pellet was washed with 1ml 
of 75% ethanol and centrifuged at 4°C for 5 min at 13000rpm. The supernatant was 
removed and the pellet was briefly allowed to air-dry. 20-30(0.1 of DEP-C water was 
then added to the RNA to resuspend the pellet.
RNA concentration was calculated by determining its OD at 260nm and 280nm and 
using the following formula:-
OD260nm x Dilution factor x 40 = (og/ml RNA
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The purity of the RNA extraction was calculated by determining its OD at 260nm and 
280nm. An A260nm : A280nm ratio of 2 is indicative of pure RNA. Only those samples 
with ratios between 1.7 and 2.1 were used.
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2.9 REVERSE TRANSCRIPTASE REACTION
Reverse transcriptase (RT) reactions were carried out in laminar flow cabinets using 
micropipettes, which were specifically allocated to this work.
cDNA was formed using the following procedure 
lfj,l oligo (dT)12'18 primers (l|ig/|ol) (Promega; C l 101) 
l(il total RNA (l|ig/|al) (see 2.20)
3fal water
Were mixed in a 0.5ml Eppendorf (Eppendorf, 0030 121.023), heated to 70°_C for 10
min and then chilled on ice. To this, the following were added:-
4|ol of a 5x buffer (250mM-Tris/HCl pH 8.3, 375mM-KCl and 15mM-MgCl2)
2|_il DTT (lOOmM) (Gibco; 510-8025 SA)
1 fol RNasin (4011/^1) (Promega; N 2511)
1 (j,l dNTPs (lOmM of each dNTP)
6fal water
1 (al Moloney murine leukaemia virus-reverse transcriptase (MMLY-RT) (40,000U/(j,l) 
(Gibco; 510-8025 SA).
The solutions were mixed and the RT reaction was carried out by incubating the 
Eppendorfs at 37°C for 1 hour. The MMLV-RT enzyme was then inactivated by 
heating to 95°C for 2 min. The cDNA was stored at -20°C until required for use in 
PCR reactions as outlined in Section 2.10.
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2.10 POLYMERASE CHAIN REACTION
A standardised polymerase chain reaction (PCR) procedure was followed in this 
study. The Eppendorf tubes used (Eppendorf, 0030 121 023) and the sterile water 
were DEPC-treated. All reagents had been aliquoted and were stored at -20°C  and all 
reactions were carried out in a laminar flow cabinet.
Each PCR tube contained the following:-
24.5 jj.1 water
5|ol lOx buffer* (lOOmM-Tris/HCl, pH 9.0, 50mM-KCl, 1% Triton X-100)
3(ji 25mM-MgCl2*
8(j,l dNTPs (1.25mM each o f dATP, dCTP, dGTP and dTTP) (Promega; U1240) 
l|j,l each o f first and second strand target primers (250ng/ml) (keratin 19 - Table 
2 .22 .1)
1 (al each o f first and second strand endogenous control primer (250ng/ml) (P-actin)
0.5|ol of 5U/)ol Taq DNA polymerase enzyme*
5(^ 1 cDNA 
*(Promega; N1862)
A drop of autoclaved mineral oil was placed in each reaction tube to prevent 
evaporation and the DNA was amplified by PCR as follows:
95°C for 1.5 min - to denature double-stranded DNA 
30 cycles: 95°C for 1.5 min. - denature
55°C for 1 min - anneal 
72°C for 3 min. - extend 
72°C for 7 min. - extend 
The reaction tubes were then stored at 4°C until analysed by gel electrophoresis as 
described in Section 2.13.
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2.11 GUIDELINES USED IN THE SELECTION OF PRIMERS.
To successfully amplify cDNA by PCR, specific primers to the gene of interest must be 
chosen to prime the cDNA for PCR amplification, a number of guidelines should be 
followed, when feasible, to design the primer pair to give successful amplification of a 
PCR product of suitable size.
♦ Specificity to the gene of interest: The fundamental requirement for a primer is that 
it should hybridise efficiently to the sequence/genes of interest with negligible 
hybridisation to other sequences/genes present in the sample. To find the most 
homologous sequences to be used as primers, DNA bases (such as the one held by 
EMBL) must be searched.
♦ Target length: The distance between the primers for which optimum amplification 
can be achieved is generally considered to between 180 and 500 bp. However, much 
longer targets may be amplified efficiently.
♦ Primer length and base composition: The length of a primer contributes to its 
specificity. It is generally considered ideal to choose oligonucleotide primers 
between 18 and 30 bases in length; however, shorter and longer primers will work. 
Long stretches of purines or pyrimidines must also be avoided. If possible primers 
should have a balanced G/C and A/T concentration and the distribution of bases 
should be as random as possible. These precautions are required to avoid areas of 
secondary structure formation or complimentarily between primers.
♦ Annealing temperature: The annealing temperature of primers is determined by 
their length and base composition. Increasing this temperature enhances 
discrimination against incorrectly annealing primers and so reduces the extension of 
incorrect nucleotides at the 3' end of the primer. It is considered advisable to choose 
primers whose melting temperature (Tm) (i.e. the temperature at which half o f the 
duplex is dissociated are between 55°C and 75°C. The Tm for a primer can be 
estimated from the following equation:
Tm=2°C (no. of A+T residues) 4°C (no. of G+C residues)
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Gene Primer Sequence/cDNA position Product size/ Reference
Cytokeratin-8
AAC AAC CTT AGG CGG CAG CT 
(cDNA position 449-468) 244 bp
Burchill et al., 1995GCC TGA GGA AGT TGA TCT CG (cDNA 
position 673-692)
Cytokeratin-18
CAA GAT CAT CGA AGG ACC TG
(cDNA position 436-454)
444bp
designed from corresponding 
rat primers in Fridm acher et 
al., 1995
CTC TCC TCA ATC TGC TGA GA 
(cDNA position 860-879)
Cytokeratin-19
GCG GGA CAA GAT TCT TGG TG
Burchill et al. (1995)CTT CAG GCC TTC GAT CTG CAT
Ep-CAM
(GA733-2)
CTG TCA TTT GCT CAA AGC TG 
(cDNA position 167-186) 368bp
Designed at NCTCCTGG ATC CAG TTG ATA ACG 
(cDNA position 517-534)
GA733-1
CAC ACC GAC GTC TGG TTG CA (cDNA 
position 355-374) 164bp
Designed at NCTCCTCC AAG TGT CTG CTG CTC A 
(cDNA position 211-229)
Table 2.8.1 Primer sequences used in RT-PCR reactions.
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2.12 USING cDNA SEQUENCE DATABASES TO CHECK 
UNIQUENESS OF PRIMERS (BLAST).
The most critical element in choice of primers for PCR is obviously that the primers 
were unique i. e. that they did not cross-react with sequences likely to be present in the 
mRNA of the cells/tissues being studied. This involved choosing primers using the 
criteria described in Section 2.11, and checking via a DNA database (e.g. EMBL, 
GenBank) what similar sequences existed. This approach is essential if  no references 
are available on RT-PCR of the mRNA in question. Even where references do exist, 
there is need for checking because:
I. The cDNA data-base is expanding rapidly and new cross-reactions may have
been discovered since the choice of primers was published;
II. Occasionally, published primers have not been well chosen and cross­
reactions have been overlooked; also, occasionally, probably due to
typographical errors, incorrect primer sequences are published.
III. Because o f the excellent search facilities available, checking sequence
uniqueness of primer sequences is a straightforward procedure.
DNA databases were accessed via the Internet by linking to large mainframe 
computers (e.g. VAX) and connecting to a UNIX system run by the Irish National 
Centre for Bioinformatics, Trinity College, Dublin.
• A mRNA or cDNA sequence of interest can be extracted from the database once 
its name(s) is known. (If the accession number or sequence deposition number are 
known these can be used to in a similar way). The following is an example of how 
to access a mRNA sequence through this system.
LOCATION: http://www3.ncbi.nlm.nih.gov/Entrez/nucleotide.htm
Then enter name of the sequence required e.g. GA733-1 [Enter]
The response to this is a list of sequences submitted which have GA733-1 as part of 
their name - including full and partial cDNA sequences from various species of 
origin. The sequence required for these studies was identified in this list as "human 
mRNA for pancreatic carcinoma marker GA733-1"; accession number: X13425.
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To reveal the complete mRNA sequence, the option GenBank Report was selected.
• BLAST (Basic Local Alignment Search Tool), a set o f similarity search programs 
designed to explore all o f the available sequence data-bases was used for 
homology searching of primers being considered as potentially suitable. The 
following is an example of how such a search was done to identify suitable 
primers.
LOCATION: http://acer.geu.tcd.ie
Select option: Biolnf Servers
Select option: US (NCBI) Servers: Blast server at NCBI
(An option to check the European (EBI) server, Fasta, is also available at this stage. 
Either the US or European servers may be used for access as they both link to the 
same databases. However, before finally selecting primers it is wise to check via both 
servers to ensure that all relevant information is accessed).
Select option: Advance BLAST search
A window then becomes available to enter the primer sequence to be checked. 
Alignment and description of the (first 0, 10, 50, 100 or 500) sequences with strongest 
homology may be requested.
Select option: Search
Depending on how busy the system is the results may be returned immediately or 
after some time. The option is available to enter an e-mail address to which the results 
will be posted.
6 8
2.13 ELECTROPHORESIS OF PCR PRODUCTS
A 3% agarose gel (NuSieve, GTG) was prepared in TBE buffer (5.4g Tris, 2.75g 
boric acid, 2ml 0.5M-EDTA pH 8.0 in 500ml water) and melted in a microwave oven. 
After allowing to cool, 0.003% of a lOmg/ml ethidium bromide solution was added to 
the gel, which was then poured into an electrophoresis apparatus (BioRad). Combs 
were placed in the gel to form wells and the gel was allowed to set.
10f.il loading buffer (50% glycerol, lmg/ml xylene cyanol, ling/ml bromophenol blue, 
ImM EDTA) was added to each 50(.il PCR sample and 20|iU was run on the gel at 80- 
90mV for approximately 2 hours. When the dye front was seen to have migrated the 
required distance, the gel was removed from the apparatus and examined on a 
transilluminator and photographed.
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2.14 ISOLATION OF RAT TYPE II PNEUMOCYTES.
2.14.1 ANIMALS AND ANAESTHESIA.
2.14.1.1 Animals.
Male Sprague-Dawley rats of 180 - 200 g were used in the experiments. The animals 
were allowed water and food ad librium.
2.14.1.2 Anaesthesia.
The animals were lightly anaesthetised with halothane prior to receiving a lethal 
intraperitioneal injection o f pentobarbital (60 mg/kg = lml/kg). The animal was laid
on its back and the areas to be incised dampened with IMS. The ventral surface skin
was removed and the abdominal vessels exposed. The major dorsal blood vessels 
were cut through with a large straight scissors.
2.14.2 DISSECTION AND PERFUSION.
The trachea was cannulated and the chest opened without puncturing the lungs. A 
portion of the thymus was removed to expose the heart. An incision was made into the 
pericardium and a cannula fed into the pulmonary artery. The cannula was connected 
by gravity feed to a reservoir of 0.15 mol/1 NaCl, which upon flowing increased the 
size of the right atrium. The atrium was cut to allow fluid to drain free. The lungs 
were artificially ventilated with 8 to lOmls o f air by means of a syringe. This was 
repeated 5 times, after which the lungs were free o f blood and white in appearance.
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2.14.3 LAVAGE AND DIGESTION.
2.14.3.1 Lavage.
The lungs were dissected free and lavaged exactly 5 times with 6-8 ml o f 0.15 mol/1 
NaCl solution. The lavage fluid was removed from the lungs by gravity, this fluid 
contained lung macrophage population.
2.14.3.2 Digestion.
The lung were digested using crystalline trypsin (Sigma T8003; 250 mg/ 100ml) 
dissolved in +Mg/Ca solution The trypsin was perfused into the lungs via the 
cannula, so that the lungs were continuously filled with trypsin solution (using about 
60 ml per lung). The lungs were allowed to digest for 30 minutes. The lobes were 
dissected from the airways and cut into cubes of 1 - 2 mm3 with a scissors. These 
were added to 5 ml of FCS and tire total volume was brought to 20 ml by the addition 
of DNase solution I (250 (.ig/ml in -M g/Ca solution). The suspension was shaken for 
5 minutes prior to filtering through a course sterile wire mesh (stainless steel tea 
strainer) and then through two sterile nylon filters (Falcon) of 100 |um and 30 ¡urn 
respectively.
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♦ Mg/Ca Solutions
Stock solutions:-
0.9%w/v NaCl
0.11M CaCl
0.15M KC1
0.10M Phosphate buffer
0.10M Na2H P 04
0.10M NaH2P 0 4
p H  to 7.4 by adding H aH 2P04 to Na2HP04  
0.20M HEPES
0.15M M gS04
+Mg/Ca Solution -Mg/Ca Solution
0.9%w/v NaCl 250ml 250ml
O.llM CaCl 5ml
0.15M KC1 10ml 10ml
Phosphate Buffer 7.5ml 7.5ml
HEPES 15ml 15ml
0.15 M gS04 2.5ml
Glucose 3.15mg 315mg
Table2.13.1 Recipe for Mg/Ca solutions for isolation of type II pneumocytes
from 1 rat.
2.14.4 PERCOLL GRADIENT CENTRIFUGATION AND DIFFERENTIAL 
CELL ATTACHMENT.
2.14.4.1 Percoll Gradient Centrifugation.
To purify the primary digest, which contains a mixture of cell types a density
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centrifugation with percoll was performed. The cell suspension was layered upon two 
percoll layers: a heavy percoll solution [65 % percoll (1.089 g/ml)] and a light percoll 
solution [27 % percoll (10.39 g/ml)]. The discontinuous density centrifugation was 
carried out at a speed of 1,850 rpm for 20 minutes at 10 °C. Following centrifugation 
the fraction located at the interface between the heavy and light percoll layers, which 
contains an enriched fraction o f type II pneumocytes was carefully removed.
2.14.4.2 Differential Cell Attachment.
The removed fraction was brought to a volume o f 40 ml by the addition of DNase 
solution II. This cell suspension was spun at 1,000 rpm for 10 minutes. The cell pellet 
was re-suspended in growth medium, ATCC supplemented with 5% v/v FCS, 2mM 
L-glutamine, 2% Penicillin-Streptomycin (Sigma Cat. No. P4458), 0.5% v/v 
Fungizone and plated on tissue culture plastic for two hours at 37 °C. The non­
adherent cells were gently removed and centrifuged. The resulting pellet was re­
suspended and a cell yield obtained. This cell suspension was then plated at the 
required density for the experiment.
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2.15 PRIMARY CULTURE OF HUMAN LUNG TUMOURS.
2.15.1 COLLECTION OF TUMOUR TISSUE SAMPLES AND 
TRANSPORTATION MEDIUM.
Primary tissue was collected in theatre after surgical resection at St. Vincents 
Hospital, Elm Park, Stillorgan, Dublin 4. This material was kindly provided by 
thorasic surgeon Mr. Vincent Lynch only after the requirements o f the hospital’s 
histopathology service for such tissue has been met. Tissue samples were placed in a 
transportation medium immediately and taken at 4 °C to the NCTCC at DCU for 
processing on the same day.
♦ Transportation Medium:
This consisted of Leibovitz L-15 medium as basal medium. As this media is 
bicarbonate free there is minimal pH fluctuation during transit. This was 
supplemented with 1% w/v o f PVP-360, 2 mM L-glutamine, 1% v/v Penicillin- 
Streptomycin (Sigma Cat. No. P4458) and 0.5%v/v fungizone.
2.15.2 DISSECTION OF TUMOUR TISSUE.
All procedures from this point on were performed in a class 2 laminar flow cabinet. 
Surgical quality gloves were worn and due care and diligence was taken in the 
disposal of any waste.
Samples were rinsed in PBS-A 3 times to remove extraneous blood prior to 
dissection. Fatty deposits, necrotic tissue and blood vessels were removed where 
possible using sterile surgical scalpels and scissors. These manipulations were 
performed on sterile petri dishes.
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2.15.3 ENZYMATIC DIGESTION.
The remain tissue was cut in to small chunks 3 - 4  mm3. These tissue fragments were 
placed in a universal and washed once with PBS-A by inversion. The tissue was then 
incubated with proteolytic enzyme mixture A or B, while stirring with a sterile 
magnetic stirrer at 37 °C.
After 30 minutes the supernatant was removed from the digest and the cells recovered 
by centrifugation at 1000 rpm for 10 minutes. The pellet was resuspened in 
prewarmed growth media.
The remaining tissue fragments from the digest were reincubated with fresh 
proteolytic enzyme for a further 30 minutes. The supernatant from the second digest 
was treated as above.
The cell suspensions from both digests were pooled and centrifuged at 1000 rpm for 
10 minutes. The resulting cell pellet was resuspended in prewarmed growth media 
and plated at high density, i.e. 10 cell per 25cm flask.
♦ Proteolytic enzyme mixture A:
Consisted of trypsin 2ml of lOx Gibco BRL trypsin in 18 ml o f MEM 
supplemented with lOU/ml o f DNase I.
♦ Proteolytic enzyme mixture B:
Consisted of 0.4mg/ml Collagenase A, 0.6mg/ml Dispase, 0.6mg/ml Pronase E in 
MEM supplemented with lOU/ml of DNase I.
2.15.4 EXPLANT TECHNIQUE.
Lung tumour tissue was cut into small cubes (2-4mm ) these were aseptically 
transferred to the growth surface of 25cm flasks. These flasks had been pre-wetted 
with 2.5mls of growth medium (which contained serum) and the excess media was 
removed. This was performed 10-15 minutes prior to the placing o f explant tissue in
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the flask. Approximately 15-20 fragments of tissue were carefully placed in the flask 
with a scalpel blade or sterile tweezers. The tissue was allowed to adhere in this 
position for approximately 30 minutes with the lids slightly loosened. Taking care not 
to dislodge the explants, 2.5mls of growth medium was added. The flasks were then 
incubated at 37°C.
2.15.5 DIFFERENTIAL TRYPSINISATION FOR THE REMOVAL OF 
FIBROBLASTS.
The procedure utilises the phenomenon that fibroblast cells detach first in a mixed 
culture treated with trypsin. Thus the presence of contaminating fibroblasts in a 
culture can be reduced or eliminated by the trypsinisation the mixed culture.
All operations were performed aseptically in a laminar flow. The culture media was 
removed from the flask and pre-warmed trypsin EDTA solution pipetted into the flask 
and the lid replaced. The flask was placed on an inverted microscope stage and the 
progress o f the trypsinisation monitored continuously under 40x and lOOx 
magnification.
As soon as the fibroblasts had detached but before the cells of interest, the flask was 
returned to the laminar flow. Avoiding unnecessary agitation of the flask, growth 
media was gently added to terminate the trypsinisation procedure. This solution which 
now contains the fibroblast cells, was gently removed by aspiration and fresh growth 
medium added.
76
2.16 TIME-LAPSE VIDEO MICROSCOPY.
Time-lapse video microscopy was carried out on a Nikon diahot inverted microscope 
(Micron Optical, Bray, Ireland) equipped with a phase contrast optics, linked to a 
Mitsubishi CCD-100 colour video camera. Images were recorded in S-VHS onto a 
Mitsubishi HS-S5600 video recorder with time-lapse capabilities. All time-lapse 
video-equipment was obtained from Laboratory Instruments (Ashbome, Ireland). 
Recording speed was set at 3.22sec/field (480 hour mode), which at normal playback 
speed resulted in an acceleration factor o f 160.
The temperature of the culture vessel was controlled by a Linkam CO 102 warm stage 
controller. This controller was adjusted to keep the culture medium inside the vessel 
at 37 C, as measured using a TB3301 probe.
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3.0 RESULTS.
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3.1 INVESTIGATION OF THE EFFECT OF BrdU EXPOSURE 
ON Ep-CAM EXPRESSION IN THE HUMAN LUNG 
CARCINOMA CELL LINES DLKP AND A549.
Previous studies in this laboratory have shown that 10|jM 5,2’-Bromodeoxyuridine 
(BrdU) induces cytokeratin (CK) 8, and 18 expression in DLKP and enhances their 
expression in A549 (McBride et al, ‘99). BrdU also induces CK-19 expression in 
DLKP and enhanced expression in A549 (Meleady et al, manuscript in preparation). 
Induced a i and a 2 integrin and enhanced (3i expression has been observed in both 
DLKP and A549 (Meleady and Clynes, manuscript submitted).
Ep-CAM is a transmembrane protein that is expressed on the baso-lateral domains of 
epithelial cell membranes. It is a homophilic cell-cell adhesion protein and is believed 
to play role in cell sorting during development. Preliminary results (Dr. Paula 
Meleady, PhD thesis, DCU 1997) suggested that Ep-CAM was induced following 
treatment with IO i^M BrdU in both DLKP and A549. Studies were thus conducted to 
further investigate this apparent induction.
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3.1.1 IMMUNOCYTOCHEMICAL ANALYSIS OF Ep-CAM EXPRESSION.
Immunocytochemistry was used to qualitatively investigate the changes in Ep-CAM 
in DLKP and A549 following treatment for 7 days with 1 OyM BrdU.
Untreated DLKP were found to be negative for Ep-CAM, Following treatment for 7 
days with 10|.iM BrdU a faint staining was observed on the cell membrane in about 
80% of the cell population with some cells showing strong staining (figure 3.1.1)
A549 cells that are untreated exhibit a slight positive staining for Ep-CAM. Following 
BrdU treatment this staining is strongly enhanced in approximately 70% of the cell 
population (figure 3.1.2).
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Figure 3.1.1 Ep-CAM expression on untreated DLKP (A) and BrdU treated DLKP (B)
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Figure 3.1.2 Ep-CAM expression on untreated A549 (A) and BrdU treated A549 (B)
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3.1.2 WESTERN BLOT ANALYSIS OF Ep-CAM EXPRESSION.
In order to obtain a quantitative assessment for BrdU induced expression of Ep-CAM 
in the lung cell lines DLKP and A549 western blot analysis was performed. Cells 
were treated for up to 21 days and time points taken at day 7, day 14 and day 21. The 
breast adenocarcinoma cell line MCF-7, which is known to express high levels of Ep- 
CAM, was used as a positive control.
In untreated DLKP cells no clearly visible band was detected in untreated cells. A 
faint band with the equivalent molecular weight for Ep-CAM (40-43 KDa.) was 
detected in cells treated for 7 days with BrdU. The intensity o f this band increased in 
cells treated for 14 days with BrdU. In cells treated for 21 days with BrdU there was 
no apparent change in the intensity of the detected band compared to the band 
obtained for 14 days BrdU (figure 3.1.3).
In A549 a faint band (40-43 KDa.) equating to the molecular weight o f Ep-CAM was 
detected in untreated cells. The intensity of this band increased slightly in cells treated 
over 14 days with 10uM BrdU. There was no apparent change in the intensity of the 
band obtained in cells treated for 21 days with BrdU compared to the band detected 
after 14 days treatment (figure 3.1.4).
The western blots for both cell lines showed unidentified lower molecular weight 
protein bands. Balzar et al. (1998) obtained a similar pattern of lower molecular 
weight products in their experiments, which they regarded as breakdown products of 
Ep-CAM.
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Figu re 3.1.3 Western blot analysis of Ep-CAM expression in DLKP
treated with BrdU.
Ep-CAM  
40 KDa
Figure 3.1.4 Western blot analysis of Ep-CAM expression in A549 treated 
with BrdU.
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3.1.3 RT-PCR ANALYSIS OF Ep-CAM mRNA EXPRESSION FOLLOWING 
BrdU TREATMENT.
RT-PCR analysis was conducted to investigate the effect o f BrdU treatment on the 
Ep-CAM (GA733-2) mRNA transcript in DLKP and A549. Time points o f 7 days, 14 
days, and 21 days o f BrdU treatment were selected. The breast adenocarcinoma cell 
line MCF-7 was used as a positive control.
Optimal primers for the gene sequence were designed and the specificity was checked 
using BLAST (see methods section 2.11) (Table 3.1.1.).
Sequence Position on cDNA
Forward Primer 5’ CTG TCA TTT GCT CAA AGC TG 3’ 167-186
Reverse Primer 5’ TGG ATC CAG TTG ATA ACG 3’ 517-534
Table 3.1.1. Sequence of primers for Ep-CAM and their cDNA nucleotide 
position.
The primers selected amplified a product of 368 base pairs as predicted
No change in the level of mRNA transcript was detected in DLKP that were treated 
with BrdU for up to 21 days (figure 3.1.5). Similarly in A549 the level o f Ep-CAM 
mRNA transcript remained unchanged over 21 days of BrdU treatment.
Thus in both cell lines the mRNA level was unchanged by treatment with 10|iM BrdU 
though both showed induced Ep-CAM protein expression. This indicated that the 
regulation o f Ep-CAM expression by BrdU is at the post-transcriptional level 
(possibly translational) level.
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Figure 3.1.5 RT-PCR analysis of Ep-CAM expression in DLKP and A549 untreated
and post- BrdU treatment.
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3.1.4 INVESTIGATION OF THE mRNA LEVELS OF GA733-1 IN BrdU
TREATED DLKP AND A549 CELLS.
RT-PCR analysis was conducted on lOfiM BrdU treated DLKP and A549 to 
investigate if  there was any change in the level o f mRNA transcript for GA733-1 
following BrdU treatment. Time points of 7 days, 14 days, and 21 days of BrdU 
treatment were selected. The breast adenocarcinoma cell line MCF-7 was used as a 
positive control.
Optimal primers for the gene sequence were designed and the specificity was checked 
using BLAST (see methods section 2.11) (Table 3.1.2).
Sequence Nucleotides
Forward Primer 5’ TCC AAG TGT CTG CTG CTC A 3’ 211-229
Reverse Primer 5’ CAC ACC GAC GTC TGG TTG CA 3’ 355-374
Table 3.1.2 Sequence of primers for GA733-1 and their cDNA nucleotide 
position.
The primers selected amplified a product of 164 base pairs as predicted.
In untreated DLKP no band equivalent to the amplified GA733-1 sequence was 
detected. In DLKP cells that had been treated for 7 days with BrdU a band was 
detected for GA733-1 product. The intensity o f this band increased after 14 days of 
BrdU treatment, and remained unchanged in intensity after 21 days o f BrdU treatment 
(figure 3.1.6).
In untreated A549 no amplified RT-PCR product was detected. In A549 cells that had 
been treated for 7, 14 and 21 days with BrdU there was also no detectable RT-PCR 
product (figure 3.1.6). Thus the induction appears to be DLKP specific, which is
8 6
unusal since induction is observed in both DLKP and A549 for most o f the markers 
studied in this laboratory.
Unfortunately we were unable to source any GA733-1 specific antibodies to examine 
changes in the levels o f the relevant protein.
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3.1.6 INVESTIGATION OF CHANGES IN FOCAL ADHESION PROTEINS
IN BRDU TREATED DLKP AND A549.
It is believed that Ep-CAM may decrease E-cadherin mediated cell-cell binding by 
decreasing the level o f the focal adhesion proteins a-catenin, P-catenin, and either 
sequestering or decreasing a-actinin.
Preliminary experiments were conducted using western blot analysis to investigate the 
changes in a-catenin and a-actinin following BrdU treatment and the induction of Ep- 
CAM. Time points were taken at 7 days, and 14 days o f BrdU treatment.
In untreated DLKP a strong band was detected at the expected molecular weight for 
a-catenin. The intensity of this band dropped after 7 days o f BrdU treatment and 
continued to drop over 14 days of BrdU treatment (figure 3.1.7).
Similarly, in A549 a strong band was detected in untreated cells for a-catenin, the 
intensity of which dropped over 14 days of BrdU treatment (figure 3.1.7)
A strong band for a-actinin was detected in untreated DLKP. The intensity o f this 
band dropped after 7 days of BrdU treatment and continued to drop in intensity after 
14 days of BrdU treatment. A similar pattern o f decrease was observed in A549 
(figure 3.1.8).
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Figure 3.1.7 Western blot analysis of a-catenin in DLKP and A549 treated 
over 14 days with BrdU.
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Figure 3.1.8 Western blot analysis of a-actinin in DLKP and A549 treated 
over 14 days with BrdU
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3.2 HALOGENATED ANALOGUES OF THYMIDINE AND 
THEIR EFFECTS ON DIFFERENTIATION.
The halogenated thymidine analogue 5-bromo-2'-deoxyuridine has been shown to 
alter the differentiation status of various cell types. The effect of other halogenated 
thymidine analogues on differentiation is less well researched, with only a limited 
number of studies existing. It was decided to investigate the ability of other 
halogenated thymidine analogues to induce differentiation in the D L K P  and A549 cell 
line models.
The following compounds were selected 5-chloro-2’-deoxyuridine (CdU), 5-fluro-5- 
deoxyuridine (5,5'-FdU), 5-bromouridine (5-BUr).
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3.2.1 SELECTION OF CONCENTRATIONS FOR DIFFERENTIATION 
ASSAYS AND MORPHOLOGICAL EFFECTS OF THYMIDINE 
ANALOGUES ON DLKP AND A549.
3.2.1.1 Toxicity profiles of thymidine analogues on DLKP and A549.
Preliminary toxicity assays were performed to determine the toxic effect o f CdU, 5,5'- 
FdU, and 5-BU. Figures 3.2.1 and 3.2.2 show the toxicity profiles obtained for DLKP 
and A549. Concentrations were chosen that would allow a 75% survival rate or 
greater (table 3.2.1). Both DLKP and A549 show a similar response profile to FdU 
and appear to have an IC50 around 3.5(iM. DLKP and A549 exhibited different CdU 
profiles. DLKP appeared to have an apparent IC50 of 13.5(iM, while A549 appeared to 
have an IC50 slightly greater then 30jaM. However subsequent studies showed that 
CdU appeared to be cumulatively cytotoxic (data not shown), thus a lower 
concentration was chosen then the toxicity profiles suggested. Both DLKP and A549 
5-BUr did not exhibit any toxicity to DLKP and A549 even at 70|oM.
jiM
5,5’ FdU 2
CdU 10
5-BU 70
Table 3.2.1 Concentrations of halogenated analogues selected for 
differentiation assays.
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Figure 3.2.1 Toxicity profile of DLKP (A) and A549 (B) in 5.5’-FdU
(±SD = Standard Deviation)
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3.2.1.2 Cellular morphology of A549 and DLKP exposed to thymidine analogues.
DLKP cells treated with 5,5'-FdU had a more spread morphology (figure 3.2.3 E and 
F) than the control DLKP cells (figure 3.2.3 A and B), which existed both as single 
cells and colonies. Though there was a change in cellular morphology following 5,5'- 
FdU treatment the degree o f cell flattening and spreading was not as great as that for 
BrdU (figure 3.2.3 C and D).
DLKP cells treated with CdU were highly flattened and cells grew predominantly as 
single cells (figure 3.2.3 G and H). The change in cellular morphology of DLKP 
treated with CdU was reminiscent of the change in cell morphology that occurs in 
DLKP following BrdU treatment. However, as noted earlier as CdU treatment is 
extended beyond 7 days a cumulative cytotoxic effect occurs, unlike BrdU, which 
does not show any cumulative cytotoxicity. 5-BUr treatment did not appear to visibly 
alter the cellular morphology of DLKP (figure 3.2.3 I and J).
A549 cells treated with 5,5'-FdU exhibited a stretched morphology (figure 3.2.4 E and 
F) compared to untreated A549 (figure 3.2.4 A and B). The increased stretching and 
flattening in morphology is not as great as observed in BrdU treated cells (figure 3.2.4 
C and D). CdU treatment o f A549 induced extensive cellular flattening and cells grew 
predominantly as single cells (figure 3.2.4 G and H). The flattening in cellular 
morphology observed following CdU treatment was more extreme than in BrdU 
treated A549 cells (figure 3.2.4 C and D). 5-BUr treatment did not appear to visibly 
alter the cellular morphology of A549 (figure 3.2.4 I and J).
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A. Untreated ceils xlOO B Untreated cells x400
£. FdU treated cells xlOO
Figure 3.2.3 The effect of haolgenated thymidine analogues on the cellular 
morphology of DLKP.
F. FdU treated cells x400
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G. CdU treated cells xlOO H. CdU treated cells x400
1.5-BU treated cells xlOO J. S-BU treated cells x400
Figure 3.2.3 Continued. The effect of halogenated thymidine analogues on the cellular 
morphology of DLKP.
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A. Untreated cells xlOO B. Untreated cells x400
C. BrdU treated cells x l 00 C. BrdU treated cells x400
D. FdU treated cells xlOO E. FdU treated cells x400
Figure 3.2.4 The effect of halogenated thymidine analogues on the cellular 
morphology of A549.
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F. CdU treated cells xlOO G. CdU treated cells x400
H. 5-BUr treated cells xlOO I. 5-BUr treated cells x400
Figure 3.2.4 Continued. The effect of halogcnated thymidine analogues on the cellular
morphology of A549
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3.2.2 ANALYSIS OF CHANGES IN MASKER PROTEIN EXPRESSION IN 
THYMIDINE ANALOGUE TREATED DLKP AND A549.
In both DLKP and A549 cells, exposure to 10|iM BrdU was found to induce or 
increase expression of CK-8, CK-18, CK-19, pi-integrin, and Ep-CAM (McBride et 
al 1999; Meleady and Clynes, manuscript submitted; results presented in this thesis). 
Using immunocytochemistry, western blot and RT-PCR analysis the expression of 
these proteins was investigated in DLKP and A549 cells exposed to CdU, 5,5'-FdU, 
and 5-BUr. A summary o f the results obtained are presented in tables 3.2.2 and 3.2.3.
Control.
TRE
BrdU Treated
ATMENT PERFOR 
5,5'-FdU Treated
VIED
CdU Treated 5-BU Treated
Immunocytochemistry Negative Induced Expression Induced Expression Induced Expression Negative-No Change
CK-8 Western Blot N/A N/A N/A N/A N/A
RT-PCR N/A N/A N/A N/A
Immunocytochemistry Negative Induced Expression Induced Expression Induced Expression Negative-No Change
CK-18 Western Blot N/A N/A N/A N/A N/A
RT-PCR N/A N/A N/A N/A N/A
Immunocytochemistry Negative Induced Expression Induced Expression Induced Expression Negative-No Change
CK-19 Western Blot N/A N/A N/A N/A N/A
RT-PCR N/A N/A N/A N/A N/A
Immunocytochemistry Slightly Positive Induced Expression Induced Expression Induced Expression Slightly Positive-No 
Change
pi Integrin Western Blot Positive Induced Expression N/A N/A N/A
RT-PCR Positive Positive-No Change N/A N/A N/A
Immunocytochemistry Negative Induced Expression Induced Expression Induced Expression Negative-No Change
Ep-CAM Western Blot Negative Induced Expression N/A N/A N/A
RT-PCR Positive Positive-No Change N/A N/A N/A
N/A = NOT AVAILABLE
Table 3.2.1 Summary of results obtained for different marker proteins in DLKP treated with various halogenated thymidine 
analogues.
• I Control.
TRE
BrdU Treated
ATMENT PERFOR 
5,5'-FdU Treated
MED
CdU Treated 5-BU Treated
Immunocytochemistry Positive Induced Expression Induced Expression Induced Expression Positive-No Change 
(same as untreated)
CK-8 Western Blot Positive Induced Expression Induced Expression Induced expression Positive-No Change 
(same as untreated)
RT-PCR Positive Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Immunocytochemistry Positive Induced Expression Induced Expression Induced Expression Positive-No Change 
(same as untreated)
CK-18 Western Blot Positive Induced Expression Induced Expression Induced Expression Positive-No Change
(same as untreated)
RT-PCR Positive Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Immunocytochemistry Positive Induced Expression Induced Expression Unclear Positive-No Change 
(same as untreated)
CK-19 Western Blot Positive Induced Expression Induced Expression Induced Expression Positive-No Change
(same as untreated)
RT-PCR Positive Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Immunocytochemistry Positive Induced Expression Down Regulation? Induced Expression Positive-No Change 
(same as untreated)
pi Integrin Western Blot Positive Induced Expression Induced Expression Induced Expression Positive-No Change
(same as untreated)
RT-PCR Positive N/A N/A N/A N/A
Immunocytochemistry Positive Induced Expression Down Regulation? Induced Expression Positive-No Change 
(same as untreated)
Ep-CAM Western Blot Positive Induced Expression Induced Expression Induced Expression Positive-No Change
(same as untreated)
RT-PCR Positive Positive-No Change 
(same as untreated)
Positive-No Change 
(same as untreated)
Positive-No Changes 
(same as untreated)
Positive-No Change 
(same as untreated)
N/A = Not Available.
Table 3.2.2 Summary of results obtained for different marker proteins in A549 treated with various halogenated thymidine 
analogues.
3.2.2.1 Changes in cytokeratin-8 expression following treatment with 
halogenated thymidine analogues.
Immunocytochemical analysis of DLKP cells for expression o f cytokeratin-8 (CK-8) 
showed induction by 2(aM 5,5'-FdU (at a level greater than or equal to 10p,M BrdU) 
(figure 3.2.5 C); and by 10pM CdU (at a level equal to 1 OpM BrdU) (figure 3.2.5 D). 
Treatment with 70pM 5-BUr did not however, induce any alteration (figure 3.2.5 E).
Immunocytochemical analysis o f A549 treated with 2j.iM 5,5'-FdU showed induction 
of CK-8 expression (which appeared greater than 10|oM BrdU) (figure 3.2.6 C). lOpM 
CdU treatment revealed enhanced expression for CK-8 protein (figure 3.2.6 D) (at a 
level comparable to 10pM BrdU); treatment with 70p.M 5-BUr did not, however 
induce any alteration (figure 3.2.6 E).
In order to obtain a quantitative result, western blot analysis was conducted for CK-8 
expression in A549 cells exposed to the halogenated thymidine analogues for up to 14 
days (figure 3.2.7).
♦ It was previously shown in this laboratory that the level o f CK-8 was enhanced 
over 14 days of treatment with BrdU (McBride et al 1999). However, such an 
induction was not observed in this experiment, though it was clearly visable with 
immunocytochemistry (figure 3.2.6 B).
♦ An increase in CK-8 protein was observed at day 7 and day 14 in 5,5'-FdU treated 
cells, this induction was greater than that observed for 10pM BrdU.
♦ 5-BU treatment appeared to decrease CK-8 substantially, this is followed by re­
induction of CK-8 by day 14. Though no such change was visible with 
immunocytochemical techniques (figure 3.2.6 E).
♦ Treatment with 10|aM CdU induced an increase in CK-8 expression. 
Unfortunately, due to the apparent cumulative cytotoxicity of CdU it was not 
possible to study changes in protein level over 14 days.
No change in the levels of CK-8 mRNA were detected by RT-RCR (figure 3.2.8) 
following 7-day treatment with 5,5'-FdU (2|a,M), BrdU (lOpM), CdU (10p.M) or 5-
1 0 2
BUr (70|iM). The main conclusion from this experiment is that the induction, at 
protein level observed for CK-8 following treatment with the base analogues must be 
at a post-transcriptional level.
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Figure 3.2.5 Immunocytochemcial analysis for cytokeratin-8 (CK-8) expression
in DLKP cells (xlOO) treated with various halogenated thymidine
analogues.
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Figure 3.2.6 Immunocytochemical analysis of cytokeratin-8 (CK-8)
expression in A549 cells (xlOO) treated with various
halogenated thymidine analogues.
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Figure 3.2.7 Western blot analysis for cytokeratin-8 (CK-8) expression in 
A549 cells following treatment with various halogenated 
thymidine analogues.
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Figure 3.2.8 RT-PCR analysis for cytokeratin-8 (CK-8) expression in A549 cells 
following treatment with various halogenated thymidine 
analogues.
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3.2.2.2 Changes in cytokeratin-18 expression following treatment with 
halogenated thymidine analogues.
Analysis by immunocytochemistry of DLKP cells treated with 2(iM 5,5'-FdU, showed 
induced expression of cytokeratin-18 (CK-18) (figure 3.2.9 C), similar to that 
obtained following 1OfiM BrdU treatment (figure 3.2.9 B). A strong induction of CK- 
18 protein expression also occurred in 10|jM  CdU treated DLKP (figure 3.2.9 D) (at a 
level greater than or equal to lOpM BrdU); treatment with 70 |jM  5-BUr did not 
appear to alter CK-18 protein expression (figure 3.2.9 E).
Immunocytochemical analysis of A549 treated with 2(iM 5,5'-FdU showed enhanced 
expression for CK-18 (figure 3.2.10 C). The level o f induced protein expression 
appears greater than enhanced expression following 10(.iM BrdU treatment (figure 
3.2.10 B). Similarly, treatment with IOjiM CdU revealed enhanced expression for 
CK-18 protein (figure 3.2.10 D), which appeared comparable to that observed in BrdU 
treatments. Accurate assessments were difficult due to the enlargement in morphology 
following 10pM CdU treatment. Exposure to 70|j,M 5-BUr did not appear to change 
protein expression levels (figure 3.2.10 E).
Western blot analysis was conducted for CK-18 expression in A549 cells treated with 
the halogenated thymidine analogues for up to 14 days to obtain a quantitative result 
(figure 3.2.11).
♦ It was previously shown in this laboratory the level o f CK-18 was enhanced 
following treatment with BrdU (McBride et al, 1999). In the data presented here, 
this increase was not clearly seen.
♦ Treatment with 5,5'-FdU resulted in an induction of CK-18 expression in the day 7 
and day 14 time points. The level o f this increase was significantly larger then that 
observed for BrdU (figure 3.2.11).
♦ 10|aM treatment of CdU for 7 days appeared to induce enhanced expression of 
CK-18. Unfortunately, due to the cumulative cytotoxicity associated with 10pM 
CdU treatment it was not possible to assess the change in CK-18 expression 
following 14 days of treatment.
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♦ The level of CK-18 appeared to be decreased after 7 days o f 5-BUr treatment, 
followed by a partial restoration by day 14. Due to time constraints it was not 
possible to investigate the validity o f this result with fresh treatments at various 
concentrations o f 5-BUr.
No change in the levels of CK-18 inRNA were detected by RT-RCR (figure 3.2.12) 
following 7-day treatment with 5,5'-FdU (2(.iM), BrdU (10p.M), CdU (10(.iM) or 5- 
BUr (70|iM). The main conclusion from this experiment is that the induction, at 
protein level observed for CK-18 following treatment with the base analogues must be 
at a post-transcriptional level.
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Figure 3.2.9 Immunocytochemical analysis of cytokeratin-18 (CK-18)
expression in DLKP cells (xlOO) treated with various
halogenated thymidine analogues.
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Figure 3.2.10 Immunocytochemical analysis of cytokeratin-18 (CK-18)
expression in A549 cells (xlOO) treated with various
halogenated thymidine analogues.
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Figure 3.2.11 Western blot analysis for cytokeratin-18 (CK-18) expression in 
A549 cells following treatment with various halogenated 
thymidine analogues.
112
d
S3
3
S.
a
«5?
a
a
d
H
re
65
oa
e ©6!V!
oa
d
H"tre
65
rt>O-
o
65V!
in
In
a
d
Hl-<re
85
i^ -rea
<ji■w
d
H"tre6»
rea
O
CK-18 (444bp) m m m  m m m  m m * f l U  M lp j ( p  “
p-actin (142bp)
Figure 3.2.12 RT-PCR analysis for cytokeratin-18 (CK-18) expression in A549 
cells following treatment with various halogenated thymidine 
analogues
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3.2.2.3 Changes in cytokeratin-19 expression following treatment with 
halogenated thymidine analogues.
Immunocytochemical analysis of DLKP cells treated with 2\xM 5,5'-FdU, showed the 
expression of cytokeratin-19 (CK-19) to be induced (figure 3.2.13 C). The intensity of 
the observed staining was comparable to that obtained following 1 OfiM BrdU 
treatment (figure 3.2.13 B). Immunocytochemical analysis also suggested an induction 
of CK-19 protein expression in 10|jM CdU treated cells (figure 3.2.13 D), (greater 
than that observed in 10|xM BrdU treatment). In contrast immunocytochemistry 
treatment with 70|aM 5-BUr did not exhibit any changes in CK-19 protein expression 
(figure 3.2.13 E).
Immunocytochemical analysis of A549 treated with 2jxM 5,5'-FdU showed induction 
for cytokeratin-19 (CK-19) expression (figure 3.2.14 C), which appeared equal to the 
expression observed following 10|j,M BrdU treatment (figure 3.2.14 B).
Immunocytochemistry of 10|J,M CdU treated cells revealed enhanced expression for 
CK-8 protein (figure 3.2.14 D) (comparable to that observed in BrdU treatment). No 
change in CK-19 protein expression occurred, in A549 treated with 70fxM 5-BUr 
(figure 3.2.14 E).
Western blot analysis for CK-19 expression in A549, following treatment with the 
halogenated thymidine analogues, was conducted (figure 3.2.15).
♦ In agreement with previous experiments the level of CK-19 was enhanced at the 
day 7 and day 14 time points following treatment with BrdU (Meleady el al, 
manuscript in preparation).
♦ In cells treated with 5,5'-FdU, an increase in CK-19 expression was observered at 
the day 7-time point. The day 14-time point o f 5,5'-FdU treatment produced a 
substantial increase in CK-19 expression.
♦ 5-BUr treated cells the expression of CK-19 appeared unchanged at the day 7 and 
day 14 time points.
♦ Treatment with 1 OjjM  CdU appears to show CK-19 expression at the day-7 time 
point.
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The effect of the halogenated thymidine analogues on CK-19 transcription rates in 
A549 was investigated with RT-PCR analysis (figure 3.2.16). Treatment by 5,5'-FdU 
(2|iiM) for 7 and 14 days did not produce any obvious alteration in the mRNA levels in 
A549. Similarly the levels if mRNA in A549 cells treated with CdU (10p.M) or 5-BUr 
(70f.iM) over 7 and 14 days did not alter mRNA levels o f CK-19. Exposure to 5-BUr 
did not appear to alter the mRNA level at the day 7 and day 14 lime points.
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Figure 3.2.13 Immunocytochemical analysis for cytokeratin-19 (CK-19) in
DLKP cells (xlOO) treated with various halogenated thymidine
analogues.
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Figure 3.2.14 Immunocytochemical analysis for cytokeratin-19 (CK-19)
expression in A549 cells (xlOO) treated with various
halogenated thymidine analogues.
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Figure 3.2.15 Western blot analysis of cytokeratin-19 (CK-19) expression in 
A549 cells following treatment with various thymidine 
analogues.
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Figure 3.2.16 RT-PCR analysis for cytokeratin-19 (CK-19) expression in A549 
cells following treatment with various halogenated thymidine 
analogues
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3.2.2.4 Changes in Ep-CAM expression following treatment with halogenated 
thymidine analogues.
Analysis by immunocytochemistry o f DLKP treated with 5,5'-FdU revealed an 
apparent induction of Ep-CAM expression (figure 3.2.17 C). Similarly CdU treatment 
induced an expression o f Ep-CAM (figure 3.2.17 D) (that was equal to or greater than 
that observed following BrdU treatment). Immunocytochemical analysis did not 
reveal an induction of Ep-CAM in 70(aM 5-BUr treated cells (figure 3.2.17 E).
A549 treated with 5,5'-FdU revealed an apparent reduction o f Ep-CAM expression by 
immunocytochemistry analysis (figure 3.2.18 C), in contrast with 1 OuM BrdU 
treatment, which induces Ep-CAM expression (figure 3.2.18 B). 10uM CdU treatment 
induced an expression of Ep-CAM (figure 3.2.18 D) (at least equal to that of 10(oM 
BrdU). Immunocytochemical analysis did not reveal an induction of Ep-CAM in 
70jj,M 5-BUr treated cells (figure 3.2.18 E).
Figure 3.2.19 shows the results o f western blot analysis of A549 treated with 
halogenated thymidine analogues.
♦ In agreement with earlier experiments (section 3.1.2) the treatment with 10|_iM 
BrdU induced Ep-CAM expression at 7 and 14 days.
♦ Exposure to 5,5'-FdU (2|iM) for 7 days induced Ep-CAM expression, Ep-CAM 
expression was further induced after 14 days of treatment, and the level of 
induction appeared to be greater than for BrdU. This result contradicts the 
observations made by immunocytochemistry, which showed a decrease in Ep- 
CAM expression. Unfortunately due to time constraints repeat experiments with 
fresh treatments was not possible.
♦ In 5-BUr treated cells there was an apparent induction o f Ep-CAM in the day 7
and day 14 time points. It is an interesting feature, since no induction of
cytokeratin-8, -18, or -19 was observed with 5-BUr treatment.
♦ Treatment with CdU did appear to induce Ep-CAM slightly over 7 days.
1 2 0
The effect o f the halogenated thymidine analogues on Ep-CAM mRNA expression 
was investigated with RT-PCR analysis (figure 3.2.20). Treatment with (10|iM) CdU 
and (70|.iM) 5-BUr for 7 days did not appear to alter the mRNA level o f Ep-CAM in 
A549. Treatment with 5,5'-FdU appeared to slightly decrease the Ep-CAM mRNA 
level. Since an increase in protein expression was observed in immunocytochemistry 
and western blot analysis, the validity of this result is questionable and may be due to 
sample degradation.
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Figure 3.2.17 Immunocytochemical analysis for Ep-CAM expression in
DLKP cells (xlOO) treated with various halogenated thymidine
analogues.
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Figure 3.2.19 Western blot analysis of Ep-CAM expression in A549 cells 
following treatment with various thymidine analogues.
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Figure 3.2.20 RT-PCR analysis for Ep-CAM expression in A549 cells following 
treatment with various halogenated thymidine analogues.
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3.2.2.5 Changes in Pi integrin expression following treatment with halogenated 
thymidine analogues.
Immunocytochemical analysis of DLKP cells treated with 2\iM  5,5'-FdU, showed 
induced expression of Pi integrin (figure 3.2.21 C), which was equivalent to that 
observed for IOjiM BrdU (figure 3.2.21 B). An induction for (3i integrin expression 
was also observed in 10pM CdU treatments (figure 3.2.21 D) (equal to 10p,M BrdU 
treatment), in contrast 70|_iM 5-BUr did not exhibit any changes in Pi integrin protein 
expression (figure 3.2.21 E).
Analysis of A549 treated with 2(iM 5,5'-FdU by immunocytochemical methods 
showed reduced expression for Pi-integrin (figure 3.2.22 C) (less then untreated A549 
cells (figure 3.2.22 A)). Induced expression for Pi integrin protein with 10(.iM CdU 
treatment (figure 3.2.22 D) (comparable to BrdU treatment); no change in protein 
expression appeared to occur in 70pM 5-BUr treatment (figure 3.2.22 E).
In order to obtain a quantitative result western blot analysis was conducted for Pi 
integrin expression in A549 cells exposed to the halogenated thymidine analogues for 
up to 14 days (figure 3.2.23).
♦ As shown previously in this laboratory the level of pi integrin expression was 
enhanced at day 7 and day 14 following treatment with BrdU (Meleady et al., 
manuscript in preparation).
♦ Induction of Pi integrin protein occurred over the 14 days of 5,5'-FdU treatment, 
which was greater then the increase observed for BrdU treatment. It also calls into 
doubt the validity of the immunocytochemical result (figure 3.2.23 C), which 
showed inhibition of Pi-integrin expression. Unfortunately due to time constraints 
it was not possible to conduct repeat experiments necessary for further 
investigation.
♦ 5-BUr treatment may have caused a slight induction in Pi integrin expression.
♦ Treatment with lOpM CdU over 7 days induced a slight increase in pi integrin 
protein expression, due to the difficulty of culturing enough cells for the assay it
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was not possible to investigate an increase in (3i integrin protein expression 
beyond 7 days.
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Figure 3.2.21 Immunocytochcmical analysis for (31-integrin expression in DLKP 
cells (xlOO) treated with various halogenated thymidine analogues.
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Figure 3.2.22 Immunocytoehemistry analysis for (31 Integrin expression in 
A549 cells (xlOO) treated with various halogenated thymidine 
analogues.
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3.3 INVESTIGATION INTO THE ABILITY OF A COMPLEX 
HORMONE SUPPLEMENTED MEDIA TO INDUCE 
DIFFERENTIATION IN THE LUNG CELL LINES DLKP 
AND A549.
Previous reports from Prof. Emura's laboratory in Hannover had shown the fetal 
hamster lung cell line M3E3/C3 had properties suggestive of a possible lung stem cell 
e.g. it is, like DLKP, cytokeratin negative. The use of a hormone supplemented 
medium caused these cells to differentiate in vitro and to acquire a type II 
pneumocyte-like phenotype (Germann et al, 1993).
The culture medium was adapted for the DLKP and A549 cell line models by 
eliminating the soft agar overlay and reducing the serum concentration to 5%.
Since the medium contained several biologically active compounds, it was proposed 
that this study would allow an assessment of alternative in v itro  induced 
differentiation pathways which might or might not be similar with the pathway(s) 
induced by the halogenated thymidine analogues, to be made of the physiological 
relevance of BrdU induced differentiation.
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3.3.1 MORPHOLOGICAL ANALYSIS.
The lung cell lines were grown for 7 days in the hormone supplemented medium 
(HSM) and any change in morphology was noted. The DLKP cells obtained a more 
squamous morphology in HSM (figure 3.3.1 B) compared to cells in normal medium 
(figure 3.3.1 A).
The cell line A549, which is often used as a model for type II pneumocytes, also 
developed a squamous morphology and an increase in the number of cytoplasmic 
granules also appeared to occur (figure 3.3.2 B) when compared to cells grown in 
normal media (figure 3.3.2 A).
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A. DLKP Untreated. B. DKLP grown in HSM.
Figure 3.3.1 Morphology change in DLKP following growth in HSM (xlOO).
A. A549 Untreated. B. A549 grown in HSM,
Figure 3.3.2 Morphology change in A549 following growth in HSM (xlOO).
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3.3.2 IMMUNOCYTOCHEMICAL ANALYSIS OF MARKER PROTEINS IN 
DLKP AND A549 GROWN IN HSM.
Immunocytochemical analysis for CK-8 expression in DLKP following growth in 
HSM showed an induction of CK-8 expression (figure 3.3.3). Similarly, cytokeratin- 
18 (figure 3.3.5) and cytokeratin-19 (figure 3.3.7) showed induction by HSM. 
Immunocytochemistry for Ep-CAM showed strong induction following growth in 
HSM (figure 3.3.9).
According to immunocytochemical analysis, A549 cells appeared to show a slight 
induction of cytokeratin-8 expression following growth in HSM (figure 3.3.4), 
cytokeratins -18 (figure 3.3.6) and -19 (figure 3.3.8) also appeared to be induced 
following growth in HSM. The expression of Ep-CAM was induced following growth 
of A549 in HSM (figure 3.3.10).
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A. Untreated DLKP. (xlOO) B. DLKP grown in HSM. (xlOO)
Figure 3.3.3 Immunocytochemistry for CK-8 expression in DLKP grown in HSM.
Figure 3.3.4 Immunocytochemistry for CK-8 expression in A549 grown in HSM.
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Figure 3.3.5 Immunocytochemistry for CK-18 expression in DLKP grown in HSM.
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Figure 3.3.6 immunocytochemistry for CK-18 expression in A549 grown in HSM.
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Figure 3.3.7 Immunocytochemistry for CK-19 expression in DLKP grown in HSM.
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Figure 3.3.8 Immunocytochemistry for CK-19 expression in A549 grown in HSM.
A. Untreated A549. (xIOO)
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Figure 3.3.9 Immunocytochemistry for Ep-CAM expression in DLKP grown in 
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Figure 3.3.10 Immunocytochemistry for Ep-CAM expression in A549 grown in 
HSM.
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3.3.3 WESTERN BLOT ANALYSIS OF MARKER PROTEINS IN DLKP 
AND A549 GROWN IN HSM.
To quantify the changes observed in the immunocytochemical analysis (section 3.3.2),
western blot analysis was performed on DLKP and A549 cells that had been treated
with HSM for 7 and 14 days.
♦ No detectable CK-8, CK-18, and CK-19 was observed in DLKP grown in HSM, 
suggesting that immunoprecipitation was required (figure 3.3.11, 3.3.12, 3.3.13).
♦ An induction in Ep-CAM expression was observed in DLKP grown in HSM for 
21 days (figure 3.3.14) confirming the result obtained by immunocytochemistry.
♦ In A549 no obvious increase was observed for CK-8 when they were grown in 
HSM (figure 3.3.11).
♦ There was an increase in CK-18 expression in A549 grown in HSM (figure 
3.3.12).
♦ CK-19 expression increased in the A549 cells cultured in HSM over 14 days, thus 
confirming the results that were obtained by immunocytochemistry (figure 3.3.13).
♦ Ep-CAM expression increased in A549 cultured in HSM for 21 days (figure 
3.3.14)
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Figure 3.3.11 Western Blot analysis of CK 8 expression in DLKP and A549 
grown in HSM.
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Figure 3.3.12 Western Blot analysis of C K 18 expression in DLKP and A549
grown in HSM.
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Figure 3.3-13 Western blot analysis for C K 19 expression in A549 and DLKP 
grown in HSM
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3.3.4 RT-PCR ANALYSIS OF MARKER PROTEIN mRNA EXPRESSION IN 
DLKP AND A549 FOLLOWING CULTURE IN HSM.
RT-PCR analysis was conducted to determine the effect of growth in HSM had on
CK-8, CK-18, and CK-19 mRNA transcript levels.
♦ There was no CK-8 (figure 3.3.15), CK-18 (figure 3.3.16), CK-19 (figure3.3.17) 
mRNA detected in DLKP. These samples were in storage (at -80°C) for some 
time. Thus degradation of sample was deemed the most likely cause for this result.
♦ Growth in HSM by A549 did not appear to alter CK-8 mRNA expression levels 
(figure 3.3.15). In contrast a slight decrease is observed in CK-18 mRNA levels 
(figure 3.3.16), even though induction of protein was obtained by western blot 
analysis. Concurrently, a slight increase in CK-19 mRNA transcript levels was 
observed over the 21 days of growth (figure 3.3.17).
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Figure 3.3.16 RT-PCR analysis for CK-18 expression in A549 and DLKP grown 
in HSM.
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3.3.5 PRELIMINARY INVESTIGATION ON THE EFFECTS OF 
DELETION OF SPECIFIC COMPONENTS IN HSM.
In order to assess what influence that various components of HSM had on the 
differentiation, experiments were conducted in which a specific factor was deleted 
from the medium. A549 cells were cultivated for 14 days and subsequently analysed 
for changes in morphology and selected marker proteins (cy to keratin-8, cytokcrat in- 
18, cytokeratin-19, and Ep-CAM) summarised in table 3.3.1.
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HSM with various components deleted
Marker Untreated. Complete HSM. EGF -Ve HSM. Hydrocortisone - 
Ve HSM.
Oestrogen -Ve 
HSM.
Insulin -Ve HSM. Cholera Toxin - 
Ve HSM.
Cytokeratin-8 Positive Same as Untreated Same as Untreated 
Definitive assessment 
not possible
Same as Untreated 
Definitive assessment 
not possible
Same as Untreated 
Definitive assessment 
not possible
Same as Untreated 
Definitive assessment 
not possible
Same as Untreated 
Definitive assessment 
not possible
Cytokeratin-18 Positive Same as Untreated Same as Untreated
Definitive assessment 
not possible
Same as Untreated
Definitive assessment 
not possible
Same as Untreated
Definitive assessment 
not possible
Same as Untreated
Definitive assessment 
not possible
Same as Untreated
Definitive assessment 
not possible
Cytokeratin-19 Positive Induced expression Induced expression Strong induction of 
expression
Induced expression No induction of 
expression
Very strong 
induction of 
expression
Ep-C AM Positive Induced expression Induced expression Strong induction of 
expression
Strong induction of 
expression
No induction o f 
expression
Strong induction of 
expression
Table 3.3.1 Comparison of changes in A549 of marker proteins grown in various ‘orms of HSM.
3.3.5.1 Alterations in A549 morphology and protein expression following deletion 
of EGF from HSM.
♦ Growth in HSM from which EGF had been deleted was accompanied by an 
alteration in morphology, when compared to untreated A549 cells and cells grown 
in complete HSM (figure 3.3.18 B). The cells still grew in tight colonies when 
compared, though some cells within these colonies showed increased flattening. 
This increased flattening was often accompanied by the formation of vacuoles 
within the cytoplasm.
♦ The expression of CK-8 in cells grown in HSM lacking EGF did not appear to 
alter (figure 3.3.19). However, assessment of this result was hampered by a 
saturation of signal, which means that subtle differences in protein level were not 
detectable.
♦ Similarly CK-18 expression did not appear to be altered following growth in HSM 
with EGF deleted. Once more assessment was hampered by a high signal strength 
(figure 3.3.20).
♦ Omission of EGF from HSM added did not seem to alter the ability of HSM to 
induce CK-19 expression in A549 cells (figure 3.3.21)
♦ Likewise the induction of Ep-CAM by HSM did not appear to be affected by the 
removal of EGF (figure 3.3.22).
3.3.5.2 Alterations in A549 morphology and protein expression following deletion 
of Hydrocortisone from HSM.
♦ Growth in HSM which had hydrocortisone deleted, had a very altered morphology 
and was unlike either untreated A549 or cells grown in complete HSM. The cells 
appeared to be much smaller in cell volume with a ‘spiky’ appearance and grew in 
loose colonies (figure 3.3.18 C). The culture also contained a sub-population of 
cells, which possessed a flattened morphology and usually grew as isolated cells.
♦ HSM from which hydrocortisone had been withdrawn did not appear to alter the 
expression of CK-8 (figure 3.3.19), though due to the high signal strength 
assessment was difficult.
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♦ Likewise the expression of CK-18 did not appear to be altered in HSM from 
which hydrocortisone was deleted (figure 3.3.20). However, in common with the 
CK-8 result, assessment was difficult due to the strong signal strength.
♦ HSM from which hydrocortisone was deleted, induced strong expression of CK- 
19 (figure 3.3.21). The strength of this induction was greater than the induction of 
CK-19 expression induced by complete HSM.
♦ Similarly the expression of Ep-CAM was greatly increased in HSM lacking 
hydrocortisone (figure 3.3.22). The level of induction was greater than the 
induction observed in complete HSM.
3.3.5.3 Alterations in A549 morphology and protein expression following deletion 
of oestrogen from HSM.
♦ The growth of A549 in oestrogen deleted HSM did not appear to alter the cellular 
morphology greatly, with the cells growing in tight colonies (figure 3.3.18 D).
♦ HSM lacking oestrogen did not appear to alter the expression of CK-8 (figure 
3.3.19). Assessment of this result was hampered by a saturation of signal, which 
prevented subtle differences in protein level to be observed.
♦ Similarly, CK-18 expression did not appear to be altered following growth in 
HSM with oestrogen deleted. Thought assessment was once more hindered by a 
high signal strength (figure 3.3.20).
♦ The removal of oestrogen from HSM did not obviously alter the ability to induce 
the expression of CK-19 (figure 3.3.21).
♦ HSM which was lacks oestrogen appeared to have an enhanced ability to induce 
Ep-CAM expression (figure 3.3.22)
3.3.5.4 Alterations in A549 morphology and protein expression following deletion 
of insulin from HSM.
♦ The withdrawal of insulin from HSM did not appear to alter the cellular 
morphology of A549 greatly from that of untreated A549 cells (figure 3.3.18 E)
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♦ HSM lacking insulin did not appear to alter the expression of CK-8, though high 
signal level made it difficult to be conclusive (figure 3.3.19).
♦ The expression of CK-18 did not appear to be induced in cells grown in insulin 
deleted HSM. This result cannot be taken as being completely definite due to the 
high signal level (figure 3.3.20).
♦ The removal of insulin did not appear to alter the ability of HSM to induce CK-19 
expression (figure 3.3.21).
♦ Insulin depleted HSM appeared to possess a decreased ability to induce Ep-CAM 
expression (figure3.3.22).
3.3.5.5 Alterations in A549 morphology and protein expression following deletion 
of cholera toxin from HSM.
♦ The deletion of cholera toxin from HSM induced a more squamous morphology, 
with an apparent increase in the number of cytoplasmic granules (figure 3.3.18 F).
♦ HSM from which cholera toxin had been withdrawn did not appear to alter the 
expression of CK-8 (figure 3.3.19). Though due to the high signal strength it is 
difficult to make a conclusive judgement.
♦ Likewise the expression of CK-18 did not appear to be altered in HSM from 
which cholera toxin was deleted (figure 3.3.20). However in common with the 
CK-8 result, assessment was difficult due to the strength of the signal.
♦ The removal of cholera toxin from HSM, increased the ability of HSM to induce 
CK-19 expression (figure 3.3.21). The strength of this signal was substantially 
greater then that observed from complete HSM.
♦ HSM from which cholera toxin was deleted induced a much stronger expression 
of Ep-CAM than that observered with cells grown in complete HSM (figure 
3.3.22).
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A. Complete HSM. (xlOO) B. EGF Deleted. (xlOO)
C. Hydrocortisone Deleted. (xlOO) D. Oestrogen Deleted. (xlOO)
Figure 3.3.18 Morphology of A549 grown in HSM with various components deleted.
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E. Insulin Deleted. (xlOO) F. Cholera Toxin. (xlOO)
Figure 3.3.18 (Continued) Morphology of A549 grown in HSM with various components
deleted .
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Figure 3.3.19 Western blot analysis of cytokeratin-8 (CK-8) expression in A549 cells 
following growth in HSM with various components deleted.
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Figure 3.3.20 Western blot analysis of cytokeratin-18 (CK-18) expression in A549 
cells following growth in HSM with various components deleted
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Figure 3.3.21 Western blot analysis of cytokeratin-19 (CK-19) expression in A549 
cells following growth in HSM with various components deleted.
Figure 3.3.22 Western blot analysis of Ep-CAM expression in A549 cells following 
growth in HSM with various components deleted.
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3.4 DEVELOPMENT OF IN VITRO MODELS OF
DIFFERENTIATION WITH PRIMARY CULTURES OF 
NORMAL LUNG AND LUNG CARCINOMA CELLS.
3.4.1 PRIMARY CUTURE AND PRELIMINARY DIFFERENTIATION 
STUDIES OF TYPE IIPNEUMOCYTES.
Type II pneumocytes were isolated from rat lung. These, were used to investigate the 
behaviour of normal cell populations in vitro and to establish a foundation for their 
use in modelling differentiation
3.4.1.1 Time-Lapse observations of isolated rat type II pneumocytes.
To investigate the effect of seeding density on proliferation and differentiation in 
isolated rat type II pneumocytes cells time-lapse studies were performed. Freshly 
isolated rat type II pneumocyte cells were plated at low density 5 x 105 and at high 
density 1.5 x 106 per well of a 12 well plate. These were then allowed to attach for 16 
hours, before the media was changed and the culture observed by time lapse.
In summary both low- and high-density cultures exhibited no proliferation from 16 
hours after isolation till the end of the experiment, which occurred when the cells died 
by apoptosis. During the assay the cells in both low- and high-density cultures became 
progressively flatter and larger, with a small decrease in lamellar body content. This is 
suggestive of the type II pneumocytes adopting a type I cell morphology. The cells in 
the high-density culture appeared to change their morphology and enter apoptosis 
slightly later then those type II cells in low-density culture.
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Figure 3.4.1 shows photos of selected time points from the time-lapse video of a low- 
density culture (LD). The observations made for this low-density culture of type II 
pneumocyte are summarised in table 3.4.1.
Figure 3.4.2 shows photos of selected time points from the time-lapse video of a high- 
density culture (HD). The observations of these cultures are summarised in table 3.4.2
Time : 16 Hrs. 
Fig. 3.4.1 A
9 cells are present in a colony. The lamellar bodies are not very 
clear.
Time : 24Hrs. 
Fig. 3.4.1 B
A large increase in the size of the colony has occurred, but with not 
increase in cell number.
Time : 32 Hrs. 
Fig. 3.4.1 C
The cells in the colony are still spreading out. The colony still 
contains 9 cells
Time : 24 Hrs. 
Fig. 3.4.1.D
The cells are now very flat and cover a large surface area.
Time : 48 Hrs. 
Fig. 3.4.1 E
Some cells have died by apoptosis
Time : 72 Hrs. 
Fig. 3.4.1 F
All cells have died buy apoptosis.
Table 3.4.1 Summary of time-lapse observations for low density culture of rat
type II pneumocytes (figure 3.4.1)
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C. 32 Hours in culture D. 40 Hours in culture.
v*
0 1 - 0 8 - 9 8  SAT 
1 2 : 1 5  03 480
E. SO Hours in culture F. 84 Hours in culture.
Figure 3.4.1 Rat type II pneumocytes cultured at low density followed by time- 
lapse video microscopy (x400).
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Time : 16 Hrs. 
Fig. 3.4.2 A
A large colony of cells is present (approx. 48 cells). These cells 
express clear lamellar bodies (arrow).
Time : 24 Hrs. 
Fig. 3.4.2 B
The cells are now covering a larger surface area. However there has 
been no cell division observed and the cell number is still approx. 48
Time : 32 Hrs. 
Fig. 3.4.2 C
The cells now cover a large surface area. The cells while obviously 
larger and flatter still possess lamellar bodies.
Time : 40 Hrs. 
Fig. 3.4.2 D
The cells now cover all the surface area. This is due to the cells 
spreading rather then cell proliferation. The cell number is still 
approx. 48.
Time: 48 Hrs. 
Fig. 3.4.2 E
Cells appear to have flattened further and some cells have begun to 
die by apoptosis
Time : 72 Hrs. 
Fig. 3.4.2 F
More cells have died by apoptosis. No cell proliferation has 
occurred.
Table 3.4.2 Summary of time lapse observations for high density culture of rat 
type II pneumocytes, (figure 3.4.2)
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A. 16 Hours in culture B. 24 Hours in culture.
C. 32 Hours in culture. D. 40 Hours in  culture.
F. 84 Hours in culture.E. §0 hours in culture.
Figure 3.4.2 Rat type II pneumocytes cultured at high density followed by time- 
lapse video microscopy (x400).
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3.4.1.2 Immunocytochemistry of isolated rat type II pneumocytes.
Preliminary investigations of changes in antigenic expression in rat type II 
pneumocytes over time in culture, were conducted. The type II pneumocytes were 
cultured for 8 days and were stained at fixed time points. The antigen chosen for study 
were:
♦ Alkaline phosphatase, which is an enzyme important in the lipid surfactant 
pathway, thus it is indicative of type II pneumocytes.
♦ Surfactant protein D, a kind gift from Dr Henk Haagsman (University of Utrecht), 
it is one of the component proteins of the surfactant produced by type II 
pneumocytes.
♦ Cytokeratin 18, is one of the main structural proteins of type I pneumocytes.
♦ Cytokeratin 19, is one of the main structural proteins of type II pneumocytes.
A summary of the results obtained is presented in table 3.4.3.
M H H D a y  0 D a y  2 D a y  4 D a y  6 D a y  8
A lka lin e  Phosphatase 90 -  95% 55 -  60% 5 0 -4 5 % 25 - 30 % 1 5 - 1 0 %
S urfac tan t P ro te in  D 95 -100 % 70 - 75 % 3 5 - 3 0 % 1 0 - 1 5 % 5 - 0 %
C y to ke ra tin -18 5 - 10% 5 - 10% 10-15 % 20 - 25 % 40 - 45 %
C ytokera tin -19 80 - 85 % 55 - 60 % 10-15 % 1 0 -1 5 % 5 - 10 %
Table 3.4.3 Percentage of cells stained for various markers over time in
culture.
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3.4.2 SELECTION AND CHARATERISATION OF HUMAN LUNG 
CARCINOMA SAMPLES.
The aim of this work was to establish the foundation for the routine primary culture of 
human carcinoma cells. Such cultures would form the bases of an in vitro model for 
studying differentiation in human lung carcinomas.
A total of 52 lung carcinoma samples were utilised in the investigation. A number of 
oesophageal tumour samples were also obtained.
The majority of samples came from patients undergoing lobectomy (removal of one or 
more constituent lobes of the lung or pneumonectomy (removal of one of the lungs). 
This type of resection for large tumours was normally reserved for non-small cell lung 
carcinoma. The second source of tissue came from investigative procedures such as 
bronchoscopy and mediastinoscopy. Both procedures are usually performed 
sequentially on the patient. The amount of tissue available from these procedures is 
very limited, usually in the range of 2-3 cm3. The tissue samples were placed 
immediately into cool (4 °C) transport media upon resection and transported at 4 °C 
promptly to the lab.
At the time of collecting the samples the histology may not have been known or 
available. However, most samples appear to have been from patients with either 
adenocarinoma or squamous cell carcinoma. It was not always clear if the samples 
were from patients with malignant or benign tumours. In a limited number of cases 
some tissue specimens were metastases from other tissues e.g. an ovarian tumour, a 
sarcoma of the uterus, and melanoma. Within the 52 samples a great deal of tissue 
heterogeneity existed e.g. size, texture, associated adipose tissue, necrosis and 
vascularisation.
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3.4.3 ENZYMATIC DISAGGREGATION OF TISSUE SAMPLES.
Two types of enzymatic digestion were investigated for their ability to dissagregate 
sample tissue and generate cultures of viable epithelial cells.
♦ The first method utilised trypsin 2 ml of lOx Gibco BRL trypsin in 18ml of MEM 
supplemented with lOU/ml of DNase I. In which the tissue was digested for 2 x 30 
minutes.
♦ The second treatment utilised 0.4 mg/ml Collagenase A, 0.6 mg/ml Dispase, 0.6 
mg/ml Pronase E in MEM supplemented with 10 U/ml of DNase I. the tissue was 
digested for 2 x 3 0  minutes.
See methods section 2.15 for a more detail account of the isolation procedure.
Neither method of enzymatic treatment appeared to confer an advantage for the 
isolation and culture of epithelial cells, (figure 3.4.3 A and B).
Epithelial colonies were usually obtained from the enzymatic digestion of the sample 
tissue. These usually only lasted for 1 or 2 passages at most and never reached 
confluency. The cultures usually became dominated by fibroblasts (figure 3.4.4).
Explants were also investigated for their ability to promote epithelial growth in vivo. 
These took longer for cells to become established and appeared to suffer similar 
amounts of fibroblast overgrowth as those cultures generated by enzymatic methods 
(figure 3.4.5).
A number of methods were investigated for their ability to prevent fibroblast 
overgrowth. These included using D-valine MEM as the basal media, the 
supplementation of the culture media with putrescence, differential trypsinisation, and 
panning of cells during isolation. None of these methods conveyed an advantage over 
a long culture time. The panning for fibroblasts during isolation was incorporated into 
the final protocol adopted as it may allow the epithelial cells some selective advantage 
during the initial culture period.
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The ability to obtain relatively pure cultures of lung carcinoma epithelial cells and to 
work with such cultures beyond 1 passage was very poor. The one culture most 
successful was from a highly malignant melanoma of the oesophagus, this culture was 
known as WS-111 (figure 3.4.6 A and B). The culture was passaged 3 times over two 
months before the melanoma cells died. The culture was slow in its growth, and 
contained a handful of contaminating fibroblast like cells, these cells subsequently 
took over (figure 3.4.6 C and D).
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A. Trypsin digest. B. Collagenase, dispase, and pronase-E digest
Figure 3.4.3 Comparison of primary culture MS-25.6 generated using different 
enzyme systems (xlOO).
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Figure 3.4.4 Overgrowth of primary culture GOK-65 with fibroblast (xlOO).
Figure 3.4.5 Outgrowth from explant after 18 days (xlOO).
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A xlOO B x400
C xlOO D x400
Figure 3.4.6 Primary culture WS-111 at passage 0 (A) and (B) showing cells with a
myeloma morphology; at passage 6 (C) and (D) showing overgrowth and 
replacement with fibroblast cells.
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3.4.4 INVESTIGATION INTO CYTOSKELETAL EXPRESSION IN 
FIBROBLAST CELLS IN  VITRO.
This study arose serendipitously when it was decided to use fibroblast cells derived 
from primary culture as negative controls for cytokeratin expression. Surprisingly, 
these cells proved to be positive.
Subsequent immunocytochemistry studies were performed on three primary cultures
of fibroblasts derived from lung carcinoma samples, which were designated -
JK-13.10 
HG-18.10 
BD-25.10
Three normal fibroblast cell cultures available from external cell culture collections 
were also analyzed
AG02603 Normal lung clinically unaffected (Source: NIH; Institute of aging)
AG02602A Normal skin clinically unaffected (Source : NIH; Institute of aging)
CCD-371u Normal lung (Source: ATCC)
The normal fibroblast cells AG02603 (lung) and AG02602A (skin) are a matched pair 
from the same patient. The skin cells are supplied at a later passage.
Immunocytochemistry was carried out using antibodies to the following antigens; 
Pan-Cytokeratin; Cytokeratin 8; Cytokeratin 18 and the results obtained are 
summarised in table 3.4.4.
Though all fibroblast cells stained positive for pan-cytokeratin (figure 3.4.8) the 
staining for specific cytokeratins was variable (figures 3.4.9 and 3.4.10). For example 
the JK-13.10 fibroblasts were negative for cytokeratins 8 and 18, the HG-18.10 
fibroblast cells were weakly positive for cytokeratin 8 and positive for cytokeratin 18, 
and BD-25.10 fibroblasts strongly positive for cytokeratins 8 and 18 (figures 3.4.9 and 
3.4.10).
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Pan-Cytokeratin Cytokeratin-8 Cytokeratin-18
AG02603
(Normal lung)
Positive Positive Positive
AG02602A
(Normal skin)
Positive Positive Positive
CCD-341u
(Normal lung)
Positive Positive Positive
JK-13.10 Positive Negative Negative
HG-18.10 Positive Weakly-Positive Positive
BD-25.10 Positive Positive N/A
Table 3.4.4 Summary of immunocytochemical analysis for cytokeratin 
expression in fibroblasts.
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Figure 3.4.8 Staining for pan-cytokeratin in various fibroblast cultures (x400).
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Figure 3.4.9 Staining for cytokeratin-8 in various fibroblast cultures (x400).
AG02603 (Lung)
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CCD-371u AG 02603 Skin AG 02603 Lung
k
.
HG-18.10 JK-13.10
AS49 Positive control
Figure 3.4.10 Staining for cytokeratin 18 in various fibroblast cultures (x400).
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4.0 DISSCUSSION.
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4.1 GENERAL INTRODUCTION.
The lung is a complex organ consisting of over 40 different cell types (Plopper, 1996), 
whose development has been divided into four chronological stages; I) the 
pseudoglandular stage, II) the canalicular stage, III) the terminal sac stage, and IV) the 
alveolar stage. It is only recently from studies of Drosophila mutants that tentative 
identification has been made of some of the developmental genes involved in lung 
morphology e.g. trachealess (Wilk et a l 1996) and branchless (Glazer and Shilo, 
1991). While progress has been made in the developmental genetics of lung 
morphogenesis, the differentiation pathway and the genes involved in development of 
specific cell types in the lung are still largely unknown. Research in this area has been 
hampered by the lack of identification of a stem cell population in vivo and/or the lack 
of in vitro cell line models to study lung cell differentiation.
What is known about lung cell differentiation comes from studies of the terminal parts 
of the differentiation tree where a specific basal cell will give rise to a discrete 
differentiated cell type, e.g. type II pneumocytes give rise to type I pneumocytes 
(Adamson and Bowden, 1979). Steps in the differentiation pathway earlier than this 
are unknown. It is hypothesised by Emura (1997) that a hierarchy exists within the 
lung cell differentiation pathway. His model envisages that a single stem cell exists 
for both the pseudostratified and simple epithelia. This single stem cell population 
conducts its role through various predifferentiated secretory cell populations, which in 
turn give rise to various functional cell types that may differentiate into further 
terminal stage cells (figure 1.3.3)
One of the principal aims of this thesis was to investigate the possible role of the cell­
cell adhesion molecule Ep-CAM in epithelial lung cell line differentiation, following 
BrdU treatment. The study utilised the poorly differentiated lung carcinoma cell line 
DLKP and the lung adenocarcinoma cell line A549 as models. The ability of 
halogenated thymidine analogues to induce differentiation was investigated. The 
investigation utilised Ep-CAM as a marker for differentiation to complement on going
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investigations of changes recently discovered in this laboratory in cytokeratin 
expression and Pi integrin expression (McBride et al., 1999; Meleady and Clynes, 
manuscript submitted).
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4.2 INDUCTION BY BrdU OF Ep-CAM EXPRESSION IN LUNG 
CELL LINES.
It is speculated that the cell line DLKP, which was derived from a lung tumour which 
was diagnosed as a poorly differentiated lung carcinoma, may serve as a model for a 
stem cell iike-population of the lung (McBride et a l, 1998). It thus may represent a 
valuable model for investigating the role of Ep-CAM in differentiating lung epithelial 
cells. The studies included a comparison with the cell line A549, which represents a 
more differentiated lung cell type, as it has been reported to express features of a type 
II pneumocyte cell (Lieber et al., 1976).
177
4.2.1 BrdU INDUCES Ep-CAM EXPRESSION IN BOTH DLKP AND A549.
Ep-CAM is described as having a wide distribution in normal human epithelia with 
expression found on the most simple, columnar and pseudostratified epithelia 
including bronchiolar and alveolar cells (Mombuerg et al., 1987)
Analysis of Ep-CAM expression by immunocytochemistry with the anti- Ep-CAM 
antibodies VU-1D9 and 323/A3 showed DLKP to be negative for Ep-CAM (figure
3.1.1) whereas A549 to be slightly positive for Ep-CAM (figure 3.1.2).
The lack of Ep-CAM expression in DLKP and the low level of expression in A549 
could be considered unusual, as Ep-CAM expression is reported to increase in most 
adenocarcinomas and de novo expression frequently occurs in carcinomas from 
squamous epithelia (Litvinov et al., 1996; Varki et al., 1984). In particular, strong Ep- 
CAM expression has been reported for small cell lung carcinoma cell lines 
(Moldenhauer et al., 1987).
Following exposure to 10 pM BrdU for 7 days, the morphology of both A549 and 
DLKP changed with the cells becoming enlarged and flattened in appearance. 
Immunocytochemical analysis revealed that the changes observed in morphology 
were accompanied by changes in the expression of Ep-CAM protein. DLKP was 
shown to express Ep-CAM de novo following BrdU treatment for 7 days. This 
staining appeared strongest in the cell membrane indicating that the protein was likely 
to be functional and to be active in the cellular physiology of BrdU-treated DLKP 
cells. In A549 cells immunocytochemical analysis revealed a similar increase and 
staining pattern for Ep-CAM protein expression following exposure to lOpM BrdU 
exposure.
While immunocytochemistry has the advantage of detecting changes in sub­
populations, which might not be noticeable in bulk methods such as western blotting, 
it should only be regarded a qualitative method, since changes in cell morphology 
may give the appearance of changes in protein expression. For this reason, western
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blot analysis was performed (section 3.1.2) to obtain quantitative results. DLKP and 
A549 were treated for 21 days with 10 (iM BrdU and time points were taken at day 7, 
day 14 and day 21. Treatment of DLKP with 10 (iM BrdU seemed to trigger de novo 
expression of Ep-CAM; as in untreated cells no protein could be detected but after 7 
days of treatment a protein band was detectable (figure 3.1.3). The expression of 
protein continued to increase until day 14, at which point it appears to have plateaued 
with no visible increase occurring between day 14 and day 21 of BrdU treatment. In 
A549 a similar pattern was observed (figure 3.1.4); untreated cells were found to 
express a low level of Ep-CAM which increased within 7 days of BrdU treatment. 
The expression of Ep-CAM continued to increase until day 14 at which point a 
plateau level was also reached.
Litvinov et al. (1996) reported that Ep-CAM was expressed in a stem cell-like 
population of cervical epithelial cells and that this expression was decreased when 
these stem cells differentiated into squamous epithelia. In metastatic disease states of 
the uterine cervix the expression patterns of the simple epithelial cell cytokeratins 8 
and 18 and of Ep-CAM were identically high (Litvinov et al., 1996).
Previous studies in our laboratory have shown that DLKP lacks the major 
cytokeratins, including cytokeratins 8 and 18 (McBride et al., 1999). The expression 
of cytokeratins 8 and 18 are indicative of early epithelial differentiation (Daly et al., 
1998). Thus the lack of these cytokeratins and of Ep-CAM expression would appear 
to confirm the theory that DLKP represents a cell population early in the 
differentiation pathway of lung epithelia.
It could be theorised that BrdU induces DLKP into a cell phenotype that represents an 
early stage in lung stem cell differentiation, involving changes in the cytoskeletal 
structure (induction of cytokeratin expression), a change in cell-cell binding as 
suggested by the induction of Ep-CAM, and a change in the recognition and affinity 
of extra-cellular matrix as implied by the induction of ai(3i and OC2 P1 integrins 
(McBride et al., 1999; Meleady and Clynes, manuscript submitted). It could be 
speculated that this stage of differentiation occurs prior to the expression of more
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specialised lung cell features such as surfactant proteins, microvilli, etc., and may be 
within stage II of the scheme proposed by Emura (section 1.3.2).
4.2.2 Ep-CAM INDUCTION BY BrdU IS AT THE POST- 
TRANSCRIPTIONAL LEVEL.
To investigate what effect BrdU had on the mRNA transcript levels for Ep-CAM, RT- 
PCR analysis was performed. The transcript levels were assessed over 21 days of 
BrdU treatment with time points of 7, 14 and 21 days.
Little is known about the regulation of Ep-CAM expression. Northern blot analysis 
identifies a 1.5kb mRNA species, which contains some recognition sequences that 
occur in the post-transcriptional control of certain proto-oncogenes and inflammatory 
mediators (Perez and Walker, 1989). Included in the 3’-non coding region of the Ep- 
CAM mRNA transcript is the consensus sequence TTATTTAT, associated with the 
inflammatory mediators (Perez and Walker, 1989). In addition, the 3’-non coding 
region of Ep-CAM contains the sequence ATTTA, which is a proposed recognition 
signal for the degradation processing of mRNA coding for a number of proto­
oncogenes, lymphokines and cytokines (Perez and Walker, 1989).
In both DLKP and A549, constitutive expression of Ep-CAM at the mRNA level 
occurred in untreated cells (figure 3.1.5). Following treatment with BrdU no change 
in levels of Ep-CAM mRNA was observed in either DLKP or A549. This result 
suggests that the BrdU induced de novo Ep-CAM protein expression in DLKP (and 
increased its expression in A549) is via post-transcriptional control mechanisms.
Studies in our laboratory (Derek Walsh, PhD. Thesis 1999) indicate that following 
BrdU treatment, the protein level and activity of eIF-4E, one of the rate limiting 
factors in translation of mRNAs with complex 5’ untranslated regions (5’-UTR), is 
increased. This increase provides for a possible explanation for an increase in Ep- 
CAM translation following BrdU treatment.
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4.2.3 ALTERATION IN FOCAL ADHESION PROTEINS FOLLOWING 
INDUCTION OF Ep-CAM BY BrdU.
Ep-CAM is believed to be a Ca2+ independent cell-cell adhesion molecule, which is 
involved in cell sorting. In vitro studies of cells transfected with Ep-CAM and non­
transfected cells show that when mixed the two cell populations will aggregate 
separately (Litvinov el al., 1994). Studies investigating the differentiation effects of 
the lectin Vicia faba  in the colon cancer cell line LS174T showed that Ep-CAM was a 
key regulatory molecule in the promotion of differentiation (Jordinson et al., 1999). 
These in vitro observations have been reflected in vivo studies which implicated Ep- 
CAM as important in the development of human fetal pancreas (Cirulli et al., 1998).
This homophilic cell-cell sorting by Ep-CAM is achieved by a disruption of cadherin 
(e.g. E-cadherin) mediated cell-cell adhesion. Litvinov et al., (1997) proposed the 
following model in which Ep-CAM-mediated disruption of adherens junctions was 
due to a redistribution of E-cadherin on the cell surface, rather than a down- 
regulation. This redistribution of E-cadherin, and hence disruption of its function, by 
Ep-CAM was via alterations in the focal adhesion proteins involved in binding E- 
cadherin to the cytoskeleton (figure 1.4.1). Specifically the focal adhesion proteins a- 
catenin, and P-catenin were down-regulated.
It was decided to investigate if the induction of Ep-CAM by BrdU induced such 
changes in focal adhesion proteins, a-catenin and a-actinin, in DLKP and A549.
The expression of Ep-CAM following BrdU exposure did induce a down-regulation 
of a-catenin in both DLKP and A549 that were treated for 21 days (figure 3.1.7). The 
level of decrease is quite impressive with a-catenin levels in both cell lines at half 
their original level following 7 days of 10|iM BrdU treatment. The level of detectable 
protein continued to decrease over the 21 days of BrdU treatment, so that by day 21 
only a very low level of a-catenin could be detected. This result is in agreement with 
the model proposed by Litvinov et al. (1997) which proposes that a-catenin levels 
decrease in response to Ep-CAM expression. This reduction of a-catenin levels would
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disrupt E-cadherin binding to the actin cytoskeleton, and hence cause its redistribution 
on the cell surface.
The expression level of a-actinin was also investigated in DLKP and A549 following 
BrdU induced expression of Ep-CAM (figure 3.1.8). A sharp level of decrease 
appeared between the level of protein detected in untreated DLKP and A549 and the 
same cells treated for 7 days with BrdU. This decrease was repeated though perhaps 
not as dramatically in cells treated for 14 day with BrdU. The observed decrease in 
the level of a-actinin of both DLKP and A549 that occurred over the 14 days of BrdU 
exposure was unexpected. The study by Litvinov et al. (1997) upon which the model 
of Ep-CAM action is based did not report any decrease in a-actinin. Rather Ep-CAM 
is believed to interact with the actin cytoskeleton via a-actinin. It possesses two 
potential binding sites on its cytoplasmic tail for the binding of a-actinin (see figure
1.5.2) (Balzar et al., 1998).
It would be interesting, in further work, to examine mRNA levels for a-catenin and a- 
actinin, and to determine if the down-regulation observed is at the transcriptional or 
post-transcriptional levels.
While disruption to E-cadherin binding is often seen as a prelude to metastatic events 
in cellular physiology, its down-regulation is also considered a normal element during 
development and differentiation (Christofori and Semb, 1999). One way E-cadherin 
function is known to be regulated is via the Rho family of small GTPases. These 
molecules regulate cellular processes by the phosphorylation of key regulatory 
proteins, members of this family include Rho A, Cdc42 and Racl, which are known to 
be involved in cell shape, cell growth and cell polarity (Tapon and Hall, 1997). 
Modulation of E-cadherin mediated cell-cell adhesion can occur via Cdc42 and Racl 
phosporylation of an intermediate target molecule IQGAP1, which competes for a- 
catenin binding with (3-catenin. This causes a reduction of a-catenin in the focal 
adhesion anchoring E-cadherin to the actin cytoskeleton, which subsequently causes 
E-cadherin to be localised on the cell membrane (Kuroda et al., 1998). It can be 
speculated that Ep-CAM modulates E-cadherin utilising this family of signalling 
molecules.
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Disruption of E-cadherin-mediated cell adhesion can also involve p-catenin. This 
mediation involves the phosporylation of tyrosine on p-catenin by the non-receptor 
tyrosine kinase Src, leading to the disassembly of the cadherin-catenin complex 
(Behrens et al., 1993). P-Catenin is an interesting protein as it is extremely 
multifunctional with roles in cell adhesion (Peifer, 1995), activation of transcription 
factors (Molenaar et al., 1996), and it is possibly involved in signal transduction via 
the EGF pathway (Hoschvetzky et al., 1999) and WNT pathways (Molenaar et al., 
1996). It is hypothesised that disruption of E-cadherin may lead to an increase in free 
P-catenin which may translocate to the nucleus and activate members of the 
TCF/LEF-1 family of transcription factors. A target for up-regulation by this family is 
the proto-oncogene myc (He et al., 1998). Such an increase in Myc protein levels has 
been observed in DLKP and A549 following BrdU treatment (Derek Walsh, PhD. 
Thesis 1999). Thus it is possible to contemplate that induction of Ep-CAM may have 
a significant influence on cell differentiation in DLKP and A549.
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4.2.4 INDUCTION OF mRNA TRANSCRIPT FOR GA733-1 IN BrdU
TREATED DLKP.
The GA733-1 gene is highly homologous to the gene for Ep-CAM (GA733-2). It is an 
intronless gene suggesting that it is due to a retro transposition (Linnenbach et al.,
1989). The mRNA transcript o f GA733-1 codes for a 35.7 KDa protein (Szala et al.,
1990). Little is known about the expression of this protein product. Limited northern 
blot data indicates that the GA733-1 mRNA and Ep-CAM mRNA is expressed 
differentially (Szala et al., 1990).
RT-PCR analysis o f untreated DLKP did not show any detectable transcripts for 
GA733-1 (figure 3.1.6). Following treatment with 10|aM BrdU, however, mRNA for 
GA733-1 was detected in DLKP after 7 days. The level o f this mRNA increased 
slightly after 14 days, at which point a plateau appeared to be reached with no 
discernible increase in cells treated for 21 days. This contrasted sharply with the 
results obtained for A549 where no mRNA for GA733-1 was detected in pre- and 
post- BrdU treated cells.
It appears that GA733-1 transcription is induced differently following 10|iM BrdU 
treatment in DLKP and A549. It could be speculated that in DLKP, BrdU induces a 
promoter or removes a suppresser o f transcription for GA733-1, while in A549 this 
change in transcription is blocked by a failure to induce such changes. This may be 
due to the difference in the differentiation status of these cells (i.e. A549 is more 
differentiated then DLKP), hence certain genes may be under different degrees of 
control. Furthermore, it suggests that Ep-CAM and GA733-1 protein expression is 
controlled via different mechanisms (at least in the cell line, DLKP), the former being 
post-transcriptional while the latter is transcriptional.
Investigation into the protein expression of GA733-1 was hindered by the lack of a 
commercially available antibody. After several attempts an antibody to the GA733-1 
protein was sourced and this was still being waited upon at the time o f writing. It was 
not known if  the antibodies used for Ep-CAM detection were able to cross-react with
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GA733-1 protein. However, protein bands with molecular weight lower than Ep- 
CAM were detected but these were regarded as background bands. Balzar el al. 
(1998) obtained a similar pattern of lower molecular weight products in their 
experiments, which they regarded as breakdown products o f Ep-CAM.
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4.3 INVESTIGATION OF THE EFFECTS HALOGENATED
THYMIDINE ANALOGUES HAVE ON THE
DIFFERENTIATION OF DLKP AND A549.
The halogenated thymidine analogue 5-Bromo-2’-deoxyUridine (BrdU) is known to 
stimulate or inhibit the differentiation o f different cell types. McBride et al. (1999) 
demonstrated that the differentiation-inducing effects of BrdU on DLKP and A549 
were not the result of simple toxic exposure, as adriamycin, for example, did not 
produce the same effect.
The exact mechanism by which BrdU exerts its differentiation-modulating effects is 
unknown though incorporation in DNA would seem to be critical (O’Neill and 
Stockdale, 1974). It was thus decided to investigate the ability o f other halogenated 
thymidine analogues to induce differentiation in DLKP and A549. For this study it 
was decided to utilise the expression of cytokeratin (CK) -8, -18, and -19, Ep-CAM, 
and Pi integrin as markers o f differentiation in the two cell lines. The halogenated 
analogues of thymidine chosen for comparison with BrdU were 5-Fluro-5- 
deoxyUridine, 5-Chloro-2-deoxyUridine, and 5-BromoUridine (their structures are 
shown in figure 4.3.1). Preliminary experiments were performed to establish toxicity 
profiles of each analogue, and from these results concentrations were selected that 
would allow a 75% or greater survival rate.
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Figure 4.3.1 Structures of halogenated thymidine analogues used for
differentiation studies.
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4.3.1 THE EFFECTS OF 5-FLURO-5-DEOXYURIDINE ON THE
DIFFERENTIATION STATUS OF DLKP AND A549.
The toxicity profile for 5-Fluro-5-deoxyUridine (5,5’-FdU) revealed that it was 
particularly cytotoxic (figure 3.2.1). A concentration of 2(j,M was selected as the 
optimum concentration to allow 75% survival in both DLKP and A549.
The change of morphology in both cell lines following 7 days of treatment with 5,5- 
FdU was investigated (figures 3.2.3 and 3.2.4). Both cell lines exhibit a reduction in 
growth compared with untreated cells, and the cells adopted a more flattened 
morphology, though not as stretched as those cells treated with BrdU. It was noted 
that DLKP seem to grow in loose colonies following treatment with 5,5'-FdU, 
whereas A549 cells were inclined to grow as single cells.
Immunocytochemical analysis was conducted to investigate if  the observed alterations 
in morphology were accompanied by changes in marker protein expression in 5,5'- 
FdU treated DLKP and A549. CK-8 expression appeared to be induced in DLKP 
(figure 3.2.5 C) following 7 days treatment. Similarly, in A549 treated with 2 |_iM 
5,5'-FdU an increase in CK-8 was observed (figure 3.2.6 C). A comparable increase 
occurred in the expression of CK-18 in both DLKP and A549 (figure 3.2.9 C and 
3.2.10 C). The expression of CK-8 and CK-18 are associated with early epithelial 
differentiation (Daly et al., 1998), hence their induction in DLKP is indicative of an 
early stage in the differentiation pathway. Both cell lines also exhibited an increase in 
CK-19, which can partner CK-8. This increase is often used as a marker for type II 
pneumocytes (Paine et al., 1995). The expression of these cytokeratins appear to 
match the expression patterns observed for BrdU-treated DLKP and A549. To 
quantify the changes in protein expression, western blot analysis was performed. 
Western blot analysis o f CK-8 expression in A549 treated with 5,5’-FdU showed a 
strong increase in protein expression after 7 days treatment, which further increased 
after 14 days treatment (figure 3.2.7). The observed increase appeared to be greater 
then that seen after BrdU treatment. Similar increase in expression was observed for 
CK-18 (figure 3.2.11) and CK-19 (figure 3.2.15) expression following 5,5’-FdU
188
treatment. These also showed greater expression than BrdU treated cells. RT-PCR 
analysis lead to the conclusion that the induction of CK-8, CK-18, and CK-19 by 5,5'- 
FdU was at a post-transcriptional level
DLKP appears to exhibit an increase in (3j integrin expression and an induction in Ep- 
CAM expression. The observations made for Pi integrin and Ep-CAM induction 5,5'- 
FdU treated DLKP are similar to those made in BrdU treated DLKP.
Immunocytochemical analysis o f A549 appeared to indicate that Pi integrin 
expression was reduced and no induction of Ep-CAM occurred. However, western 
blot analysis showed an increase in Pi integrin and an induction o f Ep-CAM 
expression. Unfortunately, due to time constraints repeat experiments with fresh 
treatments were not possible to clarify this anomaly. RT-PCR analysis o f A549 did 
not indicate any significant alteration in Ep-CAM mRNA levels indicating that 
protein induction was at a post-transcriptional level.
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4.3.2 THE EFFECTS OF 5-CHLORO-2-DEOXYURIDINE (CdU) ON THE
DIFFERENTIATION STATUS OF DLKP AND A549.
The ability of 5-Chloro-2-deoxyUridine (CdU) to induce differentiation was also 
investigated. Initial investigation into the toxicity o f CdU (figure 3.2.2) suggested that 
the ideal concentration for a 75% survival rate in DLKP was 10(oM and for A549 was 
30(iM. It was discovered subsequently that cumulative exposure to CdU was 
especially cytotoxic to A549. Thus a concentration o f 10(j,M was chosen as being less 
cytotoxic to A549 over the treatment periods.
DLKP and A549 treated with CdU for 7 days were investigated for morphological 
change. Both DLKP and A549 became very flattened and stretched (figures 3.2.3 G 
and H, and 3.2.4 G and H). The observed alteration in morphology after CdU 
treatment was very reminiscent o f the changes exhibited in DLKP and A549 after 
BrdU treatment.
Analysis of the selected marker proteins by immunocytochemistry revealed that CK- 
8, CK-18, and CK-19 were induced in DLKP following CdU treatment. In particular, 
CK-18 was strongly expressed in DLKP. Assessment o f the immunocytochemistry 
results in A549 was difficult due to the increase in cell size. It appeared that CK-8 and 
CK-18 expression was increased following CdU treatment o f A549. An increase of 
CK-19 in A549 post-CdU was also suggested.
Since immunocytochemistry is only qualitative, western blot analysis was performed 
to obtain a more quantitative result for changes in expression in A549. Unfortunately, 
due to the cumulative toxicity it was difficult to obtain a sample for 14 days treatment. 
The western blot analysis confirmed that 7 days o f CdU treatment increased the 
expression of CK-8 (figure 3.2.7), CK-18 (figure 3.2.11), CK-19 (figure 3.2.15). The 
level of increase observed for each of the cytokeratins in A549 after 7 days CdU 
treatment was comparable to the level of increase in cytokeratins in A549 after 7 days 
BrdU treatment. Treatment with (10(iM) CdU induced Ep-CAM and Pi integrin 
protein expression.
190
RT-PCR analysis o f 10|jM  treated A549 indicated that the mRNA level for CK-8, 
CK-18, CK-19, and Ep-CAM were not altered. This leads to the conclusion that CdU 
induces these proteins at a post-transcriptional level.
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4.3.3 THE EFFECTS OF 5-BROMOURIDINE (5-BUr) ON THE
DIFFERENTIATION STATUS OF DLKP AND A549.
The toxicity profiles for 5-BUr in both DLKP and A549 revealed that it did not 
appear to be very toxic. A concentration of 70|aM was chosen for the differentiation 
experiments as being the most practical. Morphological studies for DLKP and A549 
treated for 7 days with 5-BUr (figures 3.2.3 and 3.2.4) did not reveal any obvious 
alterations in morphology.
Immunocytochemical analysis of DLKP treated with 70|jM  5-BU for 7 days appeared 
to show no induction o f CK-8 (figure 3.2.5 E) and CK-19 expression (figure 3.2.13 
E). There appeared to be a very slight induction in CK-18 in DLKP. Treatment of 
A549 for 7 days with 5-BU did not reveal any alteration in CK-8, CK-18, CK-19, p i-  
integrin and Ep-CAM expression. Western blot analysis for A549 did not appear to 
show any obvious increases in CK-8 (figure 3.2.7), CK-18 (figure 3.2.11), and CK-19 
(figure 3.2.15) production, confirming the immunocytochemical observations. RT- 
PCR analysis did not indicate any change in mRNA levels of CK-8, CK-18, CK-19 in 
A549 indicating that induction is occurring at a post-transcriptional level.
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4.3.4 MECHANISMS OF BIOLOGICAL AND TOXIC ACTIONS VARY 
ACCORDING TO HALOGENATED THYMIDINE ANALOGUE.
The halogenated thymidine analogues 5,5'-FdU and CdU induced a similar pattern of 
differentiation in DLKP and A549 to that observed in BrdU treatments (Tables 4.2.1 
and 4.2.2), while according to markers investigated, the analogue 5-BUr did not 
generally induce any differentiation in either DLKP or A549, with the exception of 
Ep-CAM induction.
4.3.4.1 Mechanism of the biological action of BrdU.
The exact mechanism by which BrdU modulates differentiation has yet to be 
elucidated and a number o f models exist (section 1.4.2.1). All studies published to 
date indicate that its stable incorporation into DNA in competition with thymidine is 
required. This incorporation entails BrdU being converted to bromodeoxyuridine 
monophosphate by thymidine kinase (O’Neill and Stockdale, 1974; Morrill et al., 
1980; Cortés et al., 1987). BrdU incorporation into DNA occurs in a non-random 
fashion, with incorporation occurring into repeated nucleotide sequences (Schwartz 
and Snead, 1982). This consistency in the location of incorporation which may 
explain the reproducibility of BrdU-induced differentiation. These repeated nucleotide 
sequences include areas known as ‘fragile sites’ (Hecht et al., 1988). It is envisaged 
that breakage’s may occur at these points and these breakage’s and the associated 
chromosomal aberrations may be associated with stepwise changes in the 
differentiation o f a cell (Alexander et al., 1992). This substitution of BrdU into DNA 
may also induce effects similar to DNA-intercalating agents; these alter DNA bending 
at either major or minor groves, and in doing so alters the structure o f the promoter 
regions, and the affinity for DNA binding proteins. Lin and Riggs (1972) 
demonstrated this, when they showed that BrdU substitution in the lac operon allowed 
the lac supressor to bind with greater affinity. Thus, BrdU is likely to exert its effects 
on differentiation by alteration of an essential regulatory gene(s) that alters 
transcription o f genes involved in differentiation (Arnold et al., 1988; Rauth and 
Davidson, 1993). For example, in BrdU inhibition o f myoblast differentiation, such an
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alteration occurs with the down-regulation or complete inhibition o f the key 
regulatory gene M yoDl (Tapscott et a l,  1989; Nanthakumar and Henning 1995).
While BrdU is commonly used as an agent for the modulation of differentiation, only 
limited research has been performed on the ability o f other halogenated thymidine 
analogues. Three different analogues were selected for investigation, CdU, 5,5'-FdU, 
and 5-BUr, each possessing a different mechanism of action.
4.3.4.2 Mechanism of the biological action of CdU.
CdU like BrdU is converted into a nucleoside monophosphate (chlorodeoxyuridine 
monophosphate) by thimidine kinase and then incorporates into DNA for thymidine 
(Cortés et al., 1987). Most research on CdU has focused on its ability to generate 
chromosome breakage’s and sister chromatid exchanges. BrdU similarly possesses 
this capacity to generate such chromosome breakage’s, though CdU is a more potent 
inducer (Cortés et al., 1987). For instance, CdU is reported to induce 7-8 fold more 
sister-chromatid exchanges than BrdU, at an equal substitution level in cultured 
Chinese hamster ovary cells (O ’Neill et al., 1983). This higher rate o f sister chromatid 
exchanges associated with CdU may explain the cumulative cytotoxicity observed 
with CdU treatments of A549 and DLKP. Though only cells treated for 7 days were 
available for analysis, the pattern and strength o f induction of proteins appeared to be 
similar to that observed in BrdU treatment.
In the case o f the protein markers selected, the observed increase in protein level is 
due to changes in post-transcriptional control rather than an increase in transcription. 
This appears to be in contradiction with a mechanism of differentiation modulation 
involving alterations in DNA. Studies in our laboratory (Derek Walsh, PhD. Thesis 
1999) may reconcile this apparent contradiction, as they indicate that following BrdU 
treatment, the protein level and activity o f eIF-4E, the rate limiting factor in 
translation is increased. Thus, it appears that the substitution o f a chloro-group in 
place of a bromo-group, may induce similar alterations in DNA resulting in the 
ultimate induction o f the same marker proteins. Baker et al. (1979) noted that BrdU
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and CdU increased interferon production in the Namalwa line o f human 
lymphoblastoid cells.
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4.3.4.3 Mechanism of the biological action of 5,5'-FdU.
The treatment o f DLKP and A549 with 5,5'-FdU also induced similar changes in 
marker protein expression to treatment with BrdU. Although a similar pattern of 
expression o f differentiation exists between BrdU and 5,5'-FdU treated cells, the 
mechanisms by which these agents are thought to exert their biological effects is quite 
different.
As stated previously, BrdU is incorporated into DNA and this incorporation 
ultimately alters the expression of differentiation related proteins. In contrast, 5,5'- 
FdU is cleaved by a nucleoside phosphorylase enzyme to yield 5-flurouracil (5-FU) 
(Armstrong and Diasio, 1980). The 5-FU generated is subsequently metabolised via 
several steps to yield fluorodeoxyuridine monophosphate (FdUMP) (figure 4.3.2) 
(Pratt et al., 1994).
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Thymidine Synthase
Figure 4.3.2 Pathway of 5,5’-FdU metabolism.
FdUMP binds to thymidylate synthase, forming an irreversible covalent ternary 
complex in which enzyme, folate cofactor, and FdUMP are bound, thus inhibiting 
thymidine monophosphate production and hence DNA synthesis (Pratt et al., 1994). 
This inhibition o f DNA synthesis causes cells to be delayed in the S-phase (see figure
induce stem cell differentiation. For example, retinoic acid induced differentiation of 
the embryonal carcinoma cell line P C I3 to ‘endoderm-like’ cells is accompanied by 
such an increase in S-phase (Nishimure et al., 1983; Mummery et al., 1984). In 
contrast, terminal cell differentiation is associated with a prolonging o f the G1-phase 
of the cell cycle, thus suggesting that different molecular pathways are involved in 
terminal and stem cell differentiation (Nishimune et al., 1989). Thus, the inhibition of 
DNA synthesis and subsequent delay in S-phase in DLKP and A549 by 5,5'-FdU via 
the 5-FU metabolic pathway may trigger the molecular mechanisms required for 
differentiation.
4.2.3 for a summary o f the cell cycle). The inhibition o f cell growth in S-phase can
Sphase : begins 
when DNA synthesis
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Separates the end 
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from the 
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Figure 4.2.3 Summary of the cell cycle.
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Though inhibition o f growth may be a side effect and not a cause o f differentiation. 
Baker et al. (1979) noted that BrdU increased interferon production by the Namalwa 
line o f lymphobastoid cells while inhibiting growth. Thymidine also inhibited growth 
but had no effect on interferon production.
The similarity in the induction of marker proteins in A549 and DLKP by BrdU and 
5,5'-FdU is thus most unusual, given their different mechanisms of action. Nishimune 
et al. (1989) reported that 5-Fluro-2-deoxyuridine (5,2'-FdU)(figure 4.2.2) induced 
differentiation of the teratocarcinoma cell line F9 to produce plasminogen activator, 
while similar treatment with BrdU failed to induce such expression. In contrast, 
Kidson and deHann (1990) reported that while BrdU induced differentiation in the 
mouse melanoma cell line BL-6 and reduced tyrosine activity, any similar reduction 
in tyrosine activity observed with 5-Fluro-2-deoxyuridine was due to cytotoxicity 
effects rather than differentiation. This suggests that in A549 and DLKP that 
induction of differentiation may be via a different mechanism than DNA 
incorporation or that the two compounds induce similar differentiation pathways via 
different mechanisms. Such a similar mechanism may be the inhibition o f poly ADP- 
ribose polymerase (PARP). Pivazylan et al. (1992) reported that BrdU, CdU and 5,2'- 
FdU along with several other halogenated analogues of thymidine were good 
inhibitors of PARP. The PARP enzyme is located in the nucleus and catalyses the 
transfer o f ADP-Ribose from NAD+ to target proteins (Pivazylan et al., 1992). 
Among the list o f target proteins is eEF-2, an elongation factor in the ribosomal 
complex involved in translation. The binding to eEF-2 o f poly-ADP-ribose inhibits its 
activity, thereby halting protein synthesis (D'amours et al., 1999)
Though the pattern o f marker protein induction was similar with BrdU, 5,5'-FdU 
appeared to produce stronger induction. This may be due to an alternative element of 
5,5'-FdU mechanism of action involving RNA. As the concentration of 5-FU 
increases within the cell, the 5-FU metabolic pathway may produce other metabolites 
most notably fluorouridine triphosphate (FUTP) (figure 4.2.2) which can become 
incorporated into RNA in place o f UTP (Pratt et al., 1994). This incorporation may 
alter post-transcriptional controls (e.g. specific mRNA stability) allowing the selective 
translation o f differentiation specific mRNAs. It has been demonstrated in this
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laboratory that CK-8 and CK-18 protein expression is under post-transcriptional 
control (McBride et ah, 1999) and furthermore, upon BrdU treatment this post- 
transcriptional control is released due to changes in eIF-4E levels and activity.
4.3.4.4 Mechanism of the biological action of 5-BUr.
5-BU is reported to affect cells most during S-phase when 5-BUr is maximally 
incorporated into cellular RNA (Li et al., 1994). The incorporation of 5-BUr at high 
levels into pre-mRNA prevents splicing o f the transcripts; only if  the level of 
substitution is low (1 out o f every 10 uridines) does splicing occur normally 
(Sierakowska et al., 1989, Wansink et al., 1994). From the results obtained for 5-BUr 
treated DLKP and A549, it would appear that the induction of differentiation by 
halogenated thymidine analogues requires an alteration in DNA to produce any 
changes in marker protein (Ep-CAM induction being an exception). However, the 
failure to observe any major effects following 5-BUr treatment in both cell lines may 
have been due to the concentration utilised not being sufficiently high to induce 
differentiation.
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4.4 ELUCIDATION OF IN  VIVO DIFFERENTIATION 
THROUGH THE DEVELOPMENT OF IN  VITRO 
MODELS.
In a further attempt to develop a range o f in vitro models to elucidate the pathways of 
epithelial lung differentiation in vivo, growth of the lung cell lines DLKP and A549 in 
a medium supplemented with a variety o f growth factors and hormones was 
investigated. The establishment of primary cultures from human lung tumour samples 
and normal type II pneumocytes from rat lung was also undertaken. Development of 
such models would allow the signals, mechanisms and stages o f in vivo epithelial lung 
cell differentiation to be investigated in a controlled environment. Such models may 
also aid in the elucidation of the putative epithelial stem cell o f the lung.
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4.4.1 A MEDIUM SUPPLEMENTED WITH A VARIETY OF HORMONES 
AND GROWTH FACTORS, INDUCES DIFFERENTIATION IN DLKP 
AND A549.
The lung cell line DLKP was isolated in our laboratory from a tumour histologically 
diagnosed as a poorly differentiated lung carcinoma. It lacks many of the 
ultrastructural features associated with normal differentiated cells o f the lung, such as 
dense core granules or lamellar bodies (McBride et al., 1998). DLKP also fails to 
express many of the normal cytochemical markers associated with differentiated 
epithelial lung cells for example cytokeratin proteins, desmosomal proteins, etc. 
(McBride el al., 1998). Due to this extensive deficiency of differentiation-associated 
markers and the ability to induce the expression of some o f these markers with the 
differentiation-modulating agent BrdU, it is reasonable to regard DLKP as behaving 
at least to some extent as a human lung stem cell (McBride et al., 1999).
To date there has been no positive identification o f the stem cell population in lung 
tissue. Prof. Emura’s group in Germany has isolated a cell line (M3E3/C3) from 
hamster fetal lung tissue, which has properties of being a lung stem cell Tike’ 
population. Emura and his colleagues have described the differentiation o f this cell 
line into different functional cell types e.g. type II pneumocytes, by utilising different 
culture conditions and a complex hormone supplemented media (Germann et al., 
1993). Since DLKP shares a lot o f the cytochemical features o f M3E3/C3 such as lack 
of cytokeratin protein expression, it was decided to investigate the ability o f such a 
hormone supplemented media (HSM) to induce differentiation in DLKP and A549. It 
was hoped that the complex interaction o f the various constituent hormones and 
growth factors may replicate the in vivo system.
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4.4.1.1 Effects of a Hormone Supplemented medium on cell morphology and the 
expression of differentiation markers in DLKP and A549.
It was observed that growth of DLKP cells grown in HSM for 7 days, resulted in the 
cells developing a squamous morphology (figure 3.3.1), similarly A549 also adopted 
a squamous morphology (figure 3.3.2). The number o f cytoplasmic granules appeared 
to be increased in A549 during the 7 days of growth under HSM conditions. Since 
A549 is believed to be derived from a type II pneumocyte cell, the increase in the 
number o f cytoplasmic granules may indicate an increase in the lamellar bodies 
associated with type II cells.
The changes in morphology were seen as indicative of possible changes in protein 
expression. Thus immunocytochemical analysis was performed using CK-8, CK-18, 
CK-19, Pi-integrin, and Ep-CAM protein expression as markers o f differentiation.
Immunocytochemistry o f DLKP showed expression o f CK-8, CK-18 and CK-19 
apparently induced following growth for 7 days in HSM. As stated previously the 
expression of CK-8 and CK-18 is associated with early epithelial development 
(Casanova et al., 1995). Ep-CAM expression was also induced, suggesting that Ep- 
CAM may play a role in early epithelial differentiation. Western blot analysis was 
performed to quantify the changes in marker protein expression observed by 
immunocytochemical analysis. It was not possible to detect the cytokeratin expression 
in DLKP cells, suggesting that immunoprecipation was required.
A549 cells cultivated in HSM for 7 days appear to show slight increases in CK-8 and 
CK-18 expression by immunocytochemical analysis. The predominant cytokeratin in 
type II pneumocytes is CK-19. The detected increase in CK-19 expression was 
significant, since A549 is considered a type II pneumocyte ‘like’ cell line (Paine et 
al., 1995; Lieber et al., 1976). A549 also exhibited an increase in Ep-CAM protein 
expression shown by immunocytochemistry and western blotting after 7 days of 
growth. In A549 cells the western blot analysis confirmed a slight increase in CK-18 
protein expression. A strong increase was also observed in A549 over the 14 days of 
growth in HSM in CK-19 expression confirming the immunocytochemical results.
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The increase in cytoplasmic granules and the increase in CK-19, a marker for type II 
pneumocyte cells, may indicate that in this medium A549 is reverting to a more 
normal type II pneumocyte phenotype. Further indication came from RT-PCR 
analysis which showed a decrease in mRNA levels for CK-18, and a concurrent 
increase in the levels in CK-19 mRNA. To confirm this, further research is required 
into the expression functional proteins such as surfactant proteins and the ability to 
produce surfactant lipid. If  A549 can be induced to revert to a more type II 
pneumocyte phenotype it may provide a useful in vitro model for investigation o f type 
II pneumocyte cell biology.
Several elements of the growth medium have been identified as having possible roles 
in differentiation. The importance o f the glucocorticoid steroids, for example, was 
shown important in the maturation o f type II pneumocytes and Clara cells (Muglia et 
al. 1999; Beaulieu and Calvert 1981). EGF has also been identified as a possible key 
regulatory molecule in lung epithelial cell differentiation (Sundell et al. 1980; Gross 
et al. 1986). Studies investigating fetal lung development have shown localisation of 
EGF in the developing bronchi and around both Clara cells and Type II pneumocytes 
(Raaberg et al. 1991). Also shown to be important in lung growth and differentiation 
is insulin, with receptors for insulin been demonstrated on whole fetal lung and their 
numbers to increase during late gestation (Ulane et al. 1982).
The growth in HSM induced the expression o f differentiation related markers in both 
DLKP and A549. Since it consists of a range o f factors found physiologically, further 
analysis of the components may indicate the physiological factors controlling 
epithelial lung cell differentiation in vivo. With this hormonal treatment it would be of 
interest to identify what components lead to differentiation or if  a combination of 
factors are required. For example, cell signal transduction often requires two separate 
events, the binding o f a growth factor to its receptor and the binding of an integrin to 
its ECM (Cunha et al., 1985). Prof. Emura and colleagues employed a range of 
substrata and extracellular matrix factors during their studies and these may have 
provided additional signals.
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4.4.1.2 Assessment of the role played by individual components of HSM in the 
differentiation of DLKP and A549.
To attempt an identification o f the elements important in HSM for the observed 
induction of differentiation, experiments deleting individual components from the 
media were performed. The effect of selective deletion was assessed after 14 days in 
culture by western blot.
The removal o f EGF from HSM did not seem to change its ability to induce the 
expression of the selected marker proteins i.e. CK-8, CK-18, CK-19, and Ep-CAM 
during 14 days o f growth. Several in vivo studies have suggested that EGF and the 
EGF family have a role in regulating early lung branching morphogenesis and with 
differentiation by the induction of surfactant protein C expression (Seth et al., 1993, 
Warburton et al., 1992). Another physiological role for EGF in lung tissue is the 
induction of proliferation in mature type II pneumocytes (Haigh et al., 1989; Raaberg 
et al., 1992). In contrast to these reports of EGF being a positive modulator o f lung 
development, McCormick et al. (1995) reported that regulation of differentiation in 
the form of induced alkaline phosphatase expression, was inhibited by EGF. This 
suggests that EGF may regulate different genes, and that this regulation is both time 
and co-signalling molecule-dependant.
Surprisingly, the removal o f hydrocortisone or oestrogen from the HSM resulted in a 
slight additional induction o f CK-8, CK-19, and Ep-CAM protein expression in A549. 
This suggests that the steriod hormones are damping the inducing effect o f other 
components in HSM. According to Spiers et al., (1991) the effect o f glucocorticoid 
steriods on induction o f alkaline phosphatase in A549 is very limited, and this may be 
due to a lack of distal elements of the glucocorticoid receptor system (Ballard et al., 
1978).
In contrast, the deletion of insulin caused a profound decrease in the ability of HSM to 
cause induction of differentiation in A549. This correlates with reports of insulin 
being important in differentiation and development in other tissues, for example in the 
induction o f breast secretory epithelium (Takahashi et al., 1991; McCormick et al.,
1995) also reported that insulin, along with interferon-a and interleukin-6, induced
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alkaline phosphatase expression in A549. Insulin is reported to be able bind to 
insulin-like growth factor receptors (IGF-R), though with a lower affinity than the 
insulin-like growth factors. It is possible that insulin in this system is exerting its 
influence by binding and signalling through the IGF-R pathways. In vivo studies have 
demonstrated that the IGF family, their binding proteins and their receptors, are 
expressed in both rodent and human fetal lung in a differential manner (Lallemand et 
al., 1995). For example, the insulin growth factor binding protein-2 showed strong 
gene and protein expression in the fetal lung epithelial alveoli and airways cells 
(Klempt et al., 1992). It has been suggested that the physiological role o f IGF- 
signalling is to facilitate the signalling o f other molecules. For example, IGF-1R 
signalling is required for the mitogenic and transforming activities o f the EGF 
receptor (Coppala et al., 1994). It is of interest that insulin was the only factor whose 
deletion resulted in a decrease in the ability o f HSM to induce differentiation.
The deletion of cholera toxin from HSM resulted in a large induction o f CK-19 and 
Ep-CAM expression, suggesting that this component had a damping effect on the 
induction of proteins. Cholera toxin stimulates the adenylate cyclase pathaway to 
induce its effects.
It appears from the deletion experiments that components such as hydrocortisone, 
oestrogen and cholera toxin all inhibit strong induction o f the selected marker 
proteins. This assessment may be a bit simplistic as removal o f cholera toxin allowed 
a very strong increase in protein expression, even though oestrogen and 
hydrocortisone appeared to also suppress protein induction. It may be speculated that 
individual components stimulate various elements required for differentiation, which 
then interrelate with each other. The differentiation induced by HSM is different from 
that induced by the halogenate thymidine analogues as it is more physiologically 
relevant. Furthermore RT-PCR analysis showed HSM induced changes in the levels 
of CK-18 and CK-19 mRNA, suggesting transcriptional control unlike the thymidine 
analogues which seem to act at a post-transcriptional level.
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4.4.2 PRIMARY CULTURE OF LUNG CARCINOMAS.
Though establishment o f tumour cell lines from solid human tissue appears relatively 
simple, reports in the literature are usually on singular successes. Thus, the successful 
routine establishment o f cell lines from primary cultures o f carcinomas is still a 
distant and elusive goal. The development o f such routine cultures would potentially 
allow clinicians to design optimum therapeutic schedules and scientists a better 
understanding of the biology of tumour growth.
The principal aim o f this investigation was to evaluate the different techniques for 
generating primary cultures from human lung carcinomas, and to develop the
foundation for in vitro models to study differentiation in such cells.
This project analysed a total of 52 lung tumour samples, mainly from lobectomy 
patients. Most produced epithelial cells that grew/survived in vitro for short periods 
only before dying out or becoming overgrown with fibroblasts. Unfortunately, no cell 
lines were generated, suggesting that primary tumours are not necessarily a good 
source of material for cell line generation. If  one investigates the literature it is found 
that most success has been with marrow aspirates and effusions from patients with 
metastatic lesions (Carney et al., 1985). It may be that the more malignant/metastatic 
a cell is the more it can adapt to the artificial in vitro environment of cell culture. 
Also, solid tumours are often very necrotic and only the leading edge is viable. It is 
optimistically estimated that only 10-20 % of cells in a large tumour mass are viable 
(Leibovitz 1986). The most successful culture obtained was from a malignant 
melanoma of the oesophagus (W S-lll)(see  figure 3.4.5). The ultimate failure of this 
culture may have been due to an unsuitable in vitro culture environment.
The work to date shows that primary tumours are not necessarily an ideal tissue 
source for cell lines. However, it could be quite successful as a source for short-term 
growth of epithelial cells from tumours.
In evaluating an optimum technique that would allow cultivation of epithelial tumour 
cells with little interference from stromal cells, i.e. fibroblasts, it was decided to
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concentrate on enzymatic versus explant techniques. It was found that the explant 
method was no more successful than the enzymatic methods in either cultivation of 
epithelial tumour cells or in the reduction o f fibroblast cells, as also noted by 
Leibovitz (1986).
In order to investigate if the enzymes used to disaggregate the tissue sample could 
adversely affect the ability of epithelial cells to grow in culture, two different types of 
enzymatic disaggregation were evaluated. One involved a mix of collagenase, 
dispase, and pronase E and the other used just trypsin. Neither method seemed to 
confer an advantage to the isolation and generation o f epithelial colonies, nor was any 
major difference noted in the level o f stromal cells.
When generating primary by enzymatic means it has been suggested that the clumps 
that are retained on the 40 and 100f.iM mesh cell strainers may be the best source for 
generating epithelial cell cultures and cell lines. Me Bain et al. (1984) reported a 33% 
success rate for generating colon carcinoma cell lines from such cell clumps. In the 
procedure utilised here for generating primary cultures, only a coarse filtering was 
employed with a stainless steel tea strainer in order to filter out very large fibrous 
tissue pieces. Thus the cell suspension plated contained clumps of cells. A future 
study looking at the culture of such clumps isolated using 40 and 100 |im mesh cell 
strainers may be a more successful option for the generation o f cell lines, or in the 
general culture o f epithelial cells from tumours.
When generating primary cultures from lung carcinomas an added complication is the 
wide variety o f cell types from which the carcinoma can arise, as 40 or more different 
cell types occur within the lung (Crapo et al., 1982). Given this complexity, the 
development of optimal growth conditions is difficult. The development o f optimal 
culture conditions is important in primary culture as both growth factors and integrins 
can determine cell proliferation, differentiation and apoptosis. Hence, the 
identification o f a good general culture environment with equal emphasis on media 
and ECM would be important in any future primary culture work.
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IIf the generation of cell lines is deemed to be important two methods which could be 
evaluated for success are the transformation of cells by SV40, or the passaging of 
isolated cells in nude mice/rats several times prior to primary culture.
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4.4.3 IN VITRO DIFFERENTIATION OF FIBROBLAST CELLS.
This work arose from the serendipitous discovery that fibroblast-like cells isolated 
during primary culture o f lung carcinomas were positive for cytokeratin. The 
definition of a fibroblast is a cytokeratin-negative, vimentin-positive cell, and this 
expression pattern is considered a marker for such non-epithelial cells. Epithelial cells 
are identified as being cytokeratin-positive, and are negative for vimentin in vivo. 
However, once in an in vitro environment epithelial cells will quickly begin to express 
vimentin.
The results obtained from fibroblast cells obtained in the primary culture o f lung 
carcinoma and 3 normal fibroblast cell cultures obtained from external culture 
collections are at variance with this criterion of being a cytokeratin negative cell.
It should be noted that the pattern o f expression was not consistent across all the cells 
investigated. All cells were positive for pan-cytokeratin but varied in their expression 
for the specific cytokeratins 8 and 18, perhaps suggesting that other cytokeratins may 
be expressed besides 8 and 18, which are considered the early cytokeratin genes 
during in vivo development. As described in section 1.2.1. cytokeratin 19 can interact 
with the vimentin cytoskeleton, thus suggesting that in some cases the cytokeratin 
detected is not involved with a true cytokeratin cytoskeleton.
Since the cells were fibroblast-like only in morphology, it was important to 
investigate other antigenic markers to determine the true identity o f the cells. One 
such antigenic marker was proly-4 hydroxylase, which is considered a fibroblast 
marker (Dako). Immunocytochemical staining for this antigen indicated that the cells 
were fibroblasts. However, as staining was detected in the epithelial cells A549 and 
DLKP and the haemopoietic cell line, HL-60 (data not shown) the reliability o f using 
this antibody to define fibroblasts is questionable. Studies o f normal lung tissue 
sections have also shown that the P-subunit o f proly 4-hydroxalse can be selectively 
localised in type II pneumocytes (Kasper et al., 1994).
However, some studies have shown that under certain conditions fibroblasts can be
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induced to express cytokeratin. In a study by Giudice and Fuchs (1987) the 
transfection of epidermal keratin genes into fibroblasts was performed. It was found 
that expression o f foreign type II keratin could trigger the expression o f endogenous 
type I keratin. This induction was unidirectional i.e. type II keratin could stimulate 
endogenous type I, but type I keratin could not stimulate production of type II keratin. 
In the absence of type II keratin the type I keratin appears to associate with the 
vimentin network. Knapp and Franke (1987) found that in transformed lines of non- 
epithelial origin that rare cells emerge spontaneously that can synthesise cytokeratin - 
8 and -18. They found that in SV-40 transformed fibroblasts the cytokeratin-18 gene 
was constitutively transcribed, but broken down rapidly without its partner 
cytokeratin-8. These transformed fibroblasts were abundantly positive for vimentin 
and negative for other epithelial markers such as desmosomal protein and 
desmoplakin. The coexpression o f specific acid and basic cytokeratins can be induced 
in teratocarcinoma-derived fibroblasts treated with 5-azacytidine (5-azacytidine 
methylates DNA bases) (Darmon, 1985). Also transient cytokeratin 19 positive 
fibroblast cells have been observed in vivo during the development o f the periodontal 
ligament o f the rat molar tooth. This expression of cytokeratin was believed to be in 
response to mechanical loading (Webb et al., 1996).
Although the studies to date seem to indicate that the cells are fibroblast cells it would 
be desirable to investigate other antigens to further confirm this finding. Hence, by 
investigating the expression o f tropomyosin, and creatine phosphokinase, as markers 
for smooth muscle, along with EP-16, desmoplakin, and involcurin, as epithelial 
markers one should be able to confirm the identity of the cells. By using immunoglold 
labelling in conjugation with electron microscopy it should be possible to investigate 
the ultrastructure o f the filaments to confirm that they are true cytokeratin filaments 
and to further identify the exact cell type. It would also be desirable to perform 
western blot analysis to confirm the identity o f the antigens by their molecular weight, 
as the antibodies may be cross-reacting with some other protein type.
Thus the question arises as to why do these cells express cytokeratin? It is possible to 
create a number of theories to explain this unusual phenomenon. Knapp and Franke, 
(1987) reported the rare spontaneous synthesis of cytokeratin in transformed cells of 
non-epithelial origin. This suggests that perhaps a very low percentage sub-population
210
of fibroblast cells might express cytokeratin and during routine cell culture it is 
possible that these cells are selected out. In turn, this leads to the view that fibroblasts 
are not the homogenous stromal cells as traditionally believed.
An alternative theory is that the in vitro situation mimics either a type of wound 
healing or stress on the fibroblast cells inducing cytokeratin expression. This theory 
gains some tentative evidence from two observations. During wound repair fibroblasts 
change to myofibroblasts with an accompanying expression o f a-smooth muscle actin 
(Zhang et al., 1996). The in vitro seeding density of fibroblasts can trigger this 
differentiation from fibroblast to myofibroblast and vica versa. A third theory is that 
the in vitro culture of fibroblast cells in some way causes an inappropriate expression 
of cytokeratin. Studies have shown that the mRNA for keratin 18 is constitutively 
transcribed in fibroblasts, though no protein expression occurs, as its partner 
cytokeratin 8 is not transcribed (Knapp and Franke 1987). Thus it is possible that in 
vitro cultivation in some way loosens the regulatory control of cytokeratin 8 and in 
doing so allows cytokeratin filaments to form.
To identify which, if  any, o f the above theories are valid, the following experiments 
are suggested. By performing dilution cloning, it should be possible to identify if  a 
subpopulation exists that is keratin-positive and is being inadvertently selected for, 
during culture.
The relationship between fibroblasts and myofibroblasts is unclear and their 
relationship in repair of injury and control o f the mechanism of cytoskeletal protein 
expression uncertain. Myofibroblasts have been found in a number o f normal and 
pathological conditions. Myofibroblasts are essential to wound contraction and 
healing. Myofibroblasts differ from fibroblasts by expressing stress fibres, which 
contain smooth muscle a-actin. The myofibroblast cells are larger than fibroblasts and 
contain more cellular protein. Upon the completion o f healing myofibroblasts 
disappear. Studies have often found cells that express the features of both fibroblasts 
and myofibroblasts (Masur et al., 1996). These cells often appear to be larger, have a 
slower growth rate, and stain positive for a-smooth muscle actin. A number of studies 
exist in which the expression o f a-smooth muscle actin by lung fibroblasts and
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myofibroblasts is observed especially in pathological conditions such as bleomycin- 
induced pulmonary fibrosis and wound repair. Smooth muscle cells are mostly 
responsible for increased type I collagen expression in the lung. The emergence of 
myofibroblasts is associated with an increase in the expression of TGF-p, which is 
known to enhance smooth muscle a-actin expression and PDGF. In their study, 
Zhang et al., (1996) showed that TGF-P enhanced the expression o f cc-smooth muscle 
actin in bleomycin treated fibroblasts whereas the level o f the non-muscular P-actin 
was the same in both cell types.
Since fibroblasts differentiate into myofibroblasts at low density culture (Masur et al., 
1996). The seeding of fibroblast cells at low density may induce a potential fibroblast- 
myofibroblast interconversion. This interconversion may affect the expression of 
cytokeratin and would be worth investigating. In a similar experiment to mimic 
wound healing, a confluent culture would be scraped and the leading edge of the cells 
investigated for cytokeratin expression. A positive result in the latter experiment 
would suggest that keratin expression was involved in some way in wound healing in 
tissue remodelling.
This work is unique, as the expression o f cytokeratin in normal fibroblast cells in vitro 
has not been previously reported. It is possible that we have identified a new sub­
population within fibroblasts or a mechanism involved in wound repair and 
mechanical stress.
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4.4.4 ASSESSMENT OF DIFFERENTIATION IN ISOLATED RAT TYPE II 
CELLS BY TIME-LAPSE AND IMMUNOCYTOCHEMISTRY.
In-vitro type II pneumocytes are supposed to differentiate into type I “like” 
pneumocyte cells. Although this is widely accepted the exact sequence of 
differentiation events is poorly understood. Although reports exist on the proliferation 
of type II pneumocytes in various conditions, this proliferation is measured by 
indirect methods such as increased thymidine incorporation. As noted by Ulich et al.
(1994) this increased thymidine incorporation is not always accompanied by an 
increase in cell numbers.
It was decided to investigate the proliferation directly by using time-lapse 
photography of isolated rat type II pneumocytes. These were plated at different 
concentrations in a well of a 12-well plate. No proliferation was observed in the 
cultures from the start of the experimental observation, 16 hours after isolation. Thus, 
if  proliferation did occur with the isolated type II pneumocytes in the various culture 
conditions investigated, it transpired during the 16 hour period prior to the start o f the 
time-lapse study. During the observation period the type II pneumocytes underwent a 
morphology change to become more flattened, with substantial increase in cell surface 
area. This morphology is indicative o f a type I pneumocyte, although these cells still 
possessed lamellar bodies, thus demonstrating the potential danger o f relying on the 
presence of this feature as a sole marker for type II cells. This sequence of events 
occurred in both high and low density cultures. Other observations from the time- 
lapse study would appear to indicate that higher density cultures entered apoptosis 
later than low density cultures, and that the low density cultures produced a lot more 
membrane ruffling.
To investigate if  the observed changes in morphology o f the isolated type II 
pneumocytes were accompanied by antigenic changes indicative of the cells 
becoming type I pneumocyte ‘like’ cells, immunocytochemistry was performed. 
Isolated rat type II pneumocytes were cultured for 8 days and immunocytochemistry 
performed at certain time points. The antigens investigated showed alkaline 
phosphatase activity which is considered a marker of type II function; the expression 
of surfactant protein D, one o f the 4 surfactant proteins produced by type II cells;
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expression of cytokeratin 19, which is the dominant cytokeratin in type II 
pneumocytes; and expression of cytokeratin 18, which is the dominant cytokeratin in 
type I pneumocytes. During the 8 days in culture a gradual decrease in alkaline 
phosphatase activity was observed. This was accompanied by a decrease in surfactant 
protein D levels. Both of these results indicate a loss of type II pneumocyte surfactant 
function over time. Concurrently changes in the cytokeratin cytoskeleton occurred 
with cytokeratin 19 decreasing over the period while cytokeratin 18 levels increased, 
indicating that the isolated cells were adopting a type I cytokeratin cytoskeleton. This 
is line with the observation of Paine et al. (1995).
The lack of proliferation observed may have been due to inappropriate culture 
conditions. It is reported that the growth factor KGF (FGF-10) is important in 
proliferation of type II pneumocytes (Ulich et al., 1994). In the time-lapse studies 
conducted no proliferation was observed.
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5.0 CONCLUSIONS AND FUTURE WORK.
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5.1 CONCLUSIONS
♦♦♦ BrdU induces Ep-CAM expression.
Ep-CAM is a homophilic cell-cell adhesion molecule, which was discovered only about 
10 years ago. Treatment o f the lung epithelial cell lines DLKP and A549 with the 
differentiation-inducing agent BrdU results in the induction o f Ep-CAM. The induction 
of Ep-CAM protein expression by a simple, chemical differentiation-inducing agent in 
lung epithelial cells has not been reported previously, although it has been reported that 
dimethylsulfoxide (DMSO) treatment of the colonic cell line SW620 results in a down 
regulation of Ep-CAM (Omary et al., 1992). Little is known about Ep-CAM expression 
in lung differentiation and development; evidence for a role in differentiation was shown 
in a study by Kasper el al. (1995) which found the main location for Ep-CAM 
immunoreactivity varied within fetal lung depending on development stage. By 
demonstrating its presence in lung cell lines following BrdU-induced differentiation, an 
important indication was gained of its potential role in in vivo differentiation of lung 
cells.
♦♦♦ Ep-CAM protein expression is regulated at a post-transcriptional level.
Ep-CAM regulation was demonstrated to be post-transcriptional in both DLKP and 
A549. The control o f Ep-CAM expression has not been fully elucidated, this result 
demonstrates that post-transcriptional control mechanisms may regulate the expression of 
Ep-CAM protein during differentiation. Our laboratory has shown that eIF-4E, the rate- 
limiting factor in translation, is a target for BrdU induction in DLKP and A549 (Derek 
Walsh PhD. Thesis 1999).
5.1.1 BrdU INDUCES EP-CAM EXPRESSION IN THE LUNG CELL LINES
DLKP AND A549.
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♦♦♦ Ep-CAM induction causes a down-regulation in focal adhesion protein levels.
Down-regulation in levels of the focal adhesion proteins a-catenin and a-actinin were 
demonstrated to occur following Ep-CAM induction in DLKP and A549. The down- 
regulation of focal adhesion proteins signifies that various signalling events altering cell 
physiology occurs in response to BrdU treatment.
♦♦♦ The Ep-CAM homologue, GA733-1 is transcriptionally controlled in BrdU treated 
DLKP.
The expression of mRNA for the Ep-CAM homologue GA733-1 was induced in 10p.M 
BrdU treated DLKP. In contrast no mRNA for GA733-1 was detected prior to, or after 
10(j,M BrdU treatment o f A549. Western blot analysis was not possible due to difficulty 
in sourcing an antibody to GA733-1.
5.1.2 OTHER HALOGENATED THYMIDINE ANALOGUES HAVE
DIFFERENTIATION-INDUCING EFFECTS ON DLKP AND A549.
♦♦♦ CdU induces differentiation in DLKP andA549.
The biological action of CdU involves conversion to a nucleoside monophosphate 
(chlorodeoxyuridine monophosphate) by thymidine kinase, followed by incorporation 
into DNA in place o f thymidine. The ability o f CdU to induce differentiation in DLKP 
and A549 was assessed by its effects on protein expression levels for cytokeratin-8, 
cytokeratin-18, cytokeratin-19, Ep-CAM and Pi integrin. Studies in our laboratory have 
shown that these proteins are up-regulated in both DLKP and A549 following treatment 
with BrdU. It was demonstrated that treatment with CdU also induced up-regulation of 
these proteins. According to RT-PCR analysis, CdU did not induce any changes in the 
mRNA level for these proteins, indicating that CdU exposure alters the post-
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transcriptional/translational control of these proteins in A549. The biological action of 
CdU is similar to that o f BrdU, so it may be speculated that the similar pattern of 
differentiation observed in DLKP and A549 is as a result o f the insertion of a halogenated 
nucleotide into DNA.
♦♦♦ 5,5'-FdU induces differentiation in DLKP andA549.
The biological action of 5,5'-FdU in contrast requires its metabolism first of all to the 
base 5-flurouracil and then to Fluro-deoxyUridine Monophosphate (FdUMP). FdUMP 
inhibits thymidylate synthase and hence inhibits DNA synthesis by limiting TMP supply. 
The ability of 5,5'-FdU to induce differentiation in DLKP and A549 was assessed using 
changes in the expression o f cytokeratin-8, cytokeratin-18, cytokeratin-19, Ep-CAM and 
pi integrin. Protein analysis revealed that 2fiM 5,5'-FdU treatment induced a strong up- 
regulation of these proteins in DLKP and A549. RT-PCR analysis suggests that 5,5'-FdU 
treatment alters the post-transcriptional/ translational rather than transcriptional control of 
the expression these proteins in A549. The pattern of differentiation obtained in DLKP 
and A549 with 5,5'-FdU appeared similar to the pattern o f differentiation that results 
from BrdU treatment. This suggests that BrdU and 5,5'-FdU may activate two different 
differentiation pathways with overlapping properties. The induction of these proteins 
appeared to be stronger in cells treated with 5,5'-FdU , than BrdU. This difference in the 
strength of induction may be due to 5-FU being incorporated into RNA, thereby changing 
its structure to allow greater translation efficiency.
♦♦♦ 5-BUr does not appear to induce differentiation in DLKP orA549.
Investigations of the ability if  5-BUr (which incorporates into RNA) to induce 
differentiation revealed no such induction except for a slight induction o f Ep-CAM. 
Hence suggesting that the modulation of differentiation by thymidine analogues requires 
an interaction with DNA
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5.1.3 THE EFFECT OF A HORMONE SUPPLEMENTED MEDIUM ON LUNG 
CELL LINE DIFFERENTIATION.
*X* A complex hormone-supplemented medium induces differentiation in DLKP and 
A549.
Differentiation was induced in DLKP and A549 using a complex hormone-supplemented 
medium (HSM) to represent a more in vivo type environment. Both cells showed induced 
expression of Ep-CAM, cytokeratin-8, and -19 expression. It was unclear if  cytokeratin- 
18 was induced in A549 grown in HSM. In comparison DLKP grown in HSM appeared 
to show a slight induction in cytokeratin-18 expression. Experiments to identify the 
importance of specific components in HSM revealed that the deletion of hydrocortisone, 
and cholera toxin from HSM cause an increase in induction by the modified HSM of 
cytokeratin-19 and Ep-CAM in A549. In contrast the removal of insulin from HSM, 
reduced the ability of HSM to induce expression o f cytokeratin-19 and Ep-CAM in 
A549.
♦♦♦ Removal of specific components from HSM alters its effects on differentiation.
The differentiation-induction of HSM is due to a range of compounds found 
physiologically, acting singularly or in co-operation. It is therefore reasonable to assume 
that the observed differentiation is due to mechanisms different from that o f BrdU and the 
other halogenated thymidine analogues. It is possible to speculate that that cross talk of 
signalling between each of the components o f HSM is required to induce differentiation. 
It has been reported that culture o f a hamster fetal lung cell line in this medium, with 
different culture conditions induces differentiation to different specific lung types (Emura
1996). Thus the differentiation induced by HSM of DLKP and A549 may represent an in 
vitro model of epithelial lung cell differentiation in vivo
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5 .1 .4  D E V E L O P M E N T  O F  IN VITRO M O D E L S  O F  IN VIVO 
D I F F E R E N T I A T I O N .
♦♦♦ Preliminary development of in vitro models reflecting in vivo differentiation.
The methods for generating primary cultures for modelling differentiation in normal lung 
epithelial cells and lung tumours were established. These studies revealed that long term 
reproducible primary cultures were difficult to obtain. Further work is required to 
establish more optimum culture methods for primary cultures. Preliminary studies on the 
growth of isolated normal rat type I I  pneumocytes in vitro showed morphological and 
antigenic changes over time. These changes were consistent with the terminal 
differentiation o f type I I  pneumocytes into type I  pneumocytes. This spontaneous 
differentiation may be due to the culture environment e.g. growth factors present in the 
serum and/or extra-cellular matrix. During the isolation o f lung tumor cells cultures of 
fibroblasts were often established and these expressed the unusual feature o f cytokeratin 
protein expression, which is usually epithelial-specific. This expression may be due to the 
in vitro environment inducing changes within fibroblast cells, for example mechanical 
stress (Webb et al., 1996).
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5.2 FUTURE WORK.
♦ It has been reported that Ep-CAM directs cell-cell sorting by disrupting the function 
of E-cadherin, a Ca2+ dependent cell-cell adhesion molecule (Litvinov et a l,  1997). 
The demonstration of such disruption o f E-cadherin by protein and RT-PCR analysis 
in the lung cell lines DLKP and A549 would be o f interest, as it may form the basis of 
a model for in vivo cell-cell sorting during development.
♦ Experiments utilising BrdU-treated lung cells in 3-D culture to investigate the role of 
Ep-CAM in the formation of tissue architecture would be of great interest.
♦ BrdU alters the post-transcriptional/translational control o f Ep-CAM expression and 
it has been recently demonstrated in this laboratory that following BrdU treatment, 
the protein level and activity of eIF-4E, one of the rate limiting factors in translation 
o f mRNA is increased. (Derek Walsh PhD thesis, 1999). Future work requires 
investigation of the effect of eIF-4E transfection on Ep-CAM expression in lung 
epithelial cells.
♦ Ep-CAM is believed to disrupt E-cadherin function via alteration in the focal 
adhesion proteins. Thus further investigation is required into these focal adhesion 
proteins along with others such as p-catenin which has been implicated in a wide 
range of functions including control o f gene transcription. Also worthy o f further 
investigation are the signalling peptides from the Rho family, which are involved in 
transduction o f signals from a variety o f cell adhesion proteins e.g. the integrin 
family. Further investigation is also required on the possible targets of these changes 
in focal adhesion and signalling proteins, for example E-cadherin. It would be 
instructive to transfect Ep-CAM cDNA into DLKP and A549 to investigate what 
elements of the differentiation pathway it may control, for example a disruption of E- 
cadherin function leading to increased pi-integrin expression.
5.2.1 EP-CAM INDUCTION IN BRDU TREATED DLKP AND A549.
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♦ Increased expression of Ep-CAM is found in most adenocarcinomas and de novo 
expression also frequently occurs in carcinomas of squamous epithelia (Varki et al., 
1984, Litvinov et al., 1996). Due to these changes in expression, Ep-CAM is a target 
for those investigating the use of monoclonal antibody-chemotheraputic drug 
conjugates for anti-cancer treatment, e.g. in non small lung cell carcinoma (Elias et 
al., 1990). The ability of BrdU to enhance the expression o f Ep-CAM in carcinoma 
cells, may make it a useful adjuvant in such treatments. Preliminary in vitro and in 
vivo experiments are required to test this hypothesis.
♦ It is necessary to investigate if  the GA733-1 mRNA induction in BrdU treated DLKP 
is accompanied by protein expression.
5 .2 .2  I N V E S T I G A T I O N  O F  D I F F E R E N T I A T I O N  B Y  O T H E R  T H Y M I D I N E  
A N A L O G U E S .
♦ It would also be useful to investigate if  a wider range of haolgenated thymidine 
analogues induce differentiation in DLKP and A549 e.g. 5-FluroUridine, 5-Fluro-2- 
deoxyUridine and 5-Iodo-2’-deoxyUridine. These investigations may lead to the 
design of novel compounds that promote differentiation.
♦ The induction of differentiation by halogen thymidine analogues may be due to a 
common biological action. It has been reported that the halogenated thymidine 
analogues inhibit poly ADP-ribose polymerase (PARP) (Pivazylan et al., 1992) One 
of the results o f this inhibition is to relieve the inhibition of the ribosomal elongation 
factor eEF-2, thus allowing protein translation. Thus an investigation of eEF-2 and 
PARP activity may reveal if  such a common mechanism exists.
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5.2.3 THE EFFECT OF HSM ON LUNG CELL DIFFERENTIATION.
♦ Further development of this medium, with additional components and different 
extracellular matrices may allow the development of in vitro models o f lung function. 
Research into the components responsible for the observed differentiation in vitro, 
may lead to the identification of the in vivo mediators o f lung differentiation.
♦ Since the components o f this medium are physiologically relevant investigation is 
required to determine if markers specific for differentiated lung types (e.g. alkaline 
phosphatase and surfactant proteins for type II pneumocytes) are expressed following 
growth in HSM.
5 .2 .4  D E V E L O P M E N T  O F  IN VITRO M O D E L S  O F  IN VIVO 
D I F F E R E N T I A T I O N .
♦ Differentiation studies with primary cultures o f normal and tumour cells may allow 
an assessment to be made as to the in vivo relevance o f the results obtained from 
epithelial lung cell lines.
♦ Comparison o f the differentiation induced in A549 and DLKP by growth in HSM 
with the differentiation o f primary cultures would allow an assessment to be made of 
the in vivo relevance of HSM induced differentiation.
♦ Comparison o f the mechanism o f differentiation induced by halogenated thymidine 
analogues with that of the spontaneous differentiation in primary cultures of type II 
pneumocytes may allow the identification o f key elements of differentiation in lung 
epithelial cells. Identification such elements may allow the design of novel 
therapeutic compounds.
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